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The Wilson protein (ATP7B) is a copper transporting ATPase that is involved in
copper trafficking and homeostasis. Unlike the other known P-type ATPases, it possesses
six homologous metal binding domains at the N-terminal end. Several mutations in the
gene coding for this protein lead to Wilson disease, a hepatic disorder characterized by
impaired excretion of copper in the bile, and accumulation of copper in body organs such
as the liver, brain, kidney, and eye cornea. Characterization of various regions of
expressed and purified ATP7B has been hampered by its low stability, aggregation and
degradation.
In this research, novel methods were developed to express and purify stable Nterminal copper binding domains (MBDs), a 577 amino acid construct. These domains
were characterized by Gel Filtration, Light Scattering and Circular Dichroism. The
results indicate that the domains are polydisperse and have a larger hydrodynamic radius
relative to a globular protein of the same molecular mass.
Y532H, a novel disease-causing mutation in domains 5 and 6 of the Wilson
protein was also expressed. WD5-6(Y532H) could not be purified by established
protocols.

Therefore, it was purified using two different methods: (1) insoluble

recombinant inclusion bodies were extracted and a procedure was developed to purify the
refolded fusion protein and (2) a lower temperature procedure was developed to express

soluble non-fusion recombinant protein. The WD5-6(Y532H) protein was characterized
by Gel Filtration, Light Scattering, Circular Dichroism and Nuclear Magnetic Resonance.
The results reveal that the Y532H mutation does not affect the overall structural
organization of the native WD5-6 and the conformational stability of the protein.
However, the NMR data of the WD5-6(Y532H) recovered by refolding reveals structural
perturbations in the area around the mutation.
This work represents advances in the understanding of the function of the Nterminal region of the Wilson protein (ATP7B). The purification methods and strategies,
key findings, and new developments presented in this work will be helpful not only to the
individuals working in this field, but also to the scientific community at large.

Copyright by
Joshua Mutambuki Muia
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CHAPTER 1

WILSON PROTEIN AND COPPER HOMEOSTASIS

1.1

Introduction
Wilson protein is a copper transporting P-type ATPase. The importance of copper

metal has been known for centuries although its role in biological systems did not receive
much attention until a few decades ago. It is an essential cofactor for many enzymes, but,
through its potential to drive oxidation/reduction reactions and form free radicals, excess
copper can lead to cell toxicity and death [1]. As a result, bacterial and animal cells have
developed mechanisms to control this delicate balance of intracellular copper
concentration [2]. P-type ATPases are ATP-dependent, transmembrane pumps which
belong to one of the protein families involved in copper uptake and regulation. Several
distinct P-type ATPase subgroups designated Pi-Pv are known with type II and type IB
being dominant [3]. The PIB type is not only involved in copper trafficking, but also in
transport of other transition metal ions such as Zn2+, Cd2+, Co2+, and Pb2+ [4].
Scientists have identified and characterized two important PIB copper transporting
ATPases in humans, ATP7A and ATP7B. Defects in ATP7A and ATP7B genes, give rise
to Menkes syndrome and Wilson disease, respectively [5-8]. If not treated, these
disorders can lead to liver cirrhosis, neuropathy, coma, and eventually death. To function
effectively, these copper ATPases are believed to interact with other proteins such as
copper chaperones, metallothioneins, and cellular target proteins [9]. The mechanisms by
which these proteins coordinate copper homeostasis are not well understood.

1

In the following sections, I will examine recent advances in structural and
functional studies of ATP7B (Wilson protein) and ATP7A (Menkes protein). Although
this work is largely based on the human Wilson protein, it would not be complete without
discussing other homologous proteins that are involved in copper homeostasis in plants,
bacteria, and yeast.

Later, I will discuss the structural and functional importance of

copper chaperones and related proteins that interact with the two copper ATPases.
Copper trafficking and metabolism in relation to copper ATPases, chaperones, cuproenzymes, storage and excretion will be also examined in detail. Finally, I will address the
pathogenesis, genetics, diagnostic and therapy of Wilson's disease and associated
disorders. A brief summary of the reviewed work constitutes the last section, which paves
way into the subject of this work — the characterization of the N-terminal domains and
disease-causing mutations of the human Wilson protein.

1.2

1.2.1

Wilson and Menkes ATPases: Homologous Copper ATPases

Structural Properties of Wilson and Menkes Protein
The discovery in early 1990's of genes encoding human copper transporting

ATPases [5-7] spurred unprecedented efforts by scientists to study their biological
significance and function. It is also important to note that pioneering work on the ion
ATPase pump was laid down almost fifty years ago, and it is worthy to take a few steps
back and survey the founding work of the P-type ATPases.

Nobel Laureate Jens Skou

was the first scientist to discover the membrane potential generated by various cations in
leg nerve homogenates from crabs in 1957 [10]. He suggested that the membrane
2

potential was generated by a K+-stimulated ATPase, which later was identified as the
Na+/K+-ATPase which utilizes ATP hydrolysis as a source of energy to pump these ions
across the axonal membrane [11]. Several other related ions pumps have been
characterized since this novel discovery. They include sarcoplasmic-recticulum (SR)
Ca2+-ATPase [12] which help to control skeletal muscle contraction, the gastric H+/K+ATPase that controls stomach acidity, and the H+-ATPase that generates membrane
potential in fungal and plant cells [13].
The P-type ATPase superfamily genes have been classified into ten subfamilies as
shown in Table 1.1, of which six are associated with plants [14]. These six are: proton
pumps (PHIA subfamily), heavy metal pumps (PIB subfamily), ER-type Ca2+-ATPase (PHA
family), auto-inhibited Ca2+-ATPase (PnB subfamily), putative amino-phospholipid
ATPase (Piv subfamily), and P-type ATPase type 5 (P v ) [15]. P-type ATPases clusters,
PIA (KdpB protein), PNC (Na+/K+-ATPases), PND (Na+-ATPases) and PmB (Mg2+ATPases) are not found in plants but only in the other eukaryotic family members. An in
depth discussion of structures and functions of these sub-families is beyond the scope of
this thesis. I will describe the structural organization of the best studied members of the
group to enable better understanding of my work. The P-type ATPases under
consideration can be divided into three main categories according to their function: (1)
cell signaling,

Ca2+-ATPase; (2) electrochemical potential generating, H+-ATPase in

plants and Na+/K+-ATPases in animals; and (3) the essential micronutrient transporting
ATPases, the Cu2+-, Zn2+-, and Co2+ -ATPases.
Generally, P-type ATPases are multi-domain membrane proteins with molecular
masses in the range of 50-150 kDa. Sequence comparisons with alignment tools reveal a
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characteristic pattern of conserved residues, particularly the DKTGTLT sequence motif
in which D is a transiently phosphorylated aspartate. All are integral membrane proteins
possessing 10 hydrophobic membrane-spanning helices (TM1-TM10), though some have
only six or eight of these helices. They possess highly conserved cytoplasmic domains
that link

helices TM2, TM3, TM4, and TM5 [10]. P-type ATPases are structurally

divided into four principal functional units according to their role and position. These
units are the phosphorylation domain (P-domain), the nucleotide domain (N-domain), the
actuator (A-domain) and the membrane domain (TM-domain).

Table 1.1 The P-type ATPases subfamily.
SUBFAMILY

EXAMPLE

REFERENCE

1

PLA

KdpB proteins

[16]

2

PLB

Heavy metal pumps

[17]

3

PLIA

ER-type Ca2+-ATPase

[18]

4

PLIB

Auto-inhibited Ca2+-ATPase

5

PLIC

Na + /K+-ATPase

[21]

6

PLID

Na+-ATPases

[22]

7

PLIIA

H+-ATPase

[23]

8

PLIIB

Mg2+-ATPases

[3]

9

Piv

Putative amino-phospolipid ATPase

[24]

10

Pv

P-type ATPase type 5

[15]

[19, 20]

The Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum (SERCA, type la) is
2+
an ATP-powered Ca -pump which is well characterized [25]. It is an integral membrane
protein with molecular mass of 110 kDa, which is found in both prokaryotes and
4

eukaryotes. The SERCA gene family contains many SERCA pump isoforms generated
by alternative RNA splicing [26-30]. Expression of these isoforms is tissue dependent.
More than 20 crystal structures of SERCA Ca2+-ATPase exist [31], and commonalities
among these structures (Figure 1.1) include the presence of 10 transmembranes helices
(TM1-TM10), three cytoplasmic domains, an A-domain (actuator domain), a P-domain
(phosphorylation domain), and an N-domain (nucleotide domain)

where ATP binds

during catalysis [32-34]. Mutagenesis of residues near the center of transmembrane
domain spanning TM4, TM5, TM6, and TM8 disable Ca2+ transport; therefore, it is
suspected to be the calcium binding site [35]. In the SERCAla structure, the A-domain
is connected to the TM1-TM3 helices with unusually long linkers, regulating Ca2+
binding and release by acting as an actuator for the transmembrane gating mechanism
[36]. The A-domain contains a TGES sequence motif which has a role in
aspartylphosphate processing. The SERCAla also possesses two unique transmembrane
Ca2+ -binding sites which manifest cooperativity [37]; the two sites, denoted I and II, are
2+
located side by side, but Ca binding is sequential [38].
Unlike animals, plants and fungi possess a proton pumping ATPase (H+-ATPase)
which couples ATP hydrolysis to proton transport out of the cell forming an
electrochemical gradient across the plasma membrane. In animals, the membrane
potential is established in large part by the Na+/K+-ATPase. The plant H+-ATPase is an
approximately 100 kDa monomer which can oligomerize to form dimeric and hexameric
complexes [14]. A low resolution structure (8 A) of the Arabidopsis thaliana plasma
membrane H+-ATPase isoform 2 (AHA2) determined by electron cryo-microscopy
revealed a dimeric protein complex [39].
5

Figure 1.1 The crystal structure of sarcoplasmic reticulum Ca2+-ATPase at 2.6 A
resolution showing the nucleotide binding domain, phosphorylation domain,
transmembrane domain and the actuator domain (PBD 1SUA) Toyoshima et al. [40].

Figure 1.2 The atomic structure of H+-ATPase dimer from Arabidopsis thaliana plasma
membrane without its auto-inhibitory C-terminus determined by X-ray crystallography at
3.6 A. The four main domains, transmembrane domain, nucleotide binding domain,
phosporylation domain, and the actuator domain are shown (PBD 3B8C) Pedersen et al.
[41]-
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The H+-ATPase has N- and C-terminal segments which protrude into the cytoplasm and
ten transmembrane segments (TM1-TM10) in addition to A-, P-, N-, and R- domains.
Like Ca2+-ATPase, the P-domain contains the catalytic phosphorylated aspartate within
the canonical sequence DKTGTLT. The R-domain acts as an auto-inhibitory domain and
forms the C-terminal part of the enzyme. The atomic structure of H+-ATPase without its
auto-inhibitory C-terminus determined by X-ray crystallography at 3.6 A [41] revealed
four main domains: a transmembrane domain, a nucleotide binding domain, a
phosphorylation domain, and an actuator domain (Figure 1.2).
The Na + /K + -ATPase was the first P-type pump to be described [11], and like the
other P-type pumps, it is a membrane-bound ion pump. It generates a Na + and K+ ion
concentration gradient across the plasma membrane in animals by concurrent pumping of
Na + out of the cytoplasm and K+ into the cytosol [42, 43]. Two high resolution crystal
structures of the sodium-potassium pump were recently reported [44, 45]. The pig renal
Na+/K+-ATPase crystal structure at 3.5 A resolution reveals a heteromultimeric P-type
ATPase consisting of a- and [3-subunits. The binding sites for Na + , K + , and ATP are
located in the a-subunit that shows homology to a single subunit P-type ATPases such as
Ca2+-ATPase. The a-subunit possesses the three cytoplasmic domains—the P-domain,
the N-domain, and A-domain in addition to transmembrane domains. The p-subunit is
found in symport P-type ATPases. It routes the a- subunit to the plasma membrane and
mediates K+ ion entry [46].

The third subunit (y-subunit in kidney outer medulla)

associates with the aP-complex and regulates the pumping activity. This protein belongs
to the FXYD family, a cluster of proteins expressed in tissues that specialize in fluid or
solute transport [47]. The shark rectal gland Na+/ K + -ATPase [45] visualized at 2.4 A
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resolution depicts features similar to the porcine renal pump; the extracellular parts of the
P-subunit and FXYD protein are well characterized in the shark rectal gland pump. The
Wilson protein (ATP7B) and Menkes protein (ATP7A) found in humans are members of
the heavy metal transporting P-type ATPases (PIB subfamily) and they are commonly
referred to as the copper transporting ATPases (Cu-ATPases) [3]. ATP7A and ATP7B
are related to copper transporting ATPases found in other organisms such as the Ccc2p
pump in yeast [48, 49], the CopA copper ATPase in Enterococcus hirae [50], OsHMA9
in Oryza sativa rice [51], and CUA-1 in C. elegans [52].

Unlike the other P-type

ATPases that have been described, the heavy metal P-type ATPases were discovered
relatively recently (1989) in studies involving cadmium resistant bacteria [53].
Structurally, Cu-ATPases are yet to be fully characterized and efforts from biophysical
and theoretical chemists continue.
The Wilson protein gene ATP7B is mapped to chromosome 13ql4.3 and encodes
a protein 1465 amino acid residues long [5-7]. Its complete exon-intron structure was
determined [54] prior to discovery of the gene encoding ATP7A [55, 56], The ATP7A
gene is mapped to chromosome Xql3.3, and encodes a 160 kDa protein of 1500 amino
acid residues [57-59]. Both genes are fairly large with ATP7A spanning approximately
150 kilobase pairs of genomic DNA and containing 23 exons. The start codon, ATG is
located in the second exon. The average size of each ATP7A exon varies from 77 to 726
bp. ATP7B gene structure is very similar to ATP7A; it is made up of 21 exons ranging in
size from 77 to 1234 bp; the start codon is located in exon number one. All splice sites
starting from exon five in ATP7A and exon three in ATP7B occur in identical nucleotide
positions except for the boundary between exon seventeen and eighteen in ATP7A (exon
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fifteen and sixteen in ATP7B). These two genes are distinct from each other when
observed in the 5' region that encode for amino metal binding domains. The first four
domains of the six metal binding domains (MBDs) in ATP7B are encoded in one large
exon (exon two), while the sequence encoding similar domains in ATP7A is spread over
three exons [60].
The copper transporting ATPases ATP7A and ATP7B share general features with
non-heavy metal P-type ATPases except the former have additional N-terminal domains.
The five distinct domains that are revealed in ATP7A and ATP7B molecular organization
are illustrated in Figure 1.3: (1) the transmembrane domains consisting of eight
transmembrane domains (TM); (2) the phosphorylation domain (P-domain); (3) the
nucleotide binding domain (N-domain); (4) the actuator domain (A-domain); and (5) the
cytosolic N-terminal metal binding domains. The complete structure of these CuATPases is unknown, but many structures of isolated domains are available [61]. The
transmembrane domains, responsible for copper transport across the membrane, contains
conserved residues Asn and Tyr in seventh TM [TM7], Met and Ser in eighth TM [TM8],
and the CPC and YN sequence motifs in TM6 and TM7, respectively. The functional
importance of these conserved residues has been confirmed by mutational analysis [6264]. Mutations of the conserved Ser in TM 8 of the WNDP have been found in some
Wilson disease patients [65].
The large cytoplasmic portion between transmembrane domain TM6 and TM7 is
referred to as the adenosine triphosphate binding domain (ATP-BD) and is made up of
the nucleotide binding (N) and the phosporylation (P) domains, and contains an invariant
DKTGT sequence motif that is transiently phosphorylated at the aspartate residue during
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the ATP hydrolysis cycle [66]. Putative nucleotide and magnesium binding motifs,
TGDN and GDGXND, are also located within the N and P domains. The actuator (A)
domain lies between transmembrane domains TM4 and TM5 and possesses the invariant
sequence motif, TGE. The NMR structure of the nucleotide binding domain of WNDP
has been reported [67]; it is 17 kDa, and can bind ATP and analogs. The structure shows
a central anti-parallel six-stranded P-sheet flanked by two a-helical hairpins (Figure 1.4).
The structure is closely packed except for a flexible 29 amino acid loop located at the
junction of the p-sheet and one of the a-helical motifs. The N-domain has little sequence
homology (<25%) with the SERCA 1 N-domain, the Ca2+-ATPase, but their shared basic
structure is evident. Nucleotide binding residues (His 1069, Glul064, Glyl099, and
Gly 1101) are present in both domains. Mutation of His 1069 to glutamine is the most
common Wilson disease mutation; it probably disrupts ATP binding [68]. While the
cytosolic N-terminal domains of MNKP and WNDP protein possess six metal binding
sites, similar Cu-ATPases in prokaryote and archea have one or two. Non-heavy metal
transporting ATPases possess none.
The N-terminus of WNDP is 650 amino acids long and possesses six distinct
metal

binding

domains,

each

bearing

a conserved

repetitive

sequence

motif

GMT/HCxxC. The metal binding domains (MBDs) are roughly 60-70 residues in size
[69-71]. In addition to the six domains, the N-terminus of WNDP has a 63 amino acid
(cytosolic tail) extension located in the first domain which was found to be necessary for
trafficking in polarized hepatocytes [72]. Several high resolution structures of some of
these domains have been reported, both in their apo and metal bound forms [73-77].
Metal domains share a common structural characteristic, a pappap ferrodoxin-like fold, a
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Figure 1.3 The illustration of the structural organization of Wilson protein/Menkes
protein. The transmembrane domains are embedded in plasma membrane and f o r m a
transduction channel that allows the passage of copper ions into the vesicle.
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His 1069

Figure 1.4 The solution structure of nucleotide binding domain (PDB 2ARF). GlyllOl,
Glul064, Gly 1099, and Hisl069 are involved in ATP binding. Mutation of His 1069
causes Wilson disease, Dmitriev et al. [67].

feature also found in the human copper chaperone ATOX1 that interacts with the metal
binding domains [78]. The inter-domain linkers among the metal binding domains vary in
length. The longest is between the Wilson metal binding domain 4 (WD4) and Wilson
metal binding domain 5 (WD5) which is 57 amino acids long, and the shortest, only 8
amino acids long is between domain WD5 and WD6. The solution structure of apo WD56 reveals that this protein fragment is organized into two domains and tumbles as a unit,
and the CxxC metal binding motifs faces away from each other [73], In general, all
reported structures show homology and similarities in features for both MNKP and
WNDP but present different surface properties [79].
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1.2.2

Copper Permeases and Metallochaperones
Copper transporting ATPases in eukaryotic cells interact or associate with other

proteins and organelles in the cell to orchestrate copper trafficking. These proteins
include copper permeases that facilitate copper ion entry into cells and metallochaperones
that deliver the acquired copper either to the Cu-transporting ATPases or to
cuproenzymes.

1.2.2.1

Copper Permease: The Human Copper Transporter (hCTRl)
The hCTRl is a 23 kDa, 190 amino acid residue long integral membrane protein.

The structure, illustrated in Figure 1.5,

was solved by cyro-electron microscopy at a

resolution of 7 A [80]. The CTR proteins are involved in cellular copper uptake and have
been found in many different organisms [81]. Like the other characterized CTR-proteins
such as yeast

CTR1 [82], human CTR1 is structurally organized into

four main

domains: (1) an extracellular N-terminal domain [83]; (2) an intracellular loop connecting
the first and second putative membrane spanning helices; (3) a membrane embedded
domain that consists of 3 transmembrane helices; and (4) an intracellular C-terminal
domain. hCTRl is trimeric and contains a cone-shaped pore (~8 A at the extracellular
end, and -22 A at the intracellular side) along the central 3-fold axis which is believed to
be the copper ion passage channel. Functionally important methionine residues in the
MxxxM motif [84-86] are found in the transmembrane helix (TM2) and are strategically
positioned near the extracellular end of the pore suggesting a role in copper uptake. The
TM2 and TM3 residues provide the lining of the pore near the intracellular end while
TM2 also provides membrane or hydrophobic interactions at the extracellular end.

KEY:

A - The side view of dimer-of-trimers of hCTRl that form the cone shaped pore (copper
ion channel)
B - Cross-section of membrane embedded domains: Extracellular side
C - Cross-section of membrane embedded domains: Middle bilayer
D - Cross-section of membrane embedded domains: Intracellular side
E - T o p view from extracellular side through the 3-fold axis

Figure 1.5 The structure of human copper transporter hCTRl determined by cryoelectron microscopy depicts a cone-shaped pore that forms an entry for copper ions into
the cytosol from extracellular matrix. The MxxxM motif in the transmembrane TM2 is
near the extracellular end of the channel for copper uptake, De Feo et al. [80].
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1.2.2.2 The Human Copper Chaperone ATOX1
The yeast ATX1 metallochaperone was first discovered as an anti-oxidant
(ATX1) gene when overexpressed in oxidatively distressed yeast cells [87]. Later, its
main function was found to be shuttling of copper to the Cu-ATPase Ccc2 [49, 88]. The
human homologue of yeast ATX1, ATOX1 (also known as HAH1), is a 68 amino acid
protein that shares domain homology with the N-terminal metal binding domains of
WNDP and MNKP. ATOX1 exhibits a ferrodoxin-like fold and has a single conserved
MTCGGC copper binding motif [70, 79]. ATOX1 binds Cu(I) and delivers it to Nterminal domains of the MNKP and WNDP which are capable of binding up to six
copper ions or one copper(I) ion per MT/HCxxC motif [89, 90]. The crystal structures of
Cu(I), Hg(II), and Cd(II) bound human ATOX1 have been published [91]. The NMR
structure for apo and Cu(I) bound ATOX1 has also been reported [92]. All protein
structures show that ATOX1 exhibits a PaPPaP fold (Figure 1.6 for yeast ATX1). The
protein is homodimeric, with two monomers linked together by coordinated metal ions;
Cd(II) is tetrahedral, Hg(II) assumes distorted tetrahedral geometry and Cu(I) is depicted
as a pseudo tetrahedral because the fourth Cu-S bond, which is 2.4 A is not within the
range of primary bonding range of Cu(I)-S, Cu(I)-N, and Cu(I)-0 complexes [93, 94].

1.2.2.3 Copper Chaperone for Superoxidase Dismutase (CCS) and COX-17
The CCS copper chaperone donates Cu within the inner mitochondrial space (IMS) to
Cu,Zn-SOD, an enzyme that requires copper and zinc as co-factors [95]. Cytosolic CCS
does not deliver copper into mitochondria. Instead, it is imported as a polypeptide into
IMS (Inter Membrane Space) via Mia40/ERV1 pathway before oxidative refolding where

it is involved in activation of Cu,Zn-SOD by metallation using a labile copper pool
within the mitochondrial matrix compartment. The labile copper pool consists of a low
mass ligand complex (CuL). Binding of the copper to the ligand in the cytosol triggers
translocation of the anionic complex into the mitochondria through membrane channels.
There is speculation that a transporter exists that moves the CuL complex into the matrix
and is also capable of shuttling it back to the IMS for subsequent use by COX-17 and
SCOl [97].
The CCS structure is organized into three functionally distinct domains: I, II, and
III. Knowledge of the human CCS structure is largely derived from sequence alignments
with yeast CCS, although its domain II structure has been determined [98].

N -terminus

Figure 1.6 Solution structure of Cu(I)-ATXl. The ATX1 is a copper chaperone for Ccc2ATPase in yeast. The copper ion is shown as a brown sphere (PBD 1FD8) Arnesano et al.
[96],
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The domain I which includes the N-terminal end bears homology to human ATOX1 and
includes a MTCQSC copper binding site. Domain III forms the C-terminal region, the
smallest of the three domains, is approximately 30 amino acids in length and was shown
to activate Cu,Zn-SOD in vivo [99]. Domain II is homologous to the target protein,
Cu,Zn-SOD, and possesses a zinc binding site. COX-17 [100] is an 8.0 kDa protein that
contains 6 conserved cysteine residues in both yeast and humans and functions as a
copper chaperone in the inner mitochondrial space for Scol and COX-11, inner
mitochondrial membrane anchored proteins. Scol and COX-11 ultimately transfer copper
to COX-2 and COX-1, respectively [101]. COX-17 is also imported into IMS from
cytosol in a similar fashion to CCS. In humans, Scol works with a second Sco protein,
Sco2 to transfer copper into COX-2 to form the binuclear CUA site, while COX-11 copper
transfer into COX-1 leads to assembly of the CUB site. Incorporation of copper in yeast
cytochrome c oxidase is supported by the presence of SCOl and its homologue, SC02,
and they are suspected to activate cytochrome c oxidase [102, 103].

1.2.3

Serum Ceruloplasmin
Ceruloplasmin, also called iron ferroxidase, is a blue a2-globulin oxidase that is

mainly synthesized in hepatocytes and released into the circulation after copper insertion
and glycosylation as holoceruplasmin [104-106]. Although copper is required for
ceruloplasmin to function, its specific roles in copper trafficking and metabolism are
relatively unknown [107]. Failure to incorporate copper during synthesis leads to
production of apoceruloplasmin [104], which has a very short half-life of 5 h [108]
compared to the holo form's half-life of 5.5 days [109]. In Wilson Disease, the defective

ATP7B protein fails to incorporate copper into apoceruloplasmin. Six copper ions are
tightly bound to newly secreted ceruloplasmin. Three of these are found in mononuclear
centers where they capture electrons from reductants, while the other three form the
trinuclear cluster where oxygen is reduced to water [110, 111].
intertwines iron and copper metabolism in that oxidation of Fe

to Fe

Ceruloplasmin
is catalyzed by

ceruloplasmin. Fe2+ is the source of reducing equivalents for the reduction of oxygen at
the trinuclear cluster [112].

1.2.4

Functional Properties of Wilson and Menkes Protein
The functions of human Cu-ATPases have been largely delineated by studying the

function and properties of related copper P-type ATPases in a range of organisms. As
was discussed in preceding sections, the structural information of human Cu-ATPases in
their entirety is currently unknown, and thus, understanding of the role and importance of
each conserved amino acid residue in these proteins is not given. This has led to efforts to
characterize and elucidate structure-function relationships of these Cu-ATPases. The
review and discussion below links the existing pool on knowledge of the functional
properties of Cu-ATPases and the roles they play in copper homeostasis and serves as an
opening to the characterization of the N-terminal domains of the Wilson protein.

1.2.4.1

Importance and Chemistry of Copper
Copper (Cu), is an essential trace element found in various species belonging to

both plant and animal kingdoms [1]. It possess unique redox properties that have been
exploited by a number of enzymatic and structural proteins [113]. Copper displays four

oxidation states: metallic Cu, cuprous ion Cu(I), cupric Cu(II), and a rare trivalent Cu ion
Cu(III). Free Cu(I) does not exist in the aqueous environment of animal cells and any
Cu(I) present is oxidized quickly by oxidizing agents unless it is protected by complexes
formed within the cell. Copper is distributed by copper chaperones to cellular targets that
require copper for their enzymatic activity and is occasionally stored by metallothioneins,
a small molecular weight polypeptide. Copper drives many enzymatic reactions as an
electron transfer intermediate in cellular respiration [114], free radical defense [115-117],
cellular iron metabolism [118], and pigmentation [119, 120]. Copper also functions in
the structural stability and architectural organization of many proteins such as the copper
zinc superoxide dismutase (Cu,Zn-SOD) [121]. In accordance with hard-soft acid-base
theory, Cu(I)

is a soft acid and prefers sulfur Met/Cys as proteinaceous coordination

ligands while Cu(II) (borderline) preferentially coordinates with oxygen in Glu/Asp or
the imidazole nitrogen in His.
While copper is essential for the well-being of growing cells and their
development, excess copper is toxic and lethal. It is therefore important that the amount
of copper in a cell at any particular moment does not exceed or fall below its demand.
The capability of copper in redox (Fenton reaction) chemistry (Figure 1.7) to catalyze
transformation of a superoxide radical anion • O ' l to the hyperactive hydroxyl radical
• OH via a metal catalyzed reaction presents the potential damage that excess copper can
cause [122]. These radicals oxidize and damage plasma membrane lipids, free lipids, and
blood cell membranes.
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Figure 1.7 The transformation of a superoxide radical anion (• O ^ ) to the hyperactive
hydroxyl radical (• OH) via a copper catalyzed reaction.

1.2.4.2

Copper Uptake, Distribution and Trafficking
Copper is acquired solely through diet in humans or nutrient medium in yeast. In

the small intestines, the copper ion comes into contact with hCTRl which translocates
copper across the microvillar membrane. Divalent metal transporter 1 (DMT1) is also
thought to be involved in this process [123]. The mechanism by which the copper ion is
differentiated by hCTRl from other metal ions is not known; it may be selected by size
and charge. CTR1 is a high affinity membrane-associated copper importer protein
conserved from yeast to humans [124, 125]. In yeast, in which CTR protein function is
widely studied, the extracellular copper is delivered to one of three copper importers:
yCTRl, yCTR2, and yCTR3 [126-128]. It is first reduced to Cu(I) by plasma membrane
reductases before translocation by yCTRl or yCTR3 [127, 129].
The

conserved

"Mets"

motif

(MxxxM)

(see

Section

1.2.2.1)

in

the

transmembrane domain 2 of hCTRl acquires Cu(I) for the ultimate facilitated import into
the cytosol [84]. Unlike P-type ATPases, CTR proteins do not require ATP. The
mechanism is thought to be driven by copper concentration differences across
membranes, and by extracellular K + , as seen in yeast [130]. The two human CTR1
transporters, hCTRl and hCTR2, were discovered in complementation assays in yeast for
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the double mutant yctrl and yctr3 phenotypes, which were unable to transport copper into
cells [125, 131]. In addition to the "Mets" motif, these two copper transporters contain a
conserved, C-terminal motif HCH which was shown to be important in protein
trimerization for a functional hCTRl and interaction with the ATOX1 chaperone [132,
133]. The function of hCTR2, previously unknown due to its inability to complement a
defective double mutant yctrl and yctr3 phenotype in copper starved yeast cells [125], it
was recently shown to express in late endosomes and lysosomes where it facilitated
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Figure 1.8 The intracellular copper trafficking. Copper is delivered in cytosol in the
reduced form before transported to Wilson/Menkes protein (ATP7A/ATP7B) by ATOX1
chaperone. The chaperones that deliver copper to Mitochondria and Nucleus are not
known, though copper ligand gets into mitochondrial through membrane channels.
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cellular copper uptake [134]. CTR1 proteins are involved in permeation and export of
the anti-cancer agent cisplatin in yeast and human cancer cells. Because of this
phenomenon, copper permeases have been implicated in resistance to platinum based
anti-cancer agents by cancer cells [135-137].
Once copper reaches the cytosol, its delivery and distribution to specific targets in
the cell is undertaken by high affinity copper binding chaperones (Figure 1.8). These
chaperones protect the cell from copper toxicity by binding free copper ions, act as
copper scavengers, and inhibit non-specific copper binding by other cellular proteins
[123]. All copper chaperones except COX-17 utilize a conserved MxCxxC motif to bind
Cu(I) in a digonal geometry through the cysteine residues or trigonally by additionally
utilizing glutathione or histidine/cysteine as a third ligand [138]. COX-17 binds three
Cu(I) atoms arranged in a poly-copper cluster using the CCxC motif as exhibited by Xray absorption spectroscopy [139, 140]. Yeast chaperone ATX1 delivers copper to yeast
ATPase Ccc2 in the trans-Golgi network (TGN) [49], which subsequently translocates
copper into vesicles for ultimate insertion into ferroxidase Fet3, a multicopper containing
protein [141]. In humans, ATX1 homolog, ATOX1 delivers copper to Cu-transporting
ATPases, Menkes protein (ATP7A) and Wilson protein (ATP7B) [142-144]. These CuATPases differ in their trafficking routes, ATP7A delivers copper to cuproenzymes in the
secretory pathway while ATP7B supplies copper to ceruloplasmin, a serum ferroxidase
that binds more than 95% of copper in blood plasma [107].
Among cuproenzymes replenished with copper by ATP7A is hephaestin, a
multicopper ferroxidase homologous to ceruloplasmin that oxidizes Fe

into Fe3+ [145].

The copper chaperone for superoxide dismutase, CCS, transports copper to Cu,Zn-SOD,
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an antioxidant enzyme [146, 147]. The structural similarity between domain II of CCS
and SOD1 enables direct interaction between these two proteins for copper insertion
[148]. The COX-17 also relies on the CCxC motif to bind copper within the
mitochondrial intermembrane space to deliver it to COX-11 and Sco proteins which in
turn supply copper to the assemblage of cytochrome c oxidase complex [149, 150]. Scol
and ScoII are unique in that they bind either a single Cu(I) or Cu(II) atom [151, 152].
Under elevated copper concentrations in transfected HEK293 cells, CTR1 is readily
endocytosed by a mechanism that depends on the MxxxM motif in TM2 and is quickly
degraded in the lysosomes [153]. This process demonstrates how copper uptake by CTR1
may be controlled.

1.2.4.3

Intracellular Copper Trafficking and Regulation within Cells
The human copper transporting ATPases, ATP7A and ATP7B, play central roles

in copper movement and regulation within the cell, and possess distinct functional
properties [154], This can be deduced from their expression, distribution, and how they
are stimulated by copper concentration.

ATP7A is largely expressed in intestinal

epithelium and other main tissues except the liver, while ATP7B is chiefly expressed in
the liver but also in the kidney and placenta, and minimal quantities are found in lung,
heart, and brain tissue [5, 7, 57, 155]. In non-polarized cells and under physiological
copper concentrations, ATP7A and ATP7B are localized in the trans-Golgi network
(TGN) [156-160]. Elevated levels of copper stimulate ATP7A trafficking to the cell
periphery and ATP7B re-localization to cytoplasmic vesicles to enable efflux of excess
copper [156, 161].
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Polarized epithelial cells possess a basolateral surface that orients toward the
extracellular fluid and an apical surface that forms the interface with the luminal surface
[162], In vitro studies show that in polarized, under normal copper levels, ATP7A in
continuously shuttles between the TGN and plasma membrane while under elevated
levels it pumps copper into vesicles and across the plasma membrane. The copper loaded
vesicles move toward the basolateral membrane where they fuse with the membrane and
release copper through exocytocis. ATP7A retreats to the TGN as the copper levels
decrease [163, 164]. In like manner, the Cu-ATPase ATP7B is localized to the TGN
under basal copper level and sequesters copper within vesicles at elevated copper levels
[165]. These copper-loaded vesicles relocate to the apical canalicular membrane for
copper excretion into the bile as ATP7B reverts to the TGN [166].
It should be noted that this trafficking process forms the regulatory basis of cell
copper needs and is not unique to all polarized cells found in organisms. Other
mechanisms that may influence and modulate copper trafficking and regulation by CuATPases include specific trafficking by some cells [167], phosphorylation [168], proteinprotein interactions [9], mutations [169], copper binding affinities [170, 171], various CuATPase motifs and domains, signaling sequences [72, 172, 173] and trafficking proteins
such as syntaxin 6 [72].

1.2.4.4

The Significance of Metal Binding Domains of the Wilson protein (MBDs)
The focus and basis of the work under investigation is the structural and

functional properties of the N-terminal metal binding domains (MBDs) of WNDP. The
spatial organization of MBDs has been described in Section 1.2.1, and the current section
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focuses on their biochemical functions. There is some agreement in the published
literature on the functions of the N-terminus domains but a consensus is not yet evident
as new data continues to challenge the existing knowledge. The N-terminal domains are
the first point of interaction between copper chaperone ATOX1 and WNDP as revealed
in yeast and mammalian two hybrid systems [142, 174]. The oppositely charged surfaces
of the interacting proteins facilitate ATOX1 docking and Cu(II) transfer to MBDs
through a presumed three-coordinate intermediate [79]. When characterized as single
isolated domains, all six MBDs appear similar in structure but surface characteristics and
domain-domain interactions may give rise to different functions. The ATOX1 interacts
with all six MBDs [73, 142-144, 170]. Though ATOX1 delivers copper specifically to
metal binding site 2 (MBS 2) and MBS 4 [73, 142], the mechanism is not clear. In
excess, ATOX1 is capable of retaliating all six MBS [142, 175]. Deletions of MBS 1-5
or MBS 6 but not MBS 1-4 were found to disrupt copper-induced trafficking of ATP7B at
elevated copper levels [176]. MBS 5 and MBS 6 are in close proximity to the
transduction channel; therefore, they may have a role in passing copper ions into the
channel.
Inter-domain copper transfer does occur, but its physiological role is not clearly
understood. From a thermodynamic standpoint, Cu(I) transfer between domains is facile
[171]. A Cu(I) binding study with the N-terminus shows that each domain can accept
and release Cu(I) from ATOX1; therefore, their role might be modulated by other
proteins [170]. A recent NMR study by the Bertini group on Cu-ATOXl interactions
with N-terminal metal binding domains (residues 1-633) of WDNP reveals a Cu(I)
bridged adduct formed between MBDs 1, 2 and 4 but not MBDs 3, 5 and 6. [175]. MBDs
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3, 5 and 6 and metallated ATOX1 had a copper exchange that occurred slowly on the
NMR time scale relative to MBDs 1, 2 and 4. In turn, the Cu-ATOXl/MBD 4 titration
led to a higher steady state concentration of the adduct compared to Cu-ATOXl with
MMBD 1 and 2 despite having similar affinity for Cu(I) [170]. It is clear that MBD 4
plays an important role in copper transfer but how, where, and the cascade of events
surrounding this observation will have to wait for more information to become available.
It is possible to speculate that copper transfer in vivo may be organized in the hierarchy
seen in vitro studies and may involve other molecular interactions.
The N-terminal

domains

influence copper-induced trafficking

[177-179].

Although earlier studies had shown MBS 5 and 6, and the CPC motif were crucial for
copper trafficking [176, 177, 180], Cater et al. indicated that mutations disrupting the
catalytic cycle of ATP7B posed a greater risk [181]. Intracellular ATP7B trafficking
requires the presence of copper and acyl-phosphate formation, but not metal ion
coordination on metal binding sites, though the latter is required for efficient efflux of
copper. The study of N-terminal MBDs function and properties as a single unit has not
proceeded without difficulties.
The expression and purification of the WD 1-6 protein that is stable over a lengthy
period of time at normal temperatures has not been very successful in other laboratories
[89, 170, 175]. Under normal experimental conditions, this protein undergoes rapid
degradation within 2-3 days [175]. Developing methods that would overcome this
constraint, a subject of this thesis, will impact greatly not only on further characterization
of the N-terminal metal binding domains but also the entire Cu-ATPase (ATP7B).
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1.2.4.5

Additional Functions of Copper Transporting P-type ATPases

There is emerging evidence that copper transporting ATPases and chaperones are
involved in other biological active pathways not directly related to copper homeostasis.
The development of resistance after initial therapy by tumor cells to the anti-cancer agent
cisplatin [cis-diamminedichroloplatinum (II) or CDPP] is partly mediated by copper
transporting ATPases and chaperones as shown in vitro studies [182, 183]. The MNKP
and WNDP have been found to sequester CDPP into vesicles and confer resistance to
elevated levels of DPP [184-187]. These proteins are expressed in a variety of carcinoma
cells [188-190]. A fluorescent CDPP has been found to co-localize with tagged ATP7B
[191]. These studies may suggest that CDPP interaction with Cu-ATPases in vivo may
lead to reduced efficacy to the drug therapy. Mechanistically, this interaction is not well
understood, but recent work by Lutsenko's group sheds some light into process [183].
ATP7B does not confer resistance to CDPP directly; however, CDPP binding to ATP7B
modulates phosphorylation activity and copper efflux is accelerated. Copper deficient
cells have shown resistance to CDPP [186]. Even more intriguing is the possibility that
the human copper chaperone ATOX1 can bind a stripped CDPP in the Cu metal binding
site [192] without the chloride ligands. Binding of DPP by Cu(I) transporters is likely to
lead to unhealthy competition between the targeting pathway and copper homeostasis.
The Cu-ATPases also interact with other proteins of clinical significance.
COMMD1 (formerly known as MURR1), is a protein product coded by a defective gene
in Bedlington terrier dogs suffering from liver copper toxicosis [193, 194]. This protein
has been proposed to be involved in regulation of copper trafficking and other cellular
mechanisms [9, 195], and it has been shown to interact with the N-terminus of WNDP
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but not MNKP [196], The dynactin subunit p62 interacts with the N-terminus of WNDP,
specifically to MBDs 4-6. This interaction is copper-dependent, and may be responsible
for copper mediation through microtubules [197].

1.3

Wilson Disease
Wilson Disease (WD) is an inherited autosomal recessive disorder of copper

homeostasis that leads to accumulation of copper in key organs, such as the liver, brain
and kidneys [198]. The main cause of WD is the defective ATP7B that fails to deliver
copper to the bile excretory system. Many mutations [65, 199-203] in the ATP7B gene
alter its ability to effectively function; a database for these mutations has been created
and is maintained by the Cox laboratory at the University of Alberta, Canada
(http://www.wilsondisease.med.ualberta.ca/database.asp). If left untreated, WD can lead
to permanent organ damage, neurological, and psychological problems, eventually, death
if a liver transplant is not performed [204]. The prevalence of Wilson disease is
reportedly 1 in 30,000 births; this number might be an underestimate because many cases
remain undiagnosed or misdiagnosed [205-207].

1.3.1

The History of Wilson Disease
The historical events of Wilson disease were compiled by Walshe, who initiated

the initial treatment of Wilson disease (WD) with D-penicillamine in 1955 [208]. The
American-born neurologist Samuel Alexander Kinnier Wilson was the first physician to
describe the progressive lenticular degeneration disorder that later came to be known as
Wilson disease (WD) [209]. His original description, which was published in a single

issue of the journal Brain in March 1912 (213 pages in all) described WD as a rare,
familial, progressive, and invariable fatal disease, accompanied by neurological deficit
and liver cirrhosis. Preceding Wilson's work was Kayser who described pigmented
corneal rings (now known as Kayser-Fleischer rings or K-F) in patients suffering from
"pseudosclerosis" [210, 211],
A correlation between K-F rings and Wilson disease was not apparent because it
is not found in all patients. In 1913, Rumpel indentified excess copper deposits in the
liver of WD patients, while Vogt in 1929, Haurowitz in 1930, and later Glazebrook
[212], reported copper overloads in the liver or brain of the dying patients. Earlier in
1921, Hall had postulated that WD exhibited autosomal recessive inheritance. Cumings
[213] initiated the modern understanding of WD in 1948 by publishing a comparative
study of copper and iron content in brain, the liver, and hepatodegeneration. He was first
to propose the use of Dimercaprol for treatment of the disease. The 1950-1960's saw
discovery of ceruloplasmin deficiency in Wilson patients [214, 215] and the emergence
of treatment therapies such as Dimercaprol (BAL) [216], D-penicillamine [217, 218], and
zinc salts [219]. An advance in WD research in the 1970's and 1980's culminated in the
identification of the ATP7B gene in 1993. This has ushered WD into the molecular
genetics era [5, 7, 8].

1.3.2

Clinical Aspects and Diagnosis of Wilson Disease

The onset of the WD ranges from early age to adulthood. Children as young as 2 years
old and adults over 70 have developed the disease [220]. There are four main aspects of
WD clinical presentations: hepatic, hemolytic, neurogical and psychiatric ailments.
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Hepatic and hemolytic symptoms are manifested by chronic hepatitis, acute hepatitis,
cirrhosis, jaundice and liver failure [221]. They can be also accompanied by high serum
transaminase levels, anemia secondary to hemolysis [220], and Kayser-Fleischer rings
(K-F) (Figure 1.9) have been found in roughly 55% of patients at this stage [222]. The
K-F rings are caused by copper deposition on Descemet's membrane in the cornea.
Neurogical features which tend to present later in life include

hypokinetic speech,

dystonia, tremor, lack of motor incoordination, and inability to perform basic functions
[223]. Nearly all neurogical patients show K-F rings and may exhibit Parkinson diseaselike behavior as copper accumulates in the basal ganglia [224]. Behavioral changes,
hallucinations, depression, and anxiety are among many of the psychiatric symptoms.
Other nonclassical features that occur in WD patients are hypoparathyroidism [225],
infertility [226], renal abnormalities [227], and skeletal muscle diseases [228].

Copper metal deposits
Figure 1.9 Kayser-Fleischer ring in the cornea Descemet's membrane. A copper deposit
is the golden brown ring indicated by arrow in at the edge of the iris (220).
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The diagnosis of WD is not based on any on single procedure but an accumulation
of evidence from clinical observations and laboratory tests. Normally, cases showing
known symptoms are easily diagnosed; the results can be confirmed by laboratory tests
such as the measurement of 24 h urinary copper excretion, hepatic copper concentration,
serum 'free' copper concentration, and ceruloplasmin concentration. Since these tests can
also indicate other liver diseases, a single method diagnosis should not be relied upon as a
positive test for WD [229]. The presence of WD can be indicated by urinary copper
concentration greater than 100 (ag/24 h (>1.6 (imol/24 h), liver copper content more than
250 |ig/g dry weight (normal < 50 ng/g dry weight), serum free copper concentration
more than 25 ng/dL (normal <15 |ig/dL) [220], and D-penicillamine urine challenge test
(urinary excretion of copper

>

1600 |ng per day following D-penicillamine

administration) [230]. The determination of ceruloplasmin concentration is also
important, but it has limited usage for diagnosis.
Despite the fact that about 20% of WD patients have normal ceruloplasmin
concentration (200-400 mg/L), most patients, heterozygous WD carriers, and some
normal individuals have ceruloplasmin concentrations of less than 200 mg/L. Therefore,
the enzymatic assay method (oxidase activity) of determining ceruloplasmin levels is
preferred for Wilson disease diagnosis [231, 232], Other parameters used for diagnosis is
the presence of K-F rings described earlier. WD patients with hepatic symptoms and
neuropsychiatric disorders are likely to exhibit K-F rings [233]. Another tool that is
gaining momentum in WD diagnosis is genetic testing of first degree relatives of a patient
[234]. By mutational analysis, it is becoming easier both to confirm the presence of a
defective gene and to determine the severity of the mutation on the malfunctioning

WNDP. Even though not common, newborn screening for WD is being encouraged to
identify affected individuals early. This is done by measurement of ceruloplasmin in
Guthrie dried-blood spots or urine samples from newborn infants [235-237].

1.3.3

Treatment of the Wilson Disease
The treatment of WD is intended to decrease the copper concentration in the body

either through accelerated copper excretion or impaired copper absorption from diet.
Currently, this is accomplished by use of copper chelating drugs (Figure 1.10) and diet
management. The discovery of WD in the early twentieth century was not followed by
any form of therapy until 1948. Cumings proposed and Mandlebrote and co-workers
subsequently used BAL for treatment of WD [216, 238], Incidentally, BAL, a chelating
agent, was developed as antidote agent to the arsenical war gas lewisite [239, 240]. BAL
was a promising candidate for management of WD as it was able to remove copper from
body rapidly. BAL usefulness was overshadowed by its toxicity and the requirement of
painful intramuscular injections; a substitute was needed [208]. Now, WD is managed by
several therapies and drugs. D-penicillamine (D-PCA) is an orally administered chelating
drug [217]; it forms copper-pencillamine complexes that are excreted in urine. D-PCA
possesses a free sulfhydryl group that is capable of chelating copper. It works fairly well
for patients with hepatic symptoms [220]. Its side effects are numerous and include
Vitamin B6 deficiency, hypersensitivity, nephrotoxicity, hematuria, bone marrow
thinning, and Goodpasture's syndrome [223].
Trientine (triethylene tetramine dihydrochloride) is another copper chelating agent
that works in the same fashion as D-PCA though it has fewer side effects. It is the first
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line of defense in WD therapy, but not as effective as D-PCA. Unlike D-PCA, trientine
lacks a sulfhydryl group, is less toxic, stimulates tissue copper efflux, and patients with
neurological symptoms tend to worsen when this is used as the primary treatment [241].
Trientine has a polyamine-like structure and chelates copper to form a stable complex
using four nitrogens in a planar ring [223]. Zinc has been used to manage WD for almost
six decades [242]. Its mode of action and application is distinct from Trientine and DPCA. Zinc promotes enterocyte metallothionein synthesis. Metallotheinein has a higher
affinity for copper than zinc, and this induction promotes copper excretion [243].
Metallotheinein bound copper is not absorbed but excreted into fecal matter as cells
undergo shedding. Gastric irritation and immune suppression are just a few side effects
associated with zinc therapy [244, 245].
Ammonium tetrathiomolybdate (TM) is another copper removal agent which is no
longer used to treat WD. Its mode of action involves two mechanisms: First, it complexes
with copper in intestinal lumen, hindering absorption. Second, it inhibits copper uptake
by forming a copper complex with albumin [246]. Recently, TM was found to form a
complex with copper chaperone ATOX1 homolog, ATX1; therefore, it could inhibit
copper trafficking proteins through metal cluster formation [247]. TM was preferred for
patients with neurological signs and symptoms, but due to limited clinical trial data, this
drug is not commercially available in the United States or Europe. Patients receiving TM
may suffer from bone marrow depression and hepatotoxicity side effects [248, 249]. WD
is also managed by lifestyle change. Foods rich in copper such as liver, chocolate, nuts
and mushrooms should be avoided. Antioxidants, mainly vitamin E, have been found low
in WD patients so supplements are encouraged [220]. Liver transplantation is the last
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option for WD patients with acute liver failure who are non-responsive to medical
therapy. A prognostic scoring system for WD has been developed to assess those who
might be at higher risk and require liver transplant [250].

H3C

CH3

H,N
(A) Trientine (triethylene tetramine dihydrochloride)

NH2
(B) D-Penicillamine

H3C

SH
(C) Dimercaprol (Dimercaptopropanol)
(BAL)

NH3

c'-^-—, Mo

(D) Ammoniun tetrathiomolybdate (TM)

Figure 1.10 The copper chelating agents. They possess sulfhydryl and polyamines
functional groups that bind to copper. Ammonium tetrathiomolybdate (TM) is no longer
used for WD treatment due to its toxicity.
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1.4

Summary
Copper is an essential element required in the body for many enzymatic activities

and maintenance of structural integrity of proteins. Maintaining cellular copper
concentration within physiological limits is critical, excess copper in the body leads to
production of superoxide radicals that damage cell membranes, whereas copper deficit is
associated with pigmentation and growth disorders. The role and importance of the
copper transporting ATPase ATP7B (Wilson protein) in copper homeostasis was
discussed in detail. WNDP is structurally and functionally related to Menkes protein
(MNKP), a homologous protein that shares a complementary function with WNDP. The
Cu-ATPases belong to the heavy metal transporting P-type ATPase (PIB) subfamily and
are distinguished by their possession of N-terminal metal binding domains. Structurally,
Cu-ATPases are organized into five functional domains, the transmembrane (TM-),
phosphorylation (P-), nucleotide binding (N-), the actuator (A-), and the N-terminal metal
binding (MBD) domains. To effect copper trafficking, Cu-ATPases acquire copper from
the metallochaperone ATOX1 and deliver it either to secretory vesicles or cuproenzymes.
Copper transporting ATPases and the human copper transporter (hCTRl) are also found
to be involved in resistance to the anticancer drug cisplatin by tumor cells.
The N-terminal domains play an important role in copper transfer because they
form the first point of contact between Cu-ATPases and the metallochaperone ATOX1.
Deletion of N-terminal domains has been shown to abrogate the enzymatic activity of
Cu-ATPases. Cu-ATPase activity is in turn regulated by cellular copper levels. Several
mutations in the ATP7B gene cause WD, a disorder characterized by accumulation of
copper in key organ tissues such as the liver and kidney. WD is managed by
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administration of copper chelating agents, BAL, D-penicillamine and trientine. Zinc salts
which promote in vivo copper binding by metallothioneins are also used along with
addition to limiting copper intake through diet. Liver transplant is usually the last option
for patients who are non-responsive to treatment. Clearly, understanding the function of
both native and mutant copper metabolism proteins at the molecular level is a worthy
pursuit highly germane to human health.
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CHAPTER 2

MATERIALS AND EXPERIMENTAL METHODS

2.1

Introduction
This chapter covers the materials and methodology that were used in this study. A

description of the following major subtopics is given: materials, instrumentation,
procedures, DNA plasmids and PCR primers, and biophysical characterization of the
proteins.

2.2

Chemicals and Reagents
The chemicals and reagents are listed in Table 2.1 along with the purity level

where applicable, and the supplier's name and location. In general, all chemical and
reagents met molecular grade standards. Milli-Q water (18.2 MQ/cm) purified using US
Filter PURELAB Plus UV/UF (Millipore) was used in all experiments. The water for cell
culture and processes prone to microbial contamination were autoclaved for 30 min at
121°C. Enzymes, process kits, and purification aids are listed separately in Table 2.2.

Table 2.1 Reagents and chemicals.
Chemical/Reagent

Catalog

Acrlylamide

Percent
Purity

Supplier

Location

164855000

Acros Organics

Morris Plain, NJ

Agarose

15510-019

Invitrogen

Carlsbad, CA

Ammonium Chloride

A661-500

Fisher Scientific

Fair Lawns, NJ

99.8%
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Table 2.1 —Continued
Chemical/Reagent

Catalog

Percent
Purity

Supplier

Location

>98%

Sigma-Aldrich

St. Louis, MO

92.5-100.5%

Sigma-Aldrich

Ammonium Persulfate

A3678-25G

Ampicillin

A-9518

Antifoam A

A-5757

Sigma-Aldrich

Bis-Acrylamide

BP171-25

Fisher Scientific

Boric Acid

BP 168-1

Bromophenol Blue

B-6131

Sigma-Aldrich

Carbenicillin

762024

Bio-World

Dublin, OH

Chloramphenicol

220551

EMB Biosciences

La Jolla, CA

Coomasie Blue R-250

20278

Thermo Scientific

Rockford, IL

Coomasie Plus

23236

Pierce

Rockford, IL

Dextrose

BP350-500

DTT

1758-9030

Inalco Spa

EDTA

BP119-500

Fisher Scientific

Glutathione, reduced

G425-500

> 99 %

Sigma-Aldrich

Glycerol

G33-1

99.9%

Fisher Scientific

Guanidine HC1

50933

> 99.5%

Sigma-Aldrich

HEPES

H7006-500G

99.5%

Sigma-Aldrich

Imidazole

56750

99.5%

Sigma-Aldrich

Iodoacetamide

653k5320

Sigma-Aldrich

IPTG

1758-1400

Inalco Spa

Magnesium Chloride

BP214-500

Fisher Scientific

MEM Vitamins

75-020-C1

MediaTech

MES

BP300-100

98%

Fisher Scientific

Nickel (II) Sulfate

211085000

99%

Acros Organics

Pefabloc SC PLUS

1187601001

Sodium Dodecyl
sulfate (SDS)

1535-017

Thiamine HC1

BP892-100

>99%

>99.6%

99.8%

>99.5%

Fisher Scientific

Fisher Scientific

Herndon, VA

Roche Diagnostics

Indianapolis, IN

GIBCOBRL

Grand Island, NY

Fisher Scientific
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Milan, Italy

Table 2.1 — C o n t i n u e d
Chemical/Reagent

Catalog

Tricine

22561 1

Tricine

Percent
Purity
>98.5%

Location

Supplier
USB Corp.

Cleveland, OH

807420

MP Biochemicals

Solon, OH

Tris Base

BP152-5

Fisher Scientific

Tryptone

211713

Fisher Scientific

Tryptone

MoBio Labs

Carlsbad, CA

Tryptone

T7293-2509

Sigma-Aldrich

Urea

BP 169-500

Vitamin H

B0463

Tokyo Kasei Kogyo

Xylene Cyanol FF

BP565-10

Fisher Scientific

Yeast Extract

212720

Fisher Scientific

(13C) Glucose

CLM-1396-1

99%

99%

Tokyo, Japan

Andover, MA
Cambridge Isotope

15

( N) Ammonium
Chloride

Fisher Scientific

NLM-467-1

99%

Table 2.2 Enzymes, process kits, and purification aids.
Enzymes/Kits

Catalog

Supplier

1 kb D N A Ladder

N3232S

NEB

100 bp D N A Ladder

N3231S

NEB

BamHl

B0136S

NEB

70746

Benzonase
Bglll

Novagen

R0144S

NEB

70584-4

Novagen

Deep Vent (exo-) D N A Polymerase

M0259S

NEB

Deep Vent D N A Polymerase

M0258S

NEB

BugBuster®
Reagent

Protein Extraction

Dialysis Cassettes

66030
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Pierce

Location
Cambridge, M A

San Diego, CA

Rockford, IL

Table 2.1 —Continued
Enzymes/Kits

Catalog

Supplier

Location

DH5a Cells

Dr. Huffman's glycerol stocks

Factor Xa

Enzyme
Research

South Bend, IN

Epicentre

Madison, WI
Valencia, CA

Fast-Link DNA Ligation Kit

LK11025

HotStar HF Start DNA Polymerase

202602

Qiagen

KOD Hot Start DNA Polymerase

71086-3

Novagen

MinElute PCR Purification Kit

28004

Qiagen

Nco I

R0193

NEB

Ndel

ROlllS

NEB

pET32Xa/LIC Kit

70072

Novagen

pET41Ek/LIC Kit

71071

Novagen

QIAfilter Plasmid Midi kit

12243

Qiagen

QIAprep Spin Miniprep Kit

27106

Qiagen

QIAquick Gel Extraction Kit

28706

Qiagen

Rainbow Protein Marker
Rosetta(DE3) Cells

RPN800E
70954

GE
Novagen

Site-Directed Mutagenesis Kit

200521-5

Stratagene

TEV Protease

12575-015

Invitrogen

2.3

Piscataway, NJ

Cedar Creek ,TX

DNA Plasmids and PCR Primers
The Wilson protein cDNA encoding the entire ATP7B was kindly provided by

Professor Jonathan Gitlin of Washington University at St. Louis (now at Vanderbilt
University). The Wilson cDNA was transformed into DH5a cells and prepared glycerol
stocks were stored at -80°C. The DNA Strider 1.3 software was used to design the gene
inserts encoding the protein's domains of interest. PCR mutagenic primers were designed
and analyzed using DNA Strider 1.3 software or an online based oligo-analyzer at
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http://www.idtdna.com/analvzer/Applications/01igoAnalvzer/. The primers were ordered
from Integrated DNA Technologies, Inc. (Coralville, Iowa). The notation used for
Wilson's protein constructs and plasmids vectors is shown in Tables 2.3 and 2.6. The
primary primers (Table 2.4) were expressly designed either to amplify the genes of
interest or to incorporate mutations, whereas secondary primers (Table 2.5) were
additional primers for which need arose in the course of this work. All lyophilized
primers were resuspended in double distilled nuclease-free water to make a 200 p.M stock
solution. This stock solution was further diluted to make 10 |iM polymerase chain
reaction (PCR) working aliquots and stored at -20°C.

Table 2.3 Notation for proteins studied.
Notation

Residues in
ATP7B

WD1-6

57-633

N-terminal Domains 1-6

1731

WD5-6

485-633

N-terminal Domains 5-6

447

WD5-6(Y532H)

485-633

Y532H mutation of WD5-6

447

WD5-6(G591D)

485-633

G591 mutation o f W D 5 - 6

447

Name

bp in gene

Other protein
COMMD1

COMMD1

63

450

Table 2.4 Primary primers.

ON

Primer
COMMD1 BamHI Rev
COMMD1 Ncol Fwd
Ek/LICWD5Fwd
Ek/LICWD6Rev
GC_KD-Y532H Rev

bp
37
21
39
40
34

% GC
56.8
81.0
53.8
60.0
55.9

71.2
67.7
70.4
66.4

GC TEV PI

43

58.1

70.0

GC_TEV PII
GC TEV PIII
KD-Y532H Fwd

39
39
34

58.9
56.4

70.4

55.9

69.3
66.4

TEV PI

43

58.1

70.1

TEV PII
TEV PIII
WD1 EkLIC Forward
WD1 XaLIC Forward
WD1 XaTEVLIC Forward

39
39
45
45

58.9
56.4
60
62.2

70.4

36

52.8

69.3
71.9
72.9
66.2

WD6 EkLIC reverse

49

57.1

72.0

WD6 XaLIC Reverse

51

52.9

70.8

WD5 XaLIC Fwd

42

54.8

69.1

WD6 XaLIC Rev

42

54.9

69.1

TM °C
68.2

Sequence 5' to 3'
GTC AGT GGG GAG GGA TCC TGG ACA CCT TGG TTT CAA C
GGC CGC GAA CCA TGG CGG CGG
GAC GAC GAC AAG ATG GCA CCG CAG AAG TGC TTC TTA CAG
GAG GAG AAG CCC GGT CTA CTG GGC CAG GGA AGC ATG AAA G
CTG GAT GAC CTC TGG GTC ATG CTT GAT CTC TGC C
CCA CGC GAC CCT CAA TAA GGT TCT CAC CAC CGG TAC CCA
GAT C
GCT GGT GGC CAC GCG ACC GAA ATA AAG GTT CTC ACC ACC
CTG TGC TGG TGG CCA CGC CCT GGA AAT AAA GGT TCT CAC
GGC AGA GAT CAA GCA TGA CCC AGA GGT CAT CCA G
GAT CTG GGT ACC GGT GGT GAG AAC CTT ATT GAG GGT CGC
GTGG
GGT GGT GAG AAC CTT TAT TTC GGT CGC GTG GCC ACC AGC
GTG AGA ACC TTT ATT TCC AGG GCG TGG CCA CCA GCA CAG
GACGACGACAAGATGGTGGCCACCAGCACAGTCAGGATCTTGGGC
GGTATTGAGGGTCGCGTGGCCACCAGCACAGTCAGGATCTTGGGC
GGT ATT GAG GGT CGC GAG AAC CTT TAT TTC CAG GGC
GAGGAGAAGCCCGGTTCACTGGGCCAGGGAAGCATGAAAGCCAA
TTTCC
AGAGGAGAGTTAGAGCCTCACTGGGCCAGGGAAGCATGAAAGCC
AATTTCC
GGT ATT GAG GGT CGC ATG GCA CCG CAG AAG TGC TTC TTA
CAG
AGA GGA GAG TTA GAG CCC TAC TGG GCC AGG GAA GCA TGA
AAG

Table 2.5 Secondary primers.
bp

% GC

TM °C

pET32XaLICWD 1 -6 Fix Deletion

Primer

27

62.9

66.5

CTG AGA CCT TGG GGC ACC AAG GAA GCC

Sequence 5' to 3'

GC - pET32XaLICWD 1 -6 Fix Deletion

27

62.9

66.5

GGC TTC CTT GGT GCC CCA AGG TCT CAG

Fix GtoE at base 519

37

48.6

64.3

GGT CCG GAA ACT GCA AGA AGT AGT GAG AGT CAA AGT C

G C - F i x GtoE at base 519

37

48.6

64.3

GAC TTT GAC TCT CAC TAC TTC TTG CAG TTT CCG GAC C

Fix Insertion WD 1-6

33

60.6

68.3

GTC ATG GAG GAC TAC GCA GGC TCC GAT GGC AAC

GC - Fix Insertion WD 1-6

33

60.6

68.3

GTT GCC ATC GGA GCC TGC GTA GTC CTC CAT GAC

Fix AtoT at 395 (6709)

38

52.6

67.5

GCA AAT ATC GGT GTC TTT GGC CGA AGG GAC TGC AAC AG

Fix 2 MIS at 468,9 (6930)

37

64.8

72.3

CAC TGG GAG GCT CCC TGC AAA CCA TGC CCC GGA CAT C

Fix GtoD at 496 (7013)

35

48.5

64.3

GCT TCT TAC AGA TCA AAG GCA TGA CCT GTG CAT CC

GC - Fix AtoT at 395 (6709)

38

52.6

67.5

CTG TTG CAG TCC CTT CGG CCA AAG ACA CCG ATA TTT GC

GC - Fix 2 MIS at 468,9 (6930)

37

64.8

72.3

GAT GTC CGG GGC ATG GTT TGC AGG GAG CCT CCC AGT G

GC - Fix GtoD at 496 (7013)

35

48.5

64.3

GGA TGC ACA GGT CAT GCC TTT GAT CTG TAA GAA GC

Fix D to G ( M l ) at base 6626

37

56.7

69.1

CTC TGA TTG CCA TTG CCG GCA TGA CCT GTG CAT CCT G

Fix G to E at base 6035

37

51.3

65.4

GGT CCG GAA ACT GCA AGG AGT AGT GAG AGT CAA AGT C

GC - Fix D to G (Ml) at base 6

37

56.7

69.1

CAG GAT GCA CAG GTC ATG CCG GCA ATG GCA ATC AGA G

GC - Fix G to E at base 6035

37

51.3

65.4

GAC TTT GAC TCT CAC TAC TCC TTG CAG TTT CCG GAC C

FIX D to G (DEC 1506)

37

54.0

67.4

CTC TGA TTG CCA TTG CCG GTA TGA CCT GTG CAT CCT G

FIX G to E (DEC 1506)

37

54.0

66.9

GGT CCG GAA ACT GCA AGG AGT GGT GAG AGT CAA AGT C

GC - FIX D to G (DEC 1506)

37

54.0

67.4

CAG GAT GCA CAG GTC ATA CCG GCA ATG GCA ATC AGA G

GC - FIX G to E (DEC 1506)

37

54.0

66.9

GAC TTT GAC TCT CAC CAC TCC TTG CAG TTT CCG GAC C

Fix G to R (AA#339)

39

53.8

67.0

GGG AGT GGG ACA GAT CAC AGG TCT TCC AGT TCT CAT TCC

GC - Fix G to R (AA#339)

39

53.8

67.0

GGA ATG AGA ACT GGA AGA CCT GTG ATC TGT CCC ACT CCC

Table 2.6 Plasmid vectors.
Vector

Source

Characteristics

pET24d

Novagen

Non-fusion expression

pET32Xa/LIC

Novagen

Thioredoxin tag

pET41Ek/LIC

Novagen

Glutathione S-Transferase tag

2.4

Instrumentation
The amplification of genes and mutagenesis was performed with a Minicyler

(Model PTC-150) thermocycler, MJ Research, Inc. (Watertown, MA). Plated cells were
grown at 37°C in a gravity convection incubator, Precision 4L (Thermo Fisher Scientific,
Waltham, MA). The agarose electrophoresis was done with a Fisher Biotech
electrophoresis system, FB-SB-7120. For the culture growth, small scale growth (less
than 2 liters) was carried out in a Controlled Environment Incubator Shaker, New
Brunswick Scientific. All large scale production of protein (10 L) was done either by
using a BioFlo310® Fermentor/bioreactor (Figure 2.2) or Microferm Fermentor (New
Brunswick Scientific).
The concentrations of protein and DNA samples were spectroscopically measured
using a UV/VIS Beckman Diode Array

Spectrophotometer, DU-7400. Protein

concentration was determined by BCA assay (Pierce, Rockford, IL) and Bio-Rad protein
assay using a Benchmarker microplate reader (Bio-Rad, Hercules, CA). The protein
purification and gel filtration experiments were done with an Amersham AKTA FPLC
(product code 18-1900-26) system in an Isotemp laboratory refrigerator at 4°C (Fisher
Scientific). The list and nature of the columns that were used are shown in Figure 2.1 and
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listed in Table 2.7. Several centrifugation instruments were available; for small samples,
Eppendorf 5415 and Eppendorf Minispin (Germany) Plus centrifuges were used, while a
Sorvall RC 5B plus high speed centrifuge was used for large samples.

Figure 2.1 Purification columns for AKTA FPLC system (GE Life Sciences).

Table 2.7 Columns for protein purification and analysis (GE Life Sciences).
Column Name

Product Code

Matrix/Size

Function

DEAE Sepharose

XK 26

DEAE Sepharose FF

Cation exchange

GSTprepFF 16/10

28-9365-50

Glutathione sepharose

GST purification

HisPrep FF 16/10

28-9365-51

Nickel Sepharose

His-tag purification

HiPrep 26/10 Desalt

17-5087-01

Superdex G-25 superfine

Buffer exchange

HiLoad 26/60 Superdex 75 pg

17-1070-01

Superdex 75 prep grade

Gel filtration

HiLoad 16/60 Superdex 200 pg

17-1069-01

Superdex 200 prep grade

Gel filtration

Superdex 75HR 10/300

17-1047-01

Superdex 75, 13^M

Gel filtration

Superdex 200 10/300 GL

17-5175-01

Superdex 200, 13 nM

Gel filtration
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Figure 2.2 Bioflo®310 fermentor/bioreactor (New Brunswick Scientific).

2.5

2.5.1

Procedures

Cloning, Expression, and Purification of the N-Terminal Domains (WD1-6)
The N-terminal metal binding domains construct with a molecular weight of 61.3

kDa, includes the amino acid residues 57-633 of Wilson protein (Figure 2.3). Due to its
large size, expressing WD 1-6 as a fusion protein was most desirable. This is because
fusion tagged proteins tend to display increased cytoplasmic solubility and also simplify
the purification process [1]. The unwanted tagged protein can be easily cleaved with an
appropriate protease. To clone WD1-6, two plasmid vectors, pET41Ek/LIC and
pET32Xa/LIC that encode fusion tag proteins Glutathione S-Transferase (GST) and
Thioredoxin (TRX), respectively, were chosen. The "Ek" stands for the Enterokinase
cleavage site, -AspAspAspAspLys- while "Xa" designates the Factor Xa cleavage site, IleGluGlyArg- [2].

The cleavage sites are positioned such that all vector encoded
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sequences are cleaved from the target protein after digestion with protease.
pET41Ek/LIC is a kanamycin resistance vector while pET32XaLIC is an ampicillin
resistance vector.
The LIC in the vector notation refers to Ligation Independent Cloning (Figure
2.5), a method that facilitates the directional cloning of PCR products without use of
restriction enzymes, digestion, or ligation reactions [3, 4]. LIC utilizes the 3'—>5'
exonuclease activity of T4 DNA polymerase to create a specific 12- or 15- base singlestranded overhangs in both the amplified DNA and cloning vector. The PCR primers are
designed

by

incorporating

appropriate

5'

sequences

to

generate

overhangs

complementary to the vector's LIC cloning site. The purified PCR product is then
incubated with T4 DNA polymerase to generate compatible overhangs in the presence of
the 'recognition' deoxynucleotide. When mixed together, the PCR product and LIC
vector anneal immediately before transformation into competent E.

coli cells.

Circularized plasmid in E. coli results from covalent bond formation at vector-insert
junctions by endogenous DNA ligase. Purified plasmid DNA is then transformed into
suitable E. coli hosts for protein expression after sequencing analysis (Protocol TBI84),
Novagen [5]. A schematic of the procedure from gene amplification to plasmid DNA
recovery and sequencing is presented in Figure 2.4. The WD 1-6 LIC primers were
designed according to the LIC kit user protocol. The presence of the amplified gene insert
was confirmed by 0.8% SDS-PAGE agarose gel; it was run alongside 100 base and 1
kilobase DNA ladders for 1.25 h at 80V. The gel was stained with a 0.5 |ig/mL ethidium
bromide solution for 20 min, rinsed 3X with distilled water, and DNA visualized using an
Image Master® VDS (Amersham).
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57
IVATSTVRILGMTCQSCVKSIEDRISNLKGIISMKVSLEQG

SATVKYVPSV

VCLQQVCHQIGDMGFEASIAEGKAASWPSRSLPAQEAVVKLRVEGMTCQS
CVSSIEGKVRKLQGVVRVKVSLSNQEAVITYQPYLIQPEDLRDHVNDMGFE
AAIKSKVAPLSLGPIDIERLQSTNPKRPLSSANQNFNNSETLGHQGSHVVTL
QLRIDGMHCKSCVLNIEENIGQLLGVQSIQVSLENKTAQVKYDPSCTSPVAL
QRAIEALPPGNFKVSLPDGAEGSGTDHRSSSSHSPGSPPRNQVQGTCSTTLIA
IAGMTCASCVHSIEGMISQLEGVQQISVSLAEGTATVLYNPAVISPEELRAAI
EDMGFEASVVSESCSTNPLGNHSAGNSMVQTTDGTPTSLQEVAPHTGRLPA
NHAPDILAKSPQSTRAVAPQKCFLQIKGMTCASCVSNIERNLQKEAGVLSV
LVALMAGKAEIKQDPEVIQPLEIAQFIQDLGFEAAVMEDYAGSDGNIELTIT
GMTCASCVHNIESKLTRTNGITYASVALATSKALVKFDPEIIGPRDIIKIIEEI
G FHASLAQ 633

KEY:

Yellow - GMH/TCXXCV motif
Red - Copper binding site cysteines
2 - Glycine is added after thioredoxin tag cleavage with TEV protease.
Q- Tyrosine 532, Y532H mutation site

Figure 2.3 The amino acid sequence of WD1-6.
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The PCR product was purified with a Qiagen MiniElute PCR purification kit but the
process was not sufficient to remove residual deoxyribonucleotides that interfere with T4
DNA polymerase activity. The PCR product was further purified using a gel extraction
protocol (QIAquick Gel Extraction Kit). Quantification of the purified PCR product was
performed either by agarose gel estimation or UV absorbance measurements, depending
on the yield. The treatment of PCR product or the WD 1-6 insert with T4 DNA
polymerase to generate compatible overhangs was done according to the pET32XaLIC or
pET41 EkLIC kit instruction (Novagen). This was followed by the insert gene annealing
to the vector and transformation into Novablue Gigasingles™ competent cells (Novagen).
In most cases, the competent cell transformation followed a standard method; 10 to 20
nanograms of plasmid DNA were transformed for 5-10 min in pre-chilled competent
cells. The cells were placed on ice for 5 min with Novablue Gigasingles™ or 30 min for
other phenotypes and heat-shocked at 42°C for 15-60 sec depending on the volume of the
cells in the tube. Then, they were again pre-chilled on ice for another 2 min before adding
warm, sterilized Luria Bertani (LB) media or Super Optimal Growth (SOC) media [6, 7].
The transformed competent cells were either plated immediately in the case of
Novablue Gigasingles™ cells or the other cell phenotypes were placed in an incubator
shaking at 250 rpm set at 37°C for 1 h to recover. The cells were then plated on LB/agar
media containing antibiotics, either kanamycin (30 jj,g/mL) or ampicillin/carbenicillin
(100 |ig/mL). A secondary antibiotic in the agar media was added to screen the
transformed cells which carried genotypic resistance to that particular antibiotic. For
example, Rosetta(DE3) E. coli cells are resistant to chlorampenicol but Novablue
Gigasingles™ cells are not. The cells were incubated for 16 h at 37°C. The screening of
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Gene insert amplification.

1
Ligation of gene insert into a cloning vector (ligation
independent cloning).

1
Transformation of ligated plasmid into Gigasingles™ Novablue cells.

I
Transformed cells grown on LB/agar and appropriate antibiotic.

I
Colony screening: Single colonies inoculated in 5 mL of
LB/antibiotic, grown at 37°C, 250 rpm for 12-16 h and cells
harvested.

1
Plasmid DNA recovery: QIA prep Spin Miniprep kit (Qiagen).

1
Restriction mapping of purified plasmid DNA with BamH I and Bgl II.

I
DNA sequencing by primer extension method.

Figure 2.4 Schematic of steps from gene amplification to plasmid DNA
sequencing.
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Figure 2.5 Ligation independent cloning strategy into pET41 EkLIC vector.

colonies was done by inoculating 5 mL of LB media containing the appropriate antibiotic
with a single colony. The colonies were shaken for 12-16 h at 37°C and cells harvested
by centrifugation. Plasmid DNA from the cell pellet was recovered using a QiaPrep Spin
MiniPrep kit. It was quantified and analyzed by restriction mapping. The plasmids found
to contain the WD 1-6 gene insert were further sequenced by primer extension (Retrogen,
Inc., San Diego CA, and also by Dr. Todd Barkman, Biological Sciences, Western
Michigan University).
The WD1-6 purification summary is shown in Figure 2.6. WD1-6 protein was
first expressed by transforming either pET41Ek/WDl-6 or pET32Xa/WD 1 -6 plasmid
into Rosetta(DE3) competent cells. The transformation procedure was the same as
described in the above paragraph except that DMSO was added to certain competent cells
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Transformation of pET32Xa/WDl-6 plasmid into
Rosetta(DE3) expression cells.

i
Transformed cells grown on LB/agar and appropriate
antibiotic, single colonies inoculated in 5 mL LB/antibiotic.

1
After a 5 h growth at 37°C, 250 rpm, 5 mL cultures scaled up to 0.1-1 L
of LB/antibiotic culture, cells induced after OD6oonm=0.6 with 0.1-3 mM
IPTG. Cells induced at 28-30°C, 250 rpm and harvested after 4-6 h.

1

Protein extracted by freeze/thaw (4 rounds) and BugBuster®
reagent (simultaneously). Supernatant recovered.

I
Protein purified by Immobilized Metal Affinity Column (HisPrep
sepharose column). Protein purified further by gel filtration.

I
Cleavage of thioredoxin tag with Factor Xa or TEV protease.

I
Digested product is loaded onto HisPrep sepharose column, thioredoxin
tag binds, and WD 1-6 passes through.

I
Concentration of WD 1-6 flowthrough and gel
filtration of cleaved WD1-6.

Figure 2.6 The expression and purification summary of WD 1-6 protein using
pET32Xa/WD 1 -6 plasmid.
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to increase plasmid DNA permeation. The plated cells were incubated overnight at 37°C;
five colonies were inoculated in 5 mL LB culture containing the appropriate antibiotic
and grown in a 250 rpm shaking incubator set at 37°C for 5-6 h. The 5 mL culture was
either

induced with

a

final

concentration

of ImM

IPTG

(Isopropyl

P-D-l-

thiogalactopyranoside) or transferred to 100-500 mL LB media for further growth. The
cells grown in LB media greater than 5 mL were induced with IPTG after the optical
density at ODeoonm reached 0.5-0.6. The concentration of the sugar inducer, IPTG, was
varied to optimize expression. Protein induction was performed for 3-4 h and cells were
harvested by centrifugation at 8,000xg at 4°C for 15 min. The cell pellet was stored at 20°C when protein extraction was not started immediately. The expressed fusion protein,
TRXxaWDl-6 (derived from pET32XaLIC vector) or GST EK WD1-6 (derived from
pET41 EkLIC vector) possessed a six poly-histidine tag, (-HHHHHH-) that was utilized
in the purification protocol. To isolate the TRXx a WDl-6 fusion, the frozen cell pellet
was thawed in a 50 mL falcon tube (for a freshly harvested sample, this was disregarded)
and resuspended with 5 mL of BugBuster® protein extraction reagent per gram of pellet.
The BugBuster® protein extraction reagent buffer releases soluble proteins by breaking
and lysing the bacterial cell wall. The high viscosity due to DNA and RNA release was
lowered by adding 20 KU/mL of Benzonase (Novagen) enzyme. Supernatant containing
soluble proteins was separated from cell debris by spinning for 15 min at 16,000xg. The
supernatant was decanted or pipetted into a clean 50 mL falcon tube ready to load on a
purification column.
The HisPrep FF 16/10 is a nickel chelating sepharose column with high affinity
for poly-histidine tagged proteins. The AKTA FPLC was connected to this column,
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cleaned with 10 column volumes (CV) of water, and subsequently equilibrated with 10
CV of HisPrep binding buffer (20 mM sodium phosphate buffer, pH 7.4, 500 mM NaCl,
20 mM imidazole). The supernatant containing TRXx a WDl-6 and other proteins from
the cell was loaded onto the column at a 1 mL/min flow rate. The size of supernatant that
was loaded was always less or equal to 15 mL (3/4 CV). This step was followed by
washing the column with HisPrep binding buffer until the UV absorbance returned to the
range of baseline. The tagged bound protein was eluted either isocratically or by a
gradient from the column with elution buffer (20 mM sodium phosphate buffer, pH 7.4,
500 mM NaCl, 500 mM imidazole). The phosphate elution buffer was later substituted
with 50 mM HEPES, pH 7.5, 500 mM NaCl, 300 mM imidazole, as this was found to
stabilize the pure protein. Before elution with HEPES buffer, about 3 CV of 30 mM
imidazole in HEPES buffer was passed through the protein-bound column to remove
residual phosphate buffer. Protein fractions were characterized by SDS-PAGE and UV.
The protein fractions containing WD 1-6 were pooled together and concentrated with an
Amicon device with a 10,000 molecular weight cut-off membrane (Cat. 13622,
Millipore). If the protein was pure, it was prepared for fusion protein cleavage; otherwise,
the protein was subjected to gel filtration. To remove the TRX and His-tags from WD16, the purified protein was exchanged into Factor Xa or TEV buffer using a bench top
PD-10 desalting column or the AKTA FPLC connected to the HiPrep 26/10 Desalt
column. To determine the correct amount of Factor Xa, the purified protein was first
quantified by the BCA protein assay. The buffer conditions for Factor Xa digestion were
50 mM Tris/Cl, pH 8.0, 100 mM NaCl, 5 mM CaCl2 and for the Tobacco Etch Virus
(TEV), 50 mM Tris/Cl, pH 8.0, 1 mM DTT, 0.5 mM EDTA. After the addition of Factor
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Xa, cleavage mixture was incubated at room temperature for 16 h. TRX X a WDl-6
cleavage with Factor Xa never went beyond trial experiments; therefore, quantifying the
amount of Factor Xa needed was not done. The cleavage reaction was stopped with
protease inhibitors, 4 mM Pefabloc SC PLUS (Roche); PMSF, PhenylMethylSulphonyl
Fluoride (Sigma-Aldrich).
The cleaved protein was first exchanged into HisPrep binding buffer before
loading onto a smaller HisPrep chelating column (CV = 1 or 5 mL) at a 0.2 mL/min flow
rate using a peristaltic pump, and the flowthrough fractions that

contained WD 1-6

protein were collected. TRX or GST protein bearing the His-tag after cleavage was left
bound on the column while WD1-6 protein passed through. The WD1-6 flowthrough
was concentrated and purified further by gel filtration (Superdex 75 or 200 Sepharose
columns). The purity was determined by SDS-PAGE and the yield quantified by BCA
(bicinchoninic acid) protein assay [8] (Pierce, Rockford, IL).
The cleavage of WD 1-6 protein with Factor Xa was found to be inefficient and
accompanied by protein degradation. The Bertini group at the Center for Magnetic
Resonance, Florence, Italy had produced a WD1-6 construct containing residues 1-633
of WNDP incorporating the protease Tobacco Etch Virus (TEV) cleavage site [9].
Gateway technology (Invitrogen) was utilized to incorporate TEV cleavage site, GluAsnLeuTryPheGlnGlv- [10-12]. In this thesis, a method is described to incorporate
the TEV cleavage site directly into pET32Xa/WDl-6 as illustrated in Figure 2.7. This
was achieved by substituting all the amino acids of the Factor Xa protease site and
another 3 amino acids upstream of the site with TEV cleavage site in a three step
mutagenesis reaction involving three sets of primers: TEV PI, TEV PII, TEV PIII and
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their complementary primers (Table 2.3). The resulting plasmid construct, named
pET32TEV/WDl-6 was sequenced to confirm the incorporation of TEV cleavage site.
It was not known how the introduction of new amino acids (TEV cleavage site) would
affect the protein expression and stability. To maintain the pET32XaLIC vector
sequence, a new WDlXaTEVLIC forward primer (Table 2.3) beginning with TEV
cleavage site instead of Domain 1 of the Wilson protein was designed. Using
pET32TEV/WD 1-6 plasmid as the DNA template, the WD1-6 gene insert from the TEV
cleavage site was amplified with KOD HiFidelity Hot Start DNA polymerase. The insert
was then ligated into the pET32XaLIC Vector by LIC. This resulting plasmid was named
pET32XaTEV/WDl-6 and contained both Factor Xa and TEV cleavage sites (Figure
2.7). The plasmid was sequenced and transformed, and the protein expressed and purified
as described in Figure 2.6. Purified WD 1-6 was stored at -80°C either with protease
inhibitors added or stabilizing agents such as glycerol. Various modifications and
changes in procedures are also discussed under results and discussion in Chapter 3.

2.5.2

Cloning and Purification of WD 5-6, ATOX1 and WD 5-6(Y532H)
The structural and functional properties of the isolated WD5-6 of human Wilson

protein had been studied by members of our lab [13]. The gene inserts encoding WD5-6
and ATOX1 proteins had been previously sub-cloned by the restriction enzyme cleavage
and ligation method into pET24d+ and pETlld (Novagen), respectively. Purification of
WD5-6 and ATOX1 followed established protocols [13]. Mutagenic primers, K D Y532H Fwd and GC KD-Y532H Rev (Table 2.3), coding for substitution of tyrosine
with histidine were used to incorporate the Y532H mutation into the native WD5-6 gene.
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Figure 2.7 The T E V cleavage site's insertion into the p E T 3 2 X a / W D l - 6 plasmid.
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Site-directed mutagenesis (Stratagene) was performed using the manufacturer's
instructions. Subsequent expression studies under typical conditions resulted in high level
expression of WD5-6(Y532H) mutant protein as inclusion bodies (insoluble aggregate).
Therefore, the WD5-6(Y532H) mutant was cloned into a fusion vector. The WD5-6
gene with Y532H mutation was amplified with mutagenic primers for subsequent cloning
into pET32Xa/LIC vector using LIC (Section 2.5.1). The gene insert coding for WD5-6
and WD5-6(Y532H) mutant contains 148 amino acids, residues 485-633 of WNDP. The
sub cloned plasmids were transformed into E. coli Rosetta(DE3) cells (Novagen) for
protein expression.

2.5.2.1

Protein Expression
The cells were grown in the presence of kanamycin (30 jxg/mL) for the

pET24d/WD5-6

plasmid

and

ampicillin/carbenicillin

(100

(ig/mL)

for

the

pET32Xa/WD5-6(Y532H) and pETlld/ATOXl plasmids. Protein expression was
induced with 0.5-1 mM IPTG (final concentration). For WD5-6 protein isolation, the
cells were harvested after 4 h of induction. The protein was extracted into 20 mM
MES/Na, 0.1 mM EDTA, 1 mM DTT, pH 6.0 buffer by four rounds of freezing and
thawing in liquid nitrogen. The supernatant was applied to a DEAE-Sepharose
(Diethylaminoethyl cellulose) cation exchange column. The non-binding proteins were
stripped from the column with 20 mM MES/Na, pH 6.0, 0.1 mM EDTA, and 10 mM
DTT (low salt buffer). Elution was performed by a NaCl gradient; WD5-6 eluted at
-0.16 M NaCl. The protein containing fractions were identified by SDS-PAGE and
concentrated by an Amicon device fitted with 3,000 molecular cut-off membrane (Cat.

80

PLBC02510, Millipore) to 2-3 mL. The concentrate was then loaded on a HiLoad 26/60
Superdex 75 column (Table 2.7) and eluted with 20 mM MES/Na, pH 6.0, and 150 mM
NaCl, and 10 mM DTT.

2.5.2.2

Inclusion Body Extraction
For isolation of WD5-6(Y532H) mutant protein (Figure 2.8), TRX Xa WD5-

6(Y532H) fusion protein was extracted from the cell pellet using the 5-10 mL
BugBuster® protein extraction reagent per gram of cell pellet. Using this method, very
little soluble protein was recovered due to inclusion body formation. To increase the
yield, the inclusion bodies were processed according to BugBuster® protein extraction
reagent user protocol for inclusion bodies (Novagen). The pellet obtained from the initial
extraction was resuspended again in the same amount of BugBuster® reagent used in that
first initial step and resuspended to form a uniform mixture. Recombinant lysozyme
(Novagen) or chicken lysozyme (Sigma-Aldrich) was added to a final concentration of
lKU/mL and incubated for 5 min at room temperature. Then, two vol of BugBuster®
reagent (1 vol equals the amount of BugBuster® reagent added in the initial protein
extraction step) was added. The resuspension was mixed by mild vortexing for 1 min, and
inclusion bodies were recovered by centrifugation at 5,000xg for 15 min at 4°C. The
inclusion bodies were resuspended in 2 vol BugBuster® reagent, mixed by vortexing and
inclusion bodies were again obtained by centrifugation. This step was repeated twice. The
inclusion bodies were finally resuspended in 1 vol of BugBuster® reagent then
centrifuged at 16,000xg for 15 min at 4°C.
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2.5.2.3 Mutant Protein Refolding Procedure
The inclusion bodies so obtained were solubilized in a 50 mL polycarbonate tube
(Nalgene) with 6 M GnHCl in HisPrep binding buffer, gently mixed in an ice bath, and a
supernatant was obtained by centrifugation at 16,000xg for 30 min at 4°C. The
supernatant containing denatured fusion protein was slowly loaded onto HisPrep FF
16/10 column. The protein was refolded in situ by washing off GnHCl with 10 CV of
HisPrep binding buffer (20 mM Phosphate, pH 7.4, 500 mM NaCl, and 20 mM
imidazole). The elution was performed isocratically with 5 CV of 500 mM imidazole in
HisPrep binding buffer.

2.5.2.4 Thioredoxin Fusion Protein Cleavage
The protein fractions were verified by SDS-PAGE, concentrated, and exchanged
into Factor Xa cleavage buffer (50 mM Tris/Cl, pH 8.0, 100 mM NaCl, 5mM CaCl2)
using a PD-10 column (GE). The protein was cleaved at 37°C for 16 h by adding 0.5
U/mg of Bovine Factor Xa. Time-course cleavage products were analyzed by SDSPAGE. A significant percentage of the fusion protein precipitated out during and after
buffer exchange, requiring centrifugation to remove the insoluble debris. After
completion of digestion, Factor Xa activity was quenched by addition of a serine protease
inhibitor (4 mM Pefabloc SC PLUS), or, alternately, the protease was captured by Xarrest
agarose matrix (Novagen).
To separate thioredoxin from mutant WD5-6(Y532H), the cleavage product
was passed through a 5 mL nickel chelating HisPrep column using a small peristaltic
pump (Pump P-l, GE). The flowthrough containing cleaved WD5-6(Y532H) was
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concentrated to about 2-3 mL before loading onto the HiLoad 26/60 Superdex 75 column.
The protein was eluted with 20 mM MES/Na, pH 6.0, 150 mM NaCl, 10 mM DTT, at a
flow rate of 2.6 mL/min and a 5.2 mL fraction size. Fractions that contained pure protein,
as determined by SDS-PAGE analysis, were combined, concentrated to a total volume of
3 mL, and protease inhibitors added before storage.

2.5.2.5

Modifications of WD5-6(Y532H) Protein Expression and Purification
The purified refolded WD5-6(Y532H) mutant was found to be unstable and

readily degraded to a product of two protein fragments within a week or so. To overcome
this challenge, the purification procedure for WD5-6(Y532H) was modified in the
following way (Figure 2.8). The pET24d/WD5-6(Y532H) plasmid containing a nonfusion WD5-6(Y532H) mutant gene was transformed into Rosetta(DE3) cells according
to established protocols.

Freshly grown colonies from prepared kanamycin LB/agar

plates were inoculated into 5 mL LB and grown for 4-5 h at 250 rpm at 37°C. Each of
the 5 mL aliquots were transferred to a 100 mL LB containing 30 ng/mL of kanamycin
and grown for one hour before transferring to 1 L of LB. The 1 L cultures were grown
until the cell optical density at ODeoonm reached 0.5-0.6. Two 1-L flasks placed in an
incubator at 37°C were induced with different amounts of IPTG, 1 mM and 3 mM. After
30 min, the flask induced with 3 mM IPTG was placed in a water bath at 28-30°C, and
shaken at 200 rpm while the other flask (with ImM IPTG) remained in the shaking
incubator with the temperature lowered to 30°C. The cells were harvested after 5 h and
pellets stored at -80°C.
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The extraction of WD5-6(Y532H) protein was initiated by slow thawing of the
frozen cell pellet. Then, five rounds of freezing and thawing in liquid nitrogen were
performed. A freeze-thaw buffer (20 mM MES/Na, pH 6.0, 1 mM EDTA, 10 mM DTT)
was added in the third round. The pellet was resuspended in freeze-thaw buffer (10 mL/g
pellet), then benzonase (25 U/mL) and Pefabloc SC PLUS protease inhibitor (1 mM)
were added. The resuspension was incubated on an orbital shaker (Bellco Biotech,
Vineland, NJ) for 15 min at room temperature and 80 rpm while waiting for the viscosity
to decrease. The cell resuspension was then placed into ice cold water and sonicated (F50
Sonicator Dismembrator, Fisher Scientific) for 10 sec, 10 times at 30 sec time interval
(pulse 12). The supernatant (called S) was obtained by centrifugation at 16,000xg, and
4°C for 30 min.
The DEAE Sepharose column (CV = 60 mL) was prepared before use by
stripping unwanted protein with 4 CV of 1M NaCl, rinsing with 5 CV of water, and
equilibrating with 5 CV of low salt buffer (20 mM MES/Na, pH 6.0, 0.1 mM EDTA, 10
mM DTT). The supernatant was directly applied to the column at 1 mL/min and all
unbound protein was eluted with low salt buffer. The WD5-6(Y532H) protein was eluted
by a 1M NaCl gradient. The fractions containing WD5-6(Y532H) were pooled and
concentrated. The protein was further purified by size exclusion chromatography using
the HiLoad 16/60 Superdex 200 column. The Superdex column was cleaned with filtered
milli-Q water and equilibrated with elution buffer, 50 mM HEPES, pH 7.5, 200 mM
NaCl, and 1% glycerol. The protein was eluted at 2 mL/min for the first 20 mL of elution,
and then the flow rate was reduced to 1 mL/min for the rest of the elution. Eluted protein
was recovered in 2 mL fractions.
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The fractions containing the pure WD5-6(Y532H) were identified by both SDSPAGE analysis and UV absorbance analysis. The protein was concentrated with an
Amicon device equipped with a 3,000 molecular weight cut-off filter. The concentrate
was stored at -80°C.

Protein expression at
28 -30°C

/

Factor Xa cleavage

Protein extraction:
BugBusterx reagent

Protein extraction:
Freeze thaw method

Insoluble protein
processing/solubilization

Sonication

I

Cation exchange column

Immobilzed metal affinity
purification (poly -histkline tag)

I

I
Gel filtration

In situ refolding

I
(lei filtration

I

WD5-6(Y532H) from
optimized conditions

WD5-6(Y532H) by
refolding/Factor Xa
method
Figure 2.8 Recovery of WD5-6(Y532H) protein using two different routes.

2.5.3

Tobacco Etch Virus (TEV) Protease Purification
TEV protease cleaves protein with high specificity and efficiency, targeting a 7

amino acid cleavage site (Section 2.5.1). The purification of TEV protease was done
entirely in our laboratory, except for a small quantity obtained from Invitrogen for
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standardization purposes. The TEV-encoding plasmid was kindly supplied by Dr. Tim
Cross at Florida State University. The TEV plasmid was transformed into BL21(DE3) E.
coli cells (Novagen) according to previously described protocol. The cells were grown on
LB/agar containing 100 (ig/mL carbenicillin. Three to five colonies were inoculated in 5
mL of LB culture containing 100 |ig/mL carbenicillin and grown in a 250 rpm shaking
incubator at 37°C for 5 h. One of the culture tubes was transferred to 100 mL LB media,
grown for one hour, transferred to 1000 mL of LB with antibiotic added, and grown until
the ODeoonm reached 0.5-0.6. The TEV induction Was initiated by adding ImM IPTG final
concentration and the media was transferred to a water bath shaker at 25°C. The
induction proceeded for 4-6 h (Figure 2.9). Cells were harvested by centrifugation and
resuspended in 20 mM Tris/Cl, pH 7.9, 500 mM NaCl, 5 mM imidazole buffer, before
storage at -20°C.
To purify the TEV protease bearing a poly-histidine tag (Figure 2.10), the frozen
cells were thawed slowly. The cell pellet underwent four rounds of freezing and thawing
in liquid nitrogen. Afterwards, benzonase (25 U/mL) was added to reduce viscosity. The
cells were sonicated (F50 Sonicator Dismembrator, Fisher Scientific) 7 times for 10 sec
at 30 sec interval (Pulse 12) while placed on ice cold water before centrifuging at
16,000xg for 15 min to recover the supernatant. The supernatant was loaded onto a nickel
chelating HisPrep column equilibrated with Tris/Cl HisPrep binding buffer (20 mM
Tris/Cl, pH 7.9, 500 mM NaCl, 30 mM imidazole), which was used to remove the
unbound protein contaminants. The TEV protease was eluted with 20 mM Tris/Cl, pH
7.9, 500 mM NaCl, and 300 mM imidazole. The protein was concentrated to
approximately 5 mL; half of this concentrate was exchanged into TEV cleavage buffer
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(50 mM Tris/Cl, pH 8.0, 0.5 mM EDTA, 1 mM DTT) before storing at -80°C in 50%
glycerol, 1 mM EDTA and 5 mM DTT. Although the intention of exchanging the buffer
was to remove imidazole, it was found not to interfere with the TEV activity at 20-30 (J.M
levels. The time between TEV protease elution and storage was very critical because the
protein showed a tendency to precipitate out of solution with time.
The activity of the TEV protease was quantified using a known amount of
TRXxaTEvWDl-6 in a time-course digestion reaction since the activity of TEV varied
from batch to batch. During time-course digestion trials, samples were incubated up to 48
h with protein samples taken out periodically. The activity of purified TEV protease was
calculated as the amount in micromoles of the TRXxaTEvWDl-6 protein cleaved by one
micromole (|imole) of TEV in 16 h at room temperature (25°C) in buffer conditions, 50
mM Tris/Cl, pH 8.0, 0.5 mM EDTA, and ImM DTT. The large scale cleavage reaction
was also set up in the same conditions. The TEV protease has an added advantage over
Factor Xa protease because of its high specificity [14]. The TEV protease, since it has a
poly-histidine tag, was removed together with the His-tagged thioredoxin from the
cleaved product, WD 1-6, with a nickel chelating HisPrep column.
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Figure 2.9 Time-course induction of TEV protease with a molecular weight of 29 kDa
indicated by the arrow.
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Figure 2.10 The TEV protease amino acid sequence. The poly-histidine tag residues are
in positions two to seven.
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2.6

2.6.1

Other Proteins of Importance to this Work

Cloning of COMMD1
The finding that COMMD1 also interacts with WNDP [15] cultivated interest in

conducting further experiments between this protein and the isolated WD 1-6
multidomains. The COMMD1 cDNA was acquired from ORIGENE Technologies,
Rockville, MD. Mutagenic primers bearing Bam I and Nco I restriction sites, COMMD1
BamH I Fwd and COMMD1 Nco I Rev (Table 2.3), respectively, were designed with
DNA Strider 1.3 software. The thermocycling conditions and the mixing of PCR
components were performed according to HotStar HiFidelity PCR handbook (Qiagen). In
a PCR tube, the COMMD1 gene template, primers, dNTPs mix, HotStar DNA
polymerase buffer and nuclease-free water were mixed and amplified with HotStar DNA
polymerase (Qiagen). The amplified DNA was visualized by agarose gel electrophoresis.
The COMMD1 amplified insert was purified by gel extraction and resuspended in water.
The ligation of the COMMD1 insert into pET24d vector was performed using the
Fast-Link™ DNA ligation kit (Epicenter Biotechnologies, Madison, WI). The pET24d
and COMMD1 insert were first digested with restriction enzymes BamH I and Nco I in
BamH I buffer and cleaned up using the gel extraction method. The reaction mixture was
incubated at room temperature for 5 min before transferring to 70°C for 15 min to
inactivate Fast-Link™ DNA ligase. Cooled ligated DNA was transformed into Novablue
Gigasingles™ cells and colonies were screened after growth on LB/agar and kanamycin
(30ng/mL). The resulting plasmid DNA from screened colonies was analyzed by
restriction enzyme mapping for the insert with BamH I and Nco I. The plasmid DNA
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containing the insert was sequenced at Retrogen, Inc., San Diego, CA. The
pET24d/COMMDl plasmid was then transformed into Rosetta(DE3) cells and protein
expression was induced with 1-5 mM IPTG (final concentration). The expression of
COMMD1 protein was not successful.

2.6.2

Cloning of G591D, a Wilson Disease-Causing Mutation
The WD5-6(G591D) mutant gene was subcloned into the pET41 EkLIC vector

resulting to pET41Ek/WD5-6(G591D) construct by Patrick Ochieng, a former student in
our lab. Due to the similarity of this construct and the WD5-6(Y532H) mutant, a study
comparing the two mutations was deemed valuable to this work. The protease
enterokinase was not able to cleave the GST fusion protein efficiently, rendering the
pET41Ek/WD5-6(G591D) construct undesirable. A new construct subcloned in a
pET32XaLIC vector was prepared utilizing the same methodology used for domains
WD 1-6 and WD5- 6(Y532H) plasmid vector constructs (Sections 2.5.1 and 2.5.2). The
resulting plasmid was transformed into Rosetta(DE3) cells, then grown on LB/agar
containing 30 |ig/mL kanamycin. The resulting colonies were inoculated in 5mL
medium, scaled up, and the protein induction was performed with 1 mM final IPTG
concentration. The expressed protein formed inclusion bodies; the purification and
processing followed the refolding procedure of WD5-6(Y532H) mutant protein (Section
2.5.2). Cleavage of thioredoxin from WD5- 6(G591D) mutant protein with Factor Xa
was not successful.
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2.7

2.7.1

Biophysical Characterization and Analysis

Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis
The SDS-PAGE method analysis relies entirely on the migratory behavior of

proteins in a polyacrylamide gel based on their molecular sizes. Both 15% and 10%
Tricine SDS resolving gels were prepared from a 30% Acrylamide (w/v), 0.8% Bisacrylamide (w/v) solution. The separating and stacking gels were prepared as described
in the molecular cloning laboratory manual [16]. The mixture was degassed for 10 min
under vacuum to remove air bubbles before adding ammonium persulfate and TEMED
(N,N,N',N'-tetramethylethylenediamine) to initiate cross-linking. The mixture was
poured into a 0.75 mm thickness gel pre-cast mold, and the top overlaid with watersaturated n-butanol to form a uniform and level surface for the stacking gel overlay. The
separating gel was left for 45-60 min to polymerize; the n-butanol was washed with
distilled water and the unit dried with pressurized air. The stacking gel comb was inserted
before pouring the degassed stacking gel solution [16] mixed with ammonium persulfate
and TEMED. It took 30-45 min for the stacking gel to fully polymerize. The gels were
then dismantled before the assembly of the electrophoresis apparatus (Mighty Small II,
SE250/SE260, Amersham).
Protein samples for gel electrophoresis were prepared by mixing 6X gel loading
buffer (300 mM Tris/Cl, 600 mM DTT, 12% SDS (w/v), 0.06% bromophenol blue (w/v),
60% glycerol (v/v)) with the appropriate protein solution and water to make a IX
solution, boiled at 92°C for 10 min for cell pellet samples and 3 min for pure proteins.
The cathodic buffer (0.5M Tris/Cl, pH 8.25, 0.5% SDS) was added in the separating gel
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chamber and anodic buffer (1M Tris/Cl, pH 8.9) in the outer chamber. Samples were
loaded alongside protein molecular standards; 5-15 p.L was loaded per well. The samples
were run at 95V for 1 hour and 15 min. The gels were incubated with staining solution
(53% water (v/v), 40% methanol (v/v), 7% glacial acetic acid (v/v) and 0.25% Coomasie
Brilliant Blue R-250 (w/v)) for 30 min on a table orbital shaker at 80 rpm or microwaved
(Model R-215EW, SHARP, Osaka, Japan) for 50 sec. The excess dye was destained by
the same solution without Coomasie blue. The gels were fixed and dried using the
cellophane MiniGel drying kit (Invitrogen).

2.7.2

Gel Filtration
Gel filtration elution of a protein is dependent on the sizes of both the matrix

pores and protein size [17]. Large proteins do not enter the matrix and therefore elute in
the void volume, V0, for they move at the same flow rate as the eluting buffer. Small
proteins, having full access to the pores, elute nearly at the end of one total column
volume, Vt.

In between these two extremes, proteins of different sizes are eluted

according to their elution volume, Ve, although elution of a sample is characterized best
by the distribution coefficient, Kd, which is defined as the fraction of the stationary phase
that is available for diffusion of a given molecular species. Though comparable to Kd, the
partition coffiecient, Kav is used for protein comparison and is calculated by Equation
2.1. Since Kav is related to the size of the protein, plotting the logarithm of molecular
weight against Kav of known protein standards gives a calibration curve that can used to
estimate the unknown molecular weight of a protein. Equation 2.1 works well for
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proteins of similar shape and conformation like globular proteins. This method is also an
excellent tool to study protein-protein dimerization.

V -V
v

t

v

o

The protein sample was first quantified by the BCA protein assay, and the
concentration calculated. The gel filtration analysis was done with an FLPC AKTA
system fitted with a Superdex 200 10/300 GL column (for WD 1-6) or Superdex 75HR
10/300 for (for WD5-6 and WD5-6(Y532H)) and equilibrated with several CV of 50
mM sodium phosphate, pH 7.5, 150 mM NaCl, 10 mM DTT. A 25 p.L sample of each the
protein standards with a concentration of 1-5 mg/mL was injected onto column via a loop
and eluted with the same buffer at 0.5 mL/min. The amount of protein used per run was
approximately 25-125 p.g. The void volume, V0, was determined with Blue dextran and
the elution volume, Ve, was the same as the column volume. The calibration curve was
obtained by a plot of logarithm of molecular weights of the protein standards against the
corresponding Kav.

2.7.3

Light Scattering
Light scattering works on the principle that a high intensity, monochromatic and

collimated laser light impending on solution sample will be scattered in a manner
dependent on the properties of the solute. Light scattering can be used to determine the
molar mass, Mw; radius of gyration, rg; second virial coefficient A2, and translational
diffusion coefficient D, of the solute in solution. Static light scattering (SLS) or time
averaged fluctuations in the intensity of scattered light due to molecular motions are used

to calculate Mw, rg and A2. The Rayleigh-Gans-Debye derived model equations are used
to compute these parameters [18].

Dynamic Light Scattering (DLS) measure the

fluctuations in the intensity of scattered light at the nanosec time scale [19].

The

scattered light intensity depends on the particle size (rg,- radius of gyration) and the
magnitude of the scattering wave vector q [20], Equation 2.2, where k is radiation
wavelength, 8 is scattering angle, and q is refractive index of the solvent.

[2.2]

The most important measurement obtained from a DLS measurement is the translational
diffusion coefficient, D (units of cm2/sec), which is related to the hydrodynamic radius
RH through the Stokes-Einstein equation, Equation 2.3, where k is the Boltzmann
constant, D the translational diffusion coefficient, T the temperature and r\ the solvent
viscosity.

D = kT/67ir|RH

[2.3]

DLS-like gel filtration is also used to determine the unknown molar mass of a protein
when calibrated with protein standards of known molecular weights [21].
The Light Scattering experiments were done at the Keck Foundation
Biotechnology Resource Laboratory at Yale University. The light scattering data was
collected using a Superdex 200 (for WD 1-6) or 75 ( for WD5-6 and WD5-6(Y532H))
10/300, HR Size Exclusion Chromatography (SEC) column (GE Healthcare), connected
to an Agilent 1200 HPLC, (Agilent Technologies, Wilmington, DE) equipped with an
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autosampler. The elution from SEC was monitored by a photodiode array (PDA) UV/VIS
detector (Agilent Technologies), differential refractometer (RI) (optilab Wyatt Corp.,
Santa Barbara, CA), and a static and dynamic, multi-angle, laser light scattering (LS)
detector (HELEOS II with QELS capability, Wyatt Corp., Santa Barbara, CA). The SECUV/LS/RI system was equilibrated with 20 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM DTT buffer at the flow rate of 1 mL/min (WD 1-6) or 0.5 mL/min (WD5-6
and WD5-6 (Y532H)). Two software packages were used for data collection and
analysis: Chemstation software (Agilent Technologies, Wilmington, DE) controlled the
HPLC operation and data collection from the multi-wavelength UV/VIS detector, while
the ASTRA software (Wyatt Corp., Santa Barbara, CA) collected the data from the RI
detector, the LS detectors, and recorded the UV trace at 280 nm sent to the PDA detector.
The weight average molecular masses, Mw, were determined across the entire elution
profile in the intervals of 1 sec from static LS measurement using ASTRA software as
previously described [22]. The Hydrodynamic radii, RH, were calculated from "on-line"
dynamic LS measurements taken every 2 sec. The dynamic light scattering signal was
analyzed by the methods of cumulants [23].

2.7.4

Circular Dichroism
Circular dichroism (CD) spectroscopy utilizes the ability of the asymmetric chiral

active macromolecules to absorb circularly polarized light. CD is a useful tool for
characterization of secondary structure and unfolding properties of proteins and
polypeptides. The spectra of proteins in the far UV produce unique structural fingerprints
dependent on the geometry of the polypeptide backbone. This is because these spectra
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arise from JI-K* transitions of the amide bonds [24], For example, a-helical proteins have
spectra distinct from those of all P-sheet structures. Circularly polarized light is separated
into two vectors with equal strength with one rotating clockwise (ER) and the other
counterclockwise (EL). AS the asymmetric molecules interact with light, they absorb left
and right handed circular polarized light differently. The plane of the light is therefore
rotated and the summation of ER and El produce a single vector that is ellipsoid giving
the light a property of being elliptically polarized. The CD is thus reported in degrees
ellipticity or the difference in the absorbance of the ER and EL by the asymmetric
molecule [25].
The raw data from CD spectra in millidegrees was converted into mean residue
ellipticity, [0] (deg-cm2-decimol"1), by Equation 2.4 [26] with the parameters 0,
millidegrees; Mw, molecular weight of the protein in Dalton; c, protein concentration in
mg/ml; 1, cell pathlength in cm; NA, number of amino acid residues of the protein.

[e] = (exl00xMw)/(cxlxNA)

[2.4]

The protein samples for CD spectra measurements were purified by gel filtration
chromatography followed by exchange into 50 mM Na phosphate, pH 7.5. The protein
concentration was determined by the BCA assay (Pierce). Urea and GnHCl stock
solutions of 8 M were prepared. To accurately prepare these 8 M GnHCl stock solution,
the mass of the tube was predetermined or tared over weighing balance and refractive
index used to validate concentration. The salt was weighed into the tube and 50 mM Na
phosphate buffer added until the desired 50 mL volume was reached.
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CD spectra were acquired with a JASCO J-815 CD Spectropolarimeter. Before
acquisition, the 0.1 cm path-length cell was cleaned and rinsed with buffer. The protein
samples for measurement were prepared in two final concentrations, 14.5 p.M and 29 ^M,
depending on the pretrial CD run. The protein unfolding studies were done by preparing
samples of the same concentration but with GnHCl added to 1 to 6 M final
concentrations. The protein samples were incubated for at least an hour to equilibrate
before acquiring data. The samples were passed through a Millex®-GV 0.22 (xm filter
unit (SLGV004SL, Millipore) prior to CD spectral analysis. The CD measurements were
carried out with a 0.1 cm path-length rectangular cell. The thickness of the cell can be
obtained by measuring the transmittance of the empty cell with air as the reference. An
interference pattern is produced when transmitted radiation interact with radiation
reflected off from the two windows of the cell. The thickness t of the cell in centimeters
is obtained from the Equation 2.5, where, t is the cell thickness in centimeters and N, the
number of peaks between two wave numbers, oj and 02.

[2.5]

The cell was pre-rinsed with sample solution and filled to -300 fxL with the same sample.
The baseline or the control was the buffer without the protein. Water blanks were also
measured. The CD Spectropolarimeter, purged with nitrogen gas at 15 PSI per min was
turned on and allowed to warm up for 15 min. The scan rate was 50 nm/min and an
average of three runs was recorded for each sample. Temperature was controlled by a
single position Peltier Thermostated Cell holder, JASCO model PTC-423, cooled with a
small water pump.

The acquired data was computed, processed and tabulated using the instrument's
RIS Spectra manager software (JASCO). The secondary structure analysis was performed
with CDpro software (http://lamar.colostate.edu/~sreeram/CDPro/main.html) [27-30].
The protein unfolding analysis was based on established phenomena in which denaturants
alter the equilibrium between the native (folded) and denatured (unfolded) states of
protein [31-34]. The Gibbs free energy of unfolding was calculated by the Linear
Extrapolation Method [35], starting with by Equation 2.6, where, AG, Gibbs free energy;
R, the gas constant; In, natural logarithm; U, unfolded protein fraction; F, folded protein
fraction.

AG = - R T l n

v1 /

[2.6]

The relative concentrations of F and U were derived from CD spectra data, assuming the
protein was fully folded in the absence of denaturant. A two-state folding model was used
to determine the denatured protein fraction, Fj, using Equation 2.7, where, Y0bs is the
observed variable parameter, and Y„ and Yj are the values of Y characteristic of the
native and denatured protein [34].

Yn -Y,obs

Fd=- Y - Y
hd
n

[2.7]

The free energy of unfolding between the folded and unfolded state of the protein AG, is
calculated by Equation 2.8, where, T is the absolute temperature.
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AG = - R T l n

[2.8]

The least squares analysis method was used to obtain the free energy of unfolding,
AG H2 °, in the absence of denaturant. This value is related to free energy according to
Equation 2.9, where, AG, Gibbs free energy; m, measure of the dependence of AG on
denaturant concentration, [D], denaturant concentration.

[2.9]

2.7.5

Nuclear Magnetic Resonance Spectroscopy
The NMR technique is used for determination of protein structure and probing of

protein-protein interaction dynamics. Unlike X-ray crystallography, proteins in NMR are
studied in their aqueous form. NMR requires either a singly or doubly isotopically
labeled protein sample. To make isotopic labeled samples, cells were grown on ( 13,C)
glucose as a carbon source and on (15N) ammonium chloride as a nitrogen source. The
protein-encoding plasmid was transformed into Rosetta(DE3) cells, grown on LB/agar
containing 100 (ig/mL carbenicillin and colonies were inoculated into the media. To
express labeled protein, cells were grown in a minimal media solution.
To make a minimal media solution, 1 L of phosphate buffer (6 g Na2HPC>4, 3 g
KH2PO4, and 0.5 g NaCl) was prepared with ultrapure water, conductivity, 18.2 MQ/cm
(US Filter PURELAB Plus UV/UF, Millipore) in a clean 2.8 L flask, the pH was adjusted
to 7.2 with 0.1 M sodium hydroxide, and the buffer autoclaved. In a sterile environment
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or near a flame, 2 or 4 g of (13C) glucose and 1 g of ( 15 N) ammonium chloride were
added. The following components were also added per L of the media with a syringe
fitted with an Acrodisc® syringe (PN 4612, Pall Life Sciences, Ann Arbor, MI) 0.22
filter: 2.0 mL of 1 M MgS0 4 , 2 mL of 100 mM CaCl2, 5.0 mL of MEM Vitamin mix and
1 mL of the appropriate antibiotic (100 ng/mL ampicillin/carbecillin or 35 (ig/mL
kanamycin). Metal salts supplements were occasionally added [16]. The cells were first
grown in 5 mL LB for 6-8 h and then centrifuged in a sterile 50 mL tube at 4500xg at
37°C for 10 min. The supernatant was discarded and the cells were resuspended in 10 mL
of the minimal media. The cells were grown in a 250 rpm shaking incubator at 37°C until
the OD6oonm reached between 0.6-1.0 (this took 8-10 h) and protein expression was
induced with 1-3 mM IPTG final concentration. The induction time varied with
temperature; for protein expressed at 37°C, time ranged from 3-5 h while for 25°C, it was
4-6 h range. The cells were harvested and protein purified in the same way described in
Section 2.5.2.
The NMR protein sample was prepared under N2 in a Vac Atmospheres® Nexus
chamber; the sample was first exchanged with oxygen-depleted NMR buffer (100 mM
sodium phosphate, pH 7.2) using a PD-10 column and sample fraction containing protein
were identified with Coomasie dye (Pierce, Rockford, IL). The protein sample was
concentrated to about 600-800 |iL, then D2O was added to 10% final concentration (v/v)
and protease inhibitor (1 mM Pefabloc SC PLUS final concentration) added. In some
cases, the protein sample was first treated with 10 mM DTT to reduce disulfide bonds.
When samples were prepared in Kalamazoo, Michigan, a small amount (5-10 |aL) was
taken for concentration determination, and the remainder of the prepared NMR samples
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was shipped to the Center for Magnetic Resonance, Florence, Italy using an ice-cold box.
Samples were also prepared on site by the author during a 3 month visit to CERM in Fall
of 2007. Dr. Shenlin Wang (at the time a student at CERM) and Prof. David Huffman (on
sabbatical at CERM 2007-2008) assisted in the NMR spectral assignment.
For both WD5-6(Y532H) mutant and WD5-6 wild type, the NMR spectra for
backbone assignments were obtained through standard triple resonance experiments [36].
The backbone assignment experiments of WD5-6(Y532H) were performed on 0.2 mM
protein samples at 500 MHz (298K), Bruker® using standard pulse sequences.
Variations in the position of signals between WD5-6(Y532H) and wild type
WD5-6 were quantified through combined chemical shift variation (CSV). This was
calculated from the experimental 'H and

15

N chemical shift variations (A5 ('H) and A5

(15N), respectively), using Equation 2.10.

[2.10]

15

N-RI,

15

N-R2 and steady-state heteronuclear 'H-^N NOEs were measured at 600

MHz (298K). Processing of NMR data was accomplished with the XWINNMR program.
15

N RI and 15N R2 parameters were determined by fitting the integration values obtained

from the XWINNMR program, measured as a function of the delay within the pulse
sequence, to a single-exponential decay. The heteronuclear NOE values were obtained
from the ratio of the peak height for 'H-saturated and unsaturated spectra.
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CHAPTER 3

CHARACTERIZATION OF THE N-TERMINAL DOMAINS OF THE
HUMAN WILSON PROTEIN

3.1

Introduction
The importance of the N-terminal domains in the function of the Cu-ATPase ATP7B

is evident from several mutational studies [1-3]. For example, deletion of MBDs
leads to copper sensitivity, and an increase in the rate of phosphorylation of the Wilson
protein. MBDs 5-6, the metal binding domains closest to the membrane and transduction
channel, when deleted, lead to abrogation of the Cu-ATPase activity [4]. The
characterization of the complete N-terminal domains of the Wilson protein has been
attempted by various groups [3, 5-8] with mixed success. It is evident from these studies
that the protein's instability due to susceptibility to degradation and aggregation of the
purified multi-domain construct continues to hinder further studies, particularly with
longer procedures. Research which overcomes these challenges and elucidates the
unknown properties not only of the N-terminal domains, but also of the Wilson protein in
its entirety will be a significant contribution to this field. In this chapter, cloning,
purification and characterization of the N-terminal domains will be reported and
discussed. Major advancements in the study of the N-terminal domains of Wilson protein
are highlighted.
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3.2

Cloning of pET32Xa/WDl-6 and pET41Ek/WDl-6 Plasmids
The successful cloning of pET32Xa/WDl-6 and pET41Ek/WDl-6 plasmids

involved many trial reactions under varying conditions. The WD1-6 gene is
approximately 1731 bp in length when amplified with two sets of LIC primers, WD1
EkLIC Forward and WD6 EkLIC Reverse; WD1 XaLIC Foward and WD6 XaLIC
Reverse (Table 2.3). The primers were designed to have a slightly higher melting
temperature than the extension temperature of the PCR thermocycler. Other factors that
were considered in the primer design were guanine-cytosine content, length, intra- and
inter- primer interactions, and low sequence similarity to the non-target sites of the
template. The choice of the DNA polymerase was found to be crucial, especially in the
amplification of large pieces of DNA. The working environment was kept clean; the PCR
tubes, pipette tips and milli-Q water (US Filter PURELAB Plus UV/UF, Millipore) for
use were autoclaved (Vacuum Steam Sterilizer, M/C 3533 Castle, Rochester, NY).

3.3

PCR Reactions and Results
PCR reaction conditions utilized to amplify the gene encoding WD 1-6 gene is

shown in Tables 3.1 and 3.3 from Wilson protein cDNA.

The PCR conditions are

outlined in corresponding Tables 3.2 and 3.4. The pET41EkLIC vector target WD1-6
gene amplification was achieved by addition of an additive (1 U per 100 ng of DNA
template), Perfect Match Enhancer (Stratagene, Cedar Creek, TX). The amplified WD 1-6
gene from both reactions was visualized in a 0.8% agarose gel stained with 0.5 ng/mL of
ethidium bromide. A 0.8% agarose gel picture of amplified WD 1-6 gene for subsequent
cloning into pET41 EkLIC vector with 1 Kb DNA ladder (NEB) is shown in Figure 3.1.
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Table 3.1 The PCR reaction of WD 1-6 gene for subsequent cloning into
pET41 EkLIC vector.
Component

Volume (jiL)

Water

69.33

10X Thermopolymerase buffer (NEB)

10.0

dNTPs mix (2 mM)

10.0

Wilson protein cDNA (1.6 |ig/|iL)

6.25

WD1 EkLIC Forward (10 mM)

1.78

WD6 EkLIC Reverse (10 mM)

1.64

Deep Vent Polymerase (exo-)

2.0

Total

101.0

Table 3.2 The PCR thermocycler settings of WD 1-6 gene for subsequent cloning
into pET41 EkLIC vector.
Cycle

Temperature (°C)

Duration (min)

1

Activation cycle

95

5.0

2

Extension

72

2.0

3

Melting

95

1.0

4

Annealing

60

2.5

5

Repeat step 2 to 4 for 30 cycles

6

Extension

72

10.0

7

End/store

4

Indefinite

108

Table 3.3 The PCR reaction of WD 1-6 gene for subsequent cloning into
pET32XaLIC vector.
Component

Volume (jiL)

Water

33.3

10X KOD Hot Start polymerase buffer (Novagen)

5.0

dNTPs mix (2 mM)

5.0

Wilson protein gene (10.0 ^g/^L)

1.0

WD1 XaLIC Forward (10 mM)

0.9

WD6 XaLIC Reverse (10 mM)

0.8

KOD Hot Start DNA polymerase (Novagen)

1.0

Total

25.0

Table 3.4 The PCR thermocycler settings of WD 1-6 gene for subsequent cloning
into pET32XaLIC vector.
Cycle

Temperature (°C)

Duration (min)

1

Activation cycle

95

3.0

2

Extension

70

0.66

3

Melting

95

0.33

4

Annealing

67

0.16

Repeat steps 2 to 4 for 25 cycles

5
6

End/store

4
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Indefinite

A m p l i f i e d W D 1-6 g e n e

I K b D N A ladder
10.0 K b
8.0 K b
6.0 K b

5.0 K b
4.0 K b
3.0 K b

2.0 K b
~ l .8 K b

1.5 K b

1.0 K b

0.5 K b

Figure 3.1 A 0.8% agarose gel picture of the amplified WD1-6 gene. The -1.8 Kb
WD1-6 gene product, visualized here along with 1 Kb DNA ladder (NEB) was
subsequently cloned into pET41 EkLIC vector using the LIC method.
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3.3.1

Ligation Independent Cloning (LIC)
The amplified WD 1-6 gene inserts were incorporated into target vectors,

pET32XaLIC and pET41 EkLIC by the LIC method. This cloning technique involved
three main stages: (1) PCR product purification by agarose gel extraction; (2) treatment
of target insert with T4 DNA polymerase to generate compatible overhangs to vector; and
(3) annealing of the insert gene to the vector.

The agarose gel purification removes

residual deoxynucleotides, DNA polymerases, and any contaminating DNA that may
interfere with T4 DNA polymerase activity in the generation of overhangs. The cloning
region of pET32XaLIC and pET41 EkLIC vectors is shown in Figures 3.2 and 3.3,
respectively.
The treatment of the WD 1-6 insert with T4 DNA polymerase to generate
compatible overhangs for both target vectors was done as shown in Tables 3.5 and 3.6.
The reaction mixture was incubated for 30 min at 22°C followed by incubation for 20
min at 75°C to inactivate the T4 DNA polymerase. The treated WD 1-6 insert was
annealed to the vectors as shown in Table 3.7 by mixing the plasmid vector, treated
WD1-6 insert, and EDTA, and then incubating for 5 min at 22°C.The ligated plasmid
DNA recovered from colony screening was analyzed by restriction mapping. Both
vectors possesses Bgl II and BamH I restriction sites (see Figures 3.2 and 3.3) that lie on
either end of the LIC cloning site and therefore, can be used to map the presence of the
insert. Table 3.8 shows the reaction protocol for the restriction enzyme mapping of
pET32Xa/WDI-6, also known as double digests and shown in Figure 3.4 are the results.
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Hls-Tag

Awll

H i s H i SH1 s H i s H I s E n d
fipi/1102
I
T 7 terminator
CACCACCACCACCACTAATTGATTAATACCTAGGCTGCTAAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGC
GTG6T66T66T66T6ATTAACTAATTATGGATCCGAC6ATTT6TTTCGGGCTTTCCTTCGACTCAACC6ACGAC66T6GCGACTCGTTATT6ATCGTATTG66GAACCCC6
T 7 T e m i n a l c f Primer # 6 9 3 3 7 - 3

pET-41 Ek/LIC cloning/expression regions

Figure 3.3 pET41 EkLIC vector cloning region (Novagen, Inc.).
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Table 3.5 The WD 1-6 gene insert treatment for incorporation into pET41 EkLIC
vector.
Volume (fiL)

Volume (jiL)
WD 1-6 insert (-30 ng/^L) in TEa buffer

7.0

10X T4 DNA polymerase buffer

2.0

25 mM dATP

2.0

100 mM DTT

1.0

T4 DNA polymerase (2.5U/nL)

0.4

Water

8.4

Total

20.0

Table 3.6 The WD 1-6 gene insert treatment for pET32XaLIC vector cloning.
Component

a

Volume (fiL)

WD 1-6 insert (-50 ng/|iL) in TE buffer

4.0

1 OX T4 DNA polymerase buffer

2.0

25 mM dGTP

2.0

100 mM DTT

1.0

T4 DNA polymerase (2.5U/jiL)

0.4

Water

11.6

Total

20.0

TE Buffer; 50 mM Tris/Cl, 0 . 1 M EDTA, pH 8.0.
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Table 3.7 LIC-compatible WD 1-6 insert annealing into LIC vectors.
Component

Volume
(HL)

1

pET41 EkLIC or pET32XaLIC vector

1.0

2

T4 DNA polymerase treated WD 1-6 insert

2.0

Step

Mixed and incubated for 5 min at 22°C

3
4

25 mM EDTA

1.0

5

Incubated for further 5 min at 22°C

6

Transformation into Novablue Gigasingles™ cells

7

Colony screening, plasmid purification, and restriction enzyme mapping

Table 3.8 Double digestion of pET32Xa/WDl-6 plasmid.
Component

Volume (jiL)

Water

13.0

10 X BamH I buffer

2.0

BamH I (10U/^L)b

0.5

Bgl II ( 10 U/nL)

0.5
Total

20.0

Incubated for 2 h at 37°C followed by agarose gel electrophoresis

b

One unit (U) is defined as the amount of the enzyme required to digest 1 |ag of X DNA in 1 h at 37°C in a
total reaction of 50 (iL.
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1 Kb DNA ladder

pET32XaLIC/WDl-6

Double digest
product

10.0 Kb
8.0 Kb
6.0 Kb
5.0 Kb
4.0 Kb

6 Kb

3.0 Kb

2.0 Kb

1.8 Kb

1.5 Kb

.0 Kb

0.5 Kb

Figure 3.4 The restriction enzyme mapping of pET32Xa/WDl-6 visualized in a 0.8%
agarose gel.
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3.3.2

Construction of pET32Xa/WDl-6 Plasmid
The amplification of WD 1-6 gene by PCR (1731 bp) was found to be dependent on

several factors, including the source of DNA polymerases, additives, history of
deoxynucleotide mix, and temperature settings of the PCR thermocycler. Among several
DNA polymerases used, the Deep Vent and Deep Vent (exo-) DNA polymerase (NEB,
MA), HotStar HiFidelity polymerase (Qiagen), and KOD Hot Start DNA polymerase
(Novagen) were able to amplify the WD 1-6 gene, but not without errors. Sequenced
WD 1-6 inserts amplified with KOD Hot Start polymerase and Deep Vent (exo-)
polymerase for insertion into the pET41 EkLIC vector revealed introduction of several
missense mutations scattered throughout the sequence. The HotStar HiFidelity
polymerase had been successful in amplifying a 449 bp COMMD1 gene [9]. Further tests
of WD 1-6 amplification for insertion into the pET41 EkLIC vector were performed with
the HotStar HiFidelity polymerase. Exploration of the pET41Ek/WDl-6 construct was
discontinued after the reaction for amplification failed (in Table 3.4) to work in the
absence of solution Qc, an additive supplied with the polymerase kit (Qiagen). All
polymerases except KOD Hot start polymerase required the presence of a PCR additive,
either Perfect Match Enhancer (Stratagene) or solution Q supplied with the HotStar
HiFidelity polymerase kit (Qiagen).
The

pET32Xa/WDl-6

construct

prepared

from

both

HotStar

HiFidelity

polymerase and KOD Hot Start polymerase amplification also resulted in some
mutations. Deletions, insertion, and missense mutations were introduced during
amplification. Despite the presence of mutations and truncations, the protein from

c

An innovative PCR additive that facilitates amplification of difficult templates by modifying the melting
behavior of DNA (HotStar HiFidelity PCR Handbook 09/2005).
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pET32Xa/WD 1-6 expressed at higher level than that of pET41Ek/WDl-6. The
mutations of pET32Xa/WDl-6 were well spaced, either far from each other or separated
by one or two base pairs, and a Quickchange II XL site-directed mutagenesis kit
(Stratagene) was used to correct them following the manufacturer's instruction. In total,
13 mutations were corrected, 1 deletion, 1 insertion and 11 missense mutations. The
primers used for these corrections are listed in Table 2.4 in Section 2.3. For unknown
reasons, the corrected pET32Xa/WDl-6 mutation-free construct contained a number of
silent mutation changes that were not in the original Wilson protein cDNA obtained from
Washington University at St. Louis.
Since the construct's mRNA sequence can affect protein expression, retaining the
original Wilson protein cDNA sequence was considered important. Therefore, additional
amplifications of the gene for WD 1-6 were performed under a variety of conditions.
KOD Hot Start DNA polymerase (Novagen) amplified the WD 1-6 gene with high
efficiency and fidelity under newly optimized conditions shown in Tables 3.3 and 3.4.
This insert was cloned into the pET32XaLIC vector and adapted for subsequent work. It
was found that KOD Hot Start DNA polymerase was sensitive to both temperature and
the number of PCR cycles.
The amplification of the gene fragment WD 1-6 using various DNA polymerases
was difficult. Deep Vent, Deep Vent (exo-), and Hot Star DNA polymerases isolated
from Pyrococcus strain have fairly slow elongation rates in comparison to Thermocccus
kodakaraensis derived KOD Hot Start DNA polymerase [10], and this could be a factor
considering that the former cannot amplify this large sequence without a PCR additive.
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The PCR temperature settings, pure and fresh dNTPs, PCR additives, and a PCR
thermocycler with heated lid affect the amplification fidelity.

3.4

Strategy for Incorporating TEV Cleavage Site
The protease cleavage of a fusion protein with Factor Xa can result in incomplete

cleavage or cleavage at other sites. Therefore, a construct encoding Tobacco Etch Virus
(TEV) cleavage site was prepared, pET32XaTEV/WDl-6 (Figure 3.5). TEV protease
cleaves more efficiently than Factor Xa resulting in higher yield. The TEV restriction
site can be introduced into an expression vector using the Gateway Entry vector
pENTR/TEV/D-TOPO (Invitrogen) [5,

11] followed by Gateway recombination

(Invitrogen). Although the Gateway system is rapidly gaining popularity, it is an
expensive, fairly complex procedure, and the TEV cleavage from this system leaves four
new encoded amino acid residues at the N-terminal of the purified protein. Since the
native sequence was desired, a different method was used and is outlined below.

3.4.1

Method of Incorporating TEV Protease Cleavage Site
The incorporation of a TEV encoding site into pET32Xa/WDl-6 was performed

using two sequential steps, site-directed mutagenesis followed by LIC. Three sets of
primers and complements, TEV PI, TEV PII, and TEV PIII (see Table 2.3) were
prepared to encode the TEV cleavage site and complementary overlapping sequences
encoding the Factor Xa cleavage site (Figure 3.5) and the first 3 amino acid residues
downstream. The primers were designed for optimum annealing to the template while
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(B) pET32Xa/WDl-6: Factor Xa cleavage site

Thioredoxin

N-terminal domains (WD1-6)

Factor Xa

-Ile-Glu-Gly-Arg-

(A)pET32XaTEVAVDl-6: TEV cleavage site

Thioredoxin

N-terminal domains (WD1-6)

F a c t o r Xa

-GIu-Asp-Leu-Try-Phe-Gln-Gly-

Figure 3.5 Thioredoxin tagged WD 1-6 protein and the location of the protease cleavage
sites (A) Factor Xa (B) TEV (Tobacco Etch Virus).
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minimizing intra- and inter-primer dimer formation [12]. The synthesis of the new
plasmid encoding the TEV cleavage site, termed pET32TEV/WDl-6, was performed
stepwise with 3 mutagenic reactions using a QuickChange II XL site-directed
mutagenesis kit (examples are shown in Tables 3.9 and 3.10).
Modifications were made to place the TEV site immediately downstream of the
Factor Xa site. The newly constructed TEV/WD1-6 gene segment in pET32TEV/WDl-6
was amplified and cloned back into pET32XaLIC vector. The WD 1-6 insert containing
the TEV cleavage site was amplified using WD1 XaTEVLIC Forward and WD6 XaLIC
Reverse primers (Table 2.3) with pET32TEV/WDl-6 plasmid as the template. The PCR
product, treated to produce LIC compatible overhangs, was ligated into pET32XaLIC to
produce pET32XaTEV/WDl-6, encoding both Factor Xa and TEV cleavage sites.
Figure 3.6 shows the restriction enzyme mapping of pET32XaLIC, pET32Xa/WDl-6,
and pET32XaTEV/WDl-6 using BamH I and Bgl II endonucleases.

Table 3.9 Cycling parameters of QuickChange II XL site-directed mutagenesis
method.
Segment

Cycle

Temperature (°C)

Time (Sec)

1

1

95

60

95

50

60

50

68

60/Kb

68

420

2

3

12-18

1
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Table 3.10 The synthesis of the pET32XaTEVII/WDl-6 plasmid from
pET32XaTEVI/WDl-6 template. This is the second mutagenesis reaction in the
sequence of three.
Volume
(ML)

Component

Final mass
(ng)

1

Water

37.4

2

10X reaction Pfu polymerase buffer

5.0

3

pET32XaLICTEVI/WD 1 -6 (-6.5 ng/^L)

1.5

10.0

4

TEV PII Forward primer (10 |iM)

1.04

125.0

5

GC TEV PII Reverse primer (10 |iM)

1.06

125.0

6

DNTPs

1.0

7

QuikSolution (an additive)

3.0

8

PfuUltra HF DNA polymerase

1.0

9

Total reaction volume

10

New plasmid synthesized following parameters in Table 3.9

11

Parental DNA digested with Dpn I restriction enzyme for 2 h at 37°C

12

New plasmid transformation, colony screening, and DNA purification

13

Primer extension DNA sequencing

50.0
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Lane 1

Lane 2

Lane 3

Lane 4

1 Kb DNA Ladder
- 7.7 Kb
>-

- 5 . 8 Kb

,
*

R°OKhb

- 7.7 Kb

6.0Kb

- 5 . 8 Kb

~ 3.8 Kb

5.0Kb
4.0Kb
3.0 Kb

- 1 . 8 Kb

%
%

<

~ 1.8 Kb

\%

'>>

\%
%

2.0 Kb
1

"

5 K b

LOKb

h

\

0.5 Kb
Figure 3.6 Double digest (restriction enzyme mapping) of plasmid constructs using
BamH I and Bgl II. Lanel, pET32Xa/WDl-6; Lane 2, pET32XaTEV/WDl-6; Lane 3,
pET32XaLIC vector; Lane 4, 1 Kb Ladder (NEB). The product was visualized in a
0.8% agarose gel. The size of pET32XaLIC vector is due to migratory behavior of
linearized DNA.
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3.4.2

Discussion
The incorporation of a TEV cleavage site in expression vectors has gained

popularity, especially in the last decade [13]. The reason TEV protease is a valuable
reagent is its ability to function under a variety of conditions and its specificity compared
to Factor Xa, enterokinase, and thrombin proteases. Several factors need to be considered
when incorporating TEV cleavage sites and these include new amino acid residues and
the preservation of the native sequence. In some cases the introduction of a TEV cleavage
site has decreased the solubility of target protein, limiting its usage [13].

3.5

The Expression and Purification of WD1-6 Protein
The use of several different WD 1-6 expression vectors helped to optimize

expression and purification of the N-terminal domains. The protein expression and
purification methods were discussed in Section 2.5.1. TRXx a WDl-6 expressed from
pET32Xa/WDl-6 containing truncations is shown in Figures 3.7, 3.8 and 3.9. Missense
mutations found in the pET41Ek/WDl-6 vector led to poor yield of expressed protein,
Figure 3.10. Further trials with this DNA plasmid construct were discontinued.
Correction of all mutations (Section 3.3.2) led to high yield of expressed protein
(Figure 3.11). Mutations repair were confirmed by DNA sequencing (Retrogen, Inc.).
The induction of TRX XaT EvWDl-6 and TRX T E vWDl-6 proteins (see Table 3.11 for
further information) is shown in Figure 3.12. Subsequent steps in the purification and
thioredoxin cleavage of TRX X a WDl-6 and TRXxaTEvWDl-6 are discussed in the
following sections.
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Figure 3.7 The truncated TRXxaWDl-6 protein (~35 kDa) expressed in Rosetta(DE3)
cells transformed with pET32Xa/WDl-6. Arrow indicates protein of interest.

Figure 3.8 The truncated TRXx a WDl-6 protein (~20 kDa) expressed in Rosetta(DE3)
cells transformed with pET32Xa/WDl-6. Arrow indicates protein of interest.
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Time (min)

Figure 3.9 The truncated TRX X a WDl-6 protein (-40 kDa) expressed in Rosetta(DE3)
cells transformed with pET32Xa/WDl-6. Arrow indicates protein of interest.

Time (min)

Figure 3.10 Expression of GST EK WD1-6 protein (-92 kDa) in Rosetta(DE3) cells
transformed with pET41Ek/WDl-6. Arrow indicates protein of interest.
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Table 3.11 Notation for the expressed WD1-6 fusion protein.
Fusion protein

Cleavage site present

TRXx a WDl-6

Thioredoxin

Factor Xa

TRXTEVWD1-6

Thioredoxin

TEV

TRXxaTEV W D 1 - 6

Thioredoxin

Factor Xa/TEV

Expressed protein

Figure 3.11 The 10% Tricine SDS-PAGE gel showing TRX X a WDl-6 induction after
mutation repairs. Lane 1 (0 h), control, Lanes 2 (1 h) and 3 (4 h), expressed truncated
TRXxaWDl-6, Lane 4 (4 h), TRX X a WDl-6 after deletion mutation repair, and Lane 5 (4
h), TRXxaWDl-6 after insertion mutation repair.
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M
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2

3

4

5

6

7

8

9

225
150
102 K
76 K
52 K
38 K
31 K

M
12 k

Figure 3.12 A 1 0 % Tricine S D S - P A G E gel showing the T R X X A T E V W D L - 6 and
T R X T E V W D 1 - 6 time-course induction. Lanes 1 - 2 , control, Lanes 2 - 6 , TRX X A TEVWDL-6,
Lanes 7 - 9 , T R X T E V W D 1 - 6 , and M , full range rainbow protein marker. The arrow
indicates the protein of interest.

. 3.5.1

Immobilized Metal Affinity Chromatography (IMAC) Purification
Both TRX X a WDl-6 and T R X X a T E v W D l - 6 contain a poly-histidine tag upstream

of the N-terminal end of WD 1-6 and downstream of the thioredoxin fusion protein. This
poly-histidine tag was used in the initial purification of the cell lysate utilizing
immobilized metal-affinity chromatography (IMAC) [14, 15]; nickel ion was the
chelating agent in a Sepharose 6 Fast Flow HisPrep FF 16/10 column. The cell lysate
(supernatant) was applied to the column. Bound protein was washed with HisPrep
binding buffer (20 mM Na Phosphate, pH 7.4, 500 mM NaCl, 20 mM imidazole) to
remove contaminants and then equilibrated with 50 mM HEPES, pH 7.5, 500 mM NaCl,
30 mM imidazole. The protein elution was isocratically eluted with 50 mM HEPES, pH
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7.5, 500 mM NaCl, 300 mM imidazole. The HEPES buffer was found to stabilize WD16 relative to phosphate buffer. The T R X X a T E v W D l - 6 isocratically eluted protein is
shown in Figure 3.13.

3.5.2

Size Exclusion Chromatography
Initial IMAC chromatography did not remove all impurities. The protein was

further purified by size exclusion chromatography (gel filtration) by using either a 320
mL Superdex 7 5 2 6 / 6 0 column or a 1 2 0 mL Superdex 2 0 0 1 6 / 6 0 column. The flow rate
for the initial one sixth of the elution was set slightly higher (4X faster) than the rest of
the elution. The T R X X 3 T E V W D 1 - 6 protein eluted at - 6 5 . 6 mL, whereas cleaved W D 1 - 6
eluted at - 7 1 . 0 5 mL for the 1 2 0 mL Superdex 2 0 0 1 6 / 6 0 column (Figures 3.14 and
3.16). The conditions for the elution were 50 mM HEPES, pH 7.5, 200 mM NaCl, and
1% glycerol, 2 mL/min flow for the initial 20 mL, and then 0.5 mL/min for the rest of
elution.
Thioredoxin fusion cleavage with TEV protease is shown in Figure 3.15 and was
complete after 24 h under the conditions noted. The cleavage of thioredoxin fusion
protein with Factor Xa was unsuccessful (not shown) largely due to low yield and rapid
degradation of the purified TRX X a WDl-6 protein construct, most likely due to the
identity of the amino acid immediately after the protease site.
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4

10

14

16

20

225 k 150
102 l l m
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52 K**
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Figure 3.13 TRXxaTEvWDl-6 protein elution from a 20 mL HisPrep column. Lanes 1-8
shows fractions sampled by SDS-PAGE with corresponding elution volume at the bottom
of the gel. CL in Lane 10 is the crude cell lysate (BugBuster® protein extraction reagent
supernatant).
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102 K
76 K
52 K
38 K
31 K
24 K
17 K

12 K

M

60

66

68

74

84

Fractions (elution volume in mL)

Figure 3.14 Size exclusion chromatography of TRXxaTEvWDl-6. Lanes 1-5 shows
elution fractions (below) and the chromatogram profile (top) for Superdex 200 16/60
column. Solid black bars indicate protein trace.
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Incubation Time (h)
M

0

24

A - T r x X a T E V W D l - 6 ~ 78 k D a
B - W D 1 - 6 ~ 61.3 k D a
C - Thioredoxin (Trx) ~ 18 k D a

Figure 3.15 Time-course cleavage of thioredoxin from TRXXaTEvWDl-6 with TEV
protease (lpg TEV/100 p,g fusion protein).
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76
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31 K
24
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80
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Figure 3.16 Size exclusion chromatography of WD 1-6. The elution and chromatogram
profile for Superdex 200 16/60 column is shown on top plot. Lanes 1-5 contain sample
fractions assayed and their corresponding elution volume indicated at the bottom of the
gel. Solid black bars indicate the protein trace.
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3.5.3

Discussion
The purification of WD1-6 of Wilson protein has been a hurdle for many research

groups. The Rosenzweig group found that the solubility of the N-terminal domains (1633 amino acids), including the cytosolic tail (molar mass - 6 7 kDa) improved if cells
were induced at 16°C for 20 h [3]. DiDonato and co-workers found that - 70% of the
protein ended up in the induced cells as inclusion bodies. To recover the expressed
protein, the inclusion bodies were solubilized and the denatured protein refolded [7]. The
Bertini group [5] was able to purify WD 1-6 (1-633 amino acids) but the method used
[16] introduced four additional vector-encoded amino acid residues at the N-terminal end.
The effects of these "extra" amino acids relative to the native WD 1-6 have not been
determined. Since the first 56 amino acids of WNDP are predicted to be unstructured, we
chose not to include them in our WD1-6 construct. This probably led to the higher degree
of stability we observed.
In this work, the N-terminal region of the Wilson protein lacking the first 56
amino acids, a total molar mass of 61.3 kDa, has been purified to homogeneity utilizing
improved methods and optimized conditions. The yield and solubility of the expressed
fusion WD 1-6 protein was found to increase tremendously (3-5 times) when the culture
was induced with 3 mM IPTG and at temperature between 28-30°C. The optimal time for
induction of protein expression was 4-5 h. Protein extraction was initially done by
freezing and thawing the cell pellet 3-5 times in liquid nitrogen before resuspension in
BugBuster®

protein

TRXxaTEvWDl-6

extraction

reagent.

The

amount

of

TRXx a WDl-6

or

protein released into solution increased with incorporation of this

step. The highest yield that was achieved for TRXxaTEvWDl-6 was 55 mg fusion protein
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per liter of LB culture, corresponding to 10 mg after cleavage.

Although Rosenzweig

and co-workers were successful in cleaving WD 1-6 fusion protein with Factor Xa, it did
not work well with the construct used in this study. Instead, the purified fusion protein
readily degraded and to an extent accelerated by Factor Xa.
Buffer components and storage conditions were found to be important in
purification of WD 1-6. Both the fusion and purified WD 1-6 protein were more stable in
Tris and HEPES buffers supplemented with 1% glycerol than in phosphate buffer. This
was evaluated from the formation of precipitates at higher concentrations and degradation
during purification, thioredoxin cleavage and storage. Tris and HEPES, bearing amine
and hydroxy 1 groups, might be stabilizing the solvated WD 1-6 protein better than the
phosphate group. In spite of precipitation and time-dependent degradation of pure WD16 protein, it can be concluded that this protein entity is sufficiently stable for biophysical
and biochemical characterization.

3.6

3.6.1

The Biophysical Characterization

Gel Filtration Results and Discussion
High Resolution Gel Filtration Chromatography was utilized. A 25 (iL protein

solution of 0.2-1.0 |ig/|iL was injected into Superdex 200 10/300 GL high performance
column (CV, 24 mL). Protein standards were obtained from both Sigma-Aldrich and GE
life sciences. The gel filtration results are shown in Table 3.12 and in Figure 3.17.
Proteins fractionate according to their hydrodynamic volume in gel filtration. Proteins
with small hydrodynamic volume take longer than large proteins to elute due to a higher
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equilibration rate into pores of the medium matrix (the stationary phase). This technique
is useful in protein purification, determination of oligomeric state of complexes, and
molecular weight determination. Using the calibration curve from known protein
standards (Figure 3.17), the molecular weight of WD 1-6 was determined to be -134
kDa. WD 1-6 protein was expected to elute in the same range as Bovine Serum Albumin
which has a molecular weight of 66 kDa. WD5-6, a 15 kDa segment of the N-terminal
region, also elutes faster than expected. The difference between the estimated and actual
molar mass of WD5-6 was relatively small (40%) compared to WD1-6 (103.2%).

Although the movement of proteins in a size exclusion column depends on
hydrodynamic volume, proteins with the same physical hydrodynamic volume but
dissimilar shapes will migrate differently [17]. The molecular mass of WD1-6 could not
be determined with precision by size exclusion chromatography; therefore, further
experiments using static light scattering were performed. To further probe the shape of
WD 1-6 in relative to proteins of similar mass, its hydrodynamic radius was determined
by dynamic light scattering [18].

3.6.2

Light Scattering Results

Static and dynamic light scattering were at performed at Yale University's Keck
Biotechnology Resource Laboratory. The molar mass and hydrodynamic radius of WD16 was calculated using ASTRA software. Figure 3.18 shows the molar mass distribution
across the elution peaks of Alcohol Dehydrogenase (ADH), Bovine Serum Albumin
(BSA) and WD 1-6. The autocorrelation function or time dependence of diffusive motion,
and derived translational diffusion coefficient for WD1-6 is shown in Figure 3.19.
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Table 3.12 The molecular weights of protein standards used to plot calibration curve.
The calculated molecular weights of the N-terminal domains, WD 1-6 and WD5-6 are
shown in bold face type.
Protein

MW (Da)

Blue dextran

d

V0

Ve

vt

8.63

V£-V„

24

v,-v„

K

d

log
M.W

15.37

BSA

66000

8.63

15.04

24

6.41

15.37

0.42

11.10

CAD

29000

8.63

17.82

24

9.19

15.37

0.60

10.28

CytC

12400

8.63

19.16

24

10.53

15.37

0.69

9.43

Ovalbumin

44000

8.63

16.31

24

7.68

15.37

0.50

10.69

Conalbumin

75000

8.63

15.18

24

6.55

15.37

0.43

11.23

Aldolase

158000

8.63

13.70

24

5.07

15.37

0.33

11.97

Ferritin

440000

8.63

11.57

24

2.94

15.37

0.19

12.99

WD 1-6

134194

8.63

13.97

24

5.34

15.37

0.35

11.81

WD5-6

23609

8.63

17.81

24

9.18

15.37

0.60

10.07

Kav = (Ve-V0)/(VrVo).
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Figure 3.17 Gel filtration calibration curve. The known molecular weight protein
standards are in black while the N-terminal domains of Wilson protein, WD 1-6 and
WD5-6 are displayed in red.
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The hydrodynamic radius distribution of WD 1-6 and a BSA standard is shown in Figure
3.20.
The anomalous elution of WD 1-6 in size exclusion chromatography relative to
BSA can be explained by comparing their hydrodynamic radius, RH (Figure 3.20). The
BSA (molar mass of 66 kDa), with a hydrodynamic radius of 3.4 nm, elutes after WD1-6
(Figures 3.17 and 3.20). WD 1-6 has a larger hydrodynamic radius, and migrates faster
through the column than a compact globular protein. The static LS results also indicate
the shape of WD1-6 is nonspherical and polydisperse. This is evident from the slanted
molar mass and RH distribution across the elution peak of the protein. The interdomain
linkers are known to be flexible such that the domains can move relative to each other.
From the gel filtration data, it is possible to state that the six domains are somewhat
extended.

3.6.3

Circular Dichroism
The unfolding of WD 1-6 as a function of GnHCl denaturant concentration,

measured from 270 to 205 nm, is shown in Figure 3.21. The change in ellipticity at 222
nm was used to monitor unfolding of WD 1-6, as shown in Figure 3.22. The Gibbs free
energy of unfolding with denaturant was calculated using a two-state folding model
(Table 3.15 and Figure 3.23). The calculation of A G ^ ' 0 energy, m, and [GnHCl]i/2
values for WD 1-6 was done using the Linear Extrapolation Method [19, 20]. Results are
tabulated in Table 3.16.
The conformational stability of a protein can be expressed as the free energy
change that occurs when a protein at equilibrium and under favorable conditions

molar mass vs. time

time (min)

Figure 3.18 The molar mass distribution of WD 1-6 determined by SLS. A plot of molar
mass (g/mol) against elution time in min (gel filtration), monitored by a UV detector at
280 nm is shown. The "fragmented" lines labeled A-C are weight average MW for each
slice, i.e., measured every 1 s. A: Alcohol Dehydrogenase, ADH (blue), B: WD 1-6,
(red), C: Bovine Serum Albumin, BSA (green). The slanted distribution of MW across
the eluting peak of WD 1-6 suggests non-homogeneity of the sample while early elution
implies nonspherical shape of the protein.
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Figure 3.19 The autocorrelation function of WD1-6. Time dependence of diffusive
motion, also referred to as the intensity autocorrelation function, was determined by "on
line" DLS measurements at an angle of 100° with a 1 sec collection time. Time resolved
scatter intensity fluctuations were analyzed using ASTRA Software (Wyatt Corp., Santa
Barbara, CA) implementing the cumulants method [21]. The translational diffusion
coefficient derived from this data, shown in the graph, is used to calculate Rh using the
Einstein-Stokes equation.
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Figure 3.20 A plot of hydrodynamic radius against elution time in min (gel filtration) is
shown for WD 1-6. BSA, a globular protein with known Rh is used as a standard. The
"square dot" lines, A-B, represents the Rh distribution within the eluting peak. A: WD16 (Brown), B: BSA (Magenta). The slanted Rh distribution is indicative of a polydisperse
material in the elution peak. The Rh for a monodisperse material remains relatively
constant across the elution peak.
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Table 3.13 Molar mass of WD 1-6 by static light scattering. WD 16 exhibits
polydispersity; therefore, the molar mass given is a weighted average.
Protein

Molar mass by SLS
g/mol

Actual molar mass
g/mol

Dispersity

WD 1-6

-61,570

61,378

Polydisperse

BSA

66,000

66,000

Monodisperse

Table 3.14 Hydrodynamic radius of WD1-6. Although WD1-6 has a similar
mass to BSA, it has a larger hydrodynamic radius than BSA. Therefore, WD 1-6 is
nonspherical in shape and it can migrate faster than BSA in a gel filtration
column. * Molar mass varies due to polydispersity of the protein.

Sample

RH (nm)

Molar mass (g/mol)

Apparent shape

WD 1-6

4.09±0.09

-65,000*

Nonspherical

BSA

3.4

66,000

Spherical

reversibly changes from a folded to an unfolded state [22]. The A G / 2 0 ( f r e e energy
change in absence of denaturant) can be obtained from urea and GnHCl denaturation
curves. Most globular proteins have a conformational stability in the range of 21-63
kJ/mole, much weaker than the strength of a chemical bond [23]. The common
techniques used to monitor folded and unfolded conformations of proteins are UV
absorbance, fluorescence, and circular dichroism [24]. The CD of WD 1-6 unfolding in
the presence of denaturant has not been reported. Copper binding studies have been used
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to monitor CD from a WD1-6 protein reconstituted from inclusion bodies consisting of
residues 1-633 [6, 25]. The copper binding CD data reports a mean residue ellipticity of
4500 for apo WD 1-6, and 5000 for copper loaded WD 1-6 protein at 222 nm. Also, a
different set of a data reported by the same authors that included zinc binding studies
gives apo WD 1-6 protein a mean residue ellipticity of 5500, and 7100 for copper loaded
WD 1-6 at 222 nm.
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Figure 3.21 Unfolding of WD 1-6 under increasing ionic strength of guanidine
hydrochloride.
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Figure 3.22 WD 1-6 unfolding monitored at 222 nm with increasing molar concentration
of GnHCl.
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Table 3.15 The data set used to plot the linear extrapolation curve. The Y
represents the selected points along the WD 1-6 unfolding curve at 222 nm that
were used to calculate the free energy of unfolding.
YF

Y

FF

K

FU

YU

[AG]

[GnHCl]

-6316.28

-6214.75

0.97857

0.0219

0.02143

-1578.77

9467.442

0.59

-6316.28

-6000.42

0.93333

0.07143

0.06667

-1578.77

6538.244

1.23

-6316.28

-5885.87

0.90915

0.09993

0.09085

-1578.77

5706.553

1.48

-6316.28

-5266.91

0.7785

0.28453

0.2215

-1578.77

3114.144

2.09

-6316.28

-4976.83

0.71727

0.39418

0.28273

-1578.77

2306.488

2.31

-6316.28

-4407.76

0.59715

0.67463

0.40285

-1578.77

975.1544

2.61

-6316.28

-3977.26

0.50628

0.97521

0.49372

-1578.77

62.20582

2.84

" -6316.28

-3193.86

0.34092

1.93328

0.65908

-1578.77

-1633.26

3.27

-6316.28

-2674.67

0.23132

3.32293

0.76868

-1578.77

-2975.19

3.62

-6316.28

-2244.17

0.14045

6.11978

0.85955

-1578.77

-4488.18

4

-6316.28

-2029.84

0.09521

9.50279

0.90479

-1578.77

-5578.47

4.3

-6316.28

-1878.34

0.06323

14.81428

0.93677

-1578.77

-6678.52

4.6

-6316.28

-1726.83

0.03125

30.99688

0.96875

-1578.77

-8507.7

5.09

-6316.28

-1664.01

0.01799

54.57743

0.98201

-1578.77

-9909.35

5.6

-6316.28

-1651.08

0.01526

64.5152

0.98474

-1578.77

-10323.8

6
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[GnHCl], Molarity

Figure 3.23 WD 1-6 denaturation curve analysis using the Linear Extrapolation Method
(LEM). The Gibbs free energy calculated from selected points along denaturation curve
is plotted against denaturant concentration [GnHCl]; the y-intercept is the free energy of
unfolding in the absence of denaturant.
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Table 3.16 Conformational stability of WD 1-6. The free energy of unfolding, m*
[GnHCl] 1/2 for WD 1-6 is compared with other N-terminal domains and mutant
protein, WD5-6(Y532H).

Parameter

WD4e

WD 5-6

WD 1-6

WD5-6(Y532H) )

AGUH*°
(kJ mol"1)

44.5 ± 0.4

7.9 ± 0.6

11.0 ±0.2

8.0 ±0.0

m
(kJ mof 1 M"1)

-8.3 ±0.1

-2.8 ± 0.1

-3.8 ±0.0

-2.9 ±0.0

[GnHCl] 1/2, M

5.38

2.82

2.91

2.78

The mean residue ellipticity reported here for the WD1-6, residues 57-633 of Wilson
protein, was -6100 at 222 nm. The copper content was not quantified before CD
measurement, but purification was done in the presence of 0.5 mM EDTA. The Gibbs
free energy of unfolding of WD 1-6 in the absence of denaturant is shown in Table 3.16.
The value obtained using the linear extrapolation method was 11.04 kJ/mole. The m, the
parameter which is proportional to the amount of surface area of protein in contact with
solvent upon unfolding, [26, 27] was found to be -3.8 kJ/mole/M. The concentration at
which the protein is half denatured, the [GnHCl] !/2, was 2.9 M for WD 1-6. The
thermodynamic parameters for WD 1-6 unfolding (denaturation curve) by GnHCl have
not been previously reported.

It is recommended that future calculations be extended to

more inclusive methods like the denaturant binding model [28], Tanford's methods [29],
and the method of Stainforth et al [30].

e

From PhD Dissertation of Wilson Okumu, Western Michigan University ©2010.
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3.7

Summary
The N-terminal domains of human Wilson protein (residues 57-633 of ATP7B)

have been cloned, expressed, and purified utilizing both established protocols and newly
developed methods. WD 1-6 gene amplification was found to be dependent on the DNA
polymerase used, the nature of deoxynucleotide mixture, and PCR thermocycler settings.
DNA polymerases with faster elongation rates and fewer PCR cycles favored the process.
Amplification of an entire plasmid vector containing the WD 1-6 insert gene using sitedirected mutagenesis kit was conducted with high fidelity and specificity, however.
Three

WD1-6

expression

vectors,

pET41Ek/WDl-6,

pET32Xa/WDl-6,

and

pET32XaTEV/WDl-6 were prepared, which coded for GST and an enterokinase
cleavage site, TRX and a Factor Xa cleavage site, and TRX, and Factor Xa/TEV cleavage
sites. Work on pET41Ek/WDl-6 was discontinued due many missense mutations
introduced

by

DNA

polymerase

errors.

WD 1-6

protein

obtained

from

the

pET32Xa/WDl-6 construct readily degraded during purification and the removal of the
thioredoxin tag was inefficient. Modification of pET32Xa/WDl-6 construct to
pET32XaTEV/WD 1-6 led to a stable protein.
Expression of WD1-6 fusion protein at lower (28-30°C) than physiological
temperatures improved its cellular solubility. The protein was extracted by both
freeze/thaw and BugBuster® protein extraction reagent. The protein was subsequently
purified by Immobilized Metal Affinity Chromatography (IMAC) and Size Exclusion
Chromatography (SEC). Tobacco Etch Virus (TEV) protease that was used to cleave the
TRX tag was purified in our lab and its activity standardized. Cleaved WD1-6 was
cleaned up by both IMAC and SEC before storage. The DNA integrity after amplification
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was confirmed by primer extension sequencing and restriction enzyme mapping. Protein
expression and purification was followed by SDS-PAGE analysis.
Biophysical characterization of WD 1-6 was performed using gel filtration, light
scattering and circular dichroism techniques. The protein was found to migrate faster
than protein of similar mass in gel filtration column; therefore, estimation of its molar
mass using this technique was too high. This phenomena was also seen during light
scattering experiments, though the LS scattering data showed that the protein was
polydisperse and non-spherical. This implies that WD 1-6 is somewhat elongated. This
feature may be important in vivo in that the N-terminal domains are likely to require
flexibility to interact with cytoplasmic domains, transmembrane domains, and copper
metallochaperone. As seen in the NMR titrations of Cu-ATOXl and WD 1-6, N-terminal
metal binding domains 1, 2, and 4 are able to form a complex with Cu-ATOXl, but not 3,
5, and 6 [5]. These N-terminal metal binding domains are separated with amino acid
linkers of different lengths (see Section 1.2.1). Domains 5-6 and 1-2 are separated by an
8 amino acid and 11 amino acid linkers, respectively. Domain 4 is separated from domain
5 by a 57 amino acid linker, and a 30 amino acid linker from domain 3, which is then
separated by a 42 amino acid linker from domain 2. Since we have found that WD1-6 is
not globular in structure, we can compare these finding with reported structural studies of
CopA copper transporting ATPase in bacteria.
Limited proteolysis studies and cryo-electron microscopy have been used to
delinate structural and functional organization of the N-terminal metal binding domain of
the CopA, a bacterial Cu-ATPase from Thermatoga maritima. Hatori et al. found that N-,
A-, and N-terminal metal binding domain undergo rearrangement when apo CopA is
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metallated, and when bound to phosphate analogs [31]. The papain cleavage site at Nterminal metal binding domain-Ma helix loop is protected against papain attack when
CopA is bound to copper and phosphate analogs. This work suggests that N-terminal
metal binding domains'

association with A-domain

lead to

overall

domainal

reorganization, and thus, aid the protein to attain required conformations for
phosphorylation, copper transfer, and regulation. This work is also supported by Stokes et
al. through a cryo-electron microscopy studies of CopA [32], The N-terminal metal
binding domain was found to be localized within the cytoplasmic domains, N-, A-, and Pdomains. It is hypothesized that N-terminal metal binding domain interact with N-domain
in the absence of copper and prevents ATP binding. This state is likely disrupted by
metallated metallochaperone docking on N-terminal metal binding domain and
commencement of copper efflux through the transduction channel. We hypothesize that
the N-terminal metal binding domains of human Wilson protein, WD 1-6, follow a
similar mechanism. We suggest that domains 3, 5 and 6 are not available for ATOX1
docking; they are likely to be associated with cytoplamsic domains in a copper free state.
The long linkers separating these domains may permit domainal arrangement in which
domains 1, 2, and 4 are facing away from cytoplasmic domains for possible interaction
with metallated ATOX1. Binding of copper on N-terminal metal binding domains
initiates the conformational changes in WNDP leading to activation of the enzyme. This
arrangement may constitute the control mechanism for copper binding, translocation and
the ATP hydrolysis as the energy source.
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CHAPTER 4

CHARACTERIZATION OF Y532H MUTATION OF THE HUMAN WILSON
PROTEIN

4.1

Introduction
Over 260 disease-causing mutations have been found in the gene encoding the copper

transporting ATP7B (Wilson protein) [1-6]. The geographical distribution of the
mutations is as diverse as the world population itself; stretching all the way from
Hungary to Brazil. Because of this large number, the characterization and analysis of
these mutations has remained at the genetic and clinical levels [7]. Although computer
modeling is gaining momentum, no structures exist for full length Wilson protein [8]. To
advance the understanding of the molecular basis for these mutations, the Y532H
mutation (Figure 4.1) was selected due to (1) its location within the N-terminal domains
5 and 6, which have been extensively studied and (2) its proximity to the interfacial
region between domains 5 and 6.
This chapter begins with a description of site-directed mutagenesis and cloning of the
WD5-6(Y532H) mutation. The protein purification and biophysical characterization
steps are then summarized as described in Section 2.4.2, followed by results and
discussion. Findings from the research are also highlighted.
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Domain 5

Domain 6

Figure 4.1 The NMR structure of WD5-6. The position of the Y532 amino acid residue
(also called Y48 when numbered from position 485 of the human Wilson protein) is
shown in red (PDB 2EW9).

4.2

4.2.1

Construction of pET24d/WD5-6(Y532H), pET32Xa/WD5-6(Y532H) Plasmids

PCR Reactions and Results
The Y532H mutation, in which the amino acid tyrosine is substituted with

histidine, was incorporated into pET24d/WD5-6 by site-directed mutagenesis. The
cloning of pET24d/WD5-6 vector containing the N-terminal domains 5 and 6 of Wilson
protein has been described before in a paper published by members of our lab and the
Bertini group at the Center for Magnetic Resonance, Florence, Italy [9], The PCR
reaction conditions for Y532H mutagenesis are shown in Tables 4.1 and 4.2. The PCR
product is shown in the Figure 4.2 along with the pET24d/WD5-6 DNA template.
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Table 4.1 The PCR mutagenesis reaction of WD5-6(Y532H).
Volume
(ttL)

Component

Final mass
(ng)

1

Water

2

1 OX PfuUltra polymerase buffer

5.0

3

pET24d/WD5-6 DNA (-7.4 ng/^L)

1.35

10.0

4

KD-Y532H Fwd primer (10 |iM)

1.2

125.0

5

GC KD-Y532H Rev primer (10 pM)

1.2

125.0

6

dNTPs Mix

1.0

7

Quiksolution (Additive)

3.0

8

PfuUltra HF DNA polymerase

1.0

9

Total reaction volume

10

New plasmid synthesized following parameters in Table 4.2

11

Parental DNA digested with Dpn I restriction enzyme for 2 hours at 37°C

12

New plasmid transformation , colony screening and DNA purification

13

Primer extension DNA sequencing

37.25

50.0

Table 4.2 The cycling parameters of WD5-6(Y532H) mutagenesis.
Segment

Cycle

Temperature (°C)

Time (sec)

1

1

95

60

95

50

60

50

68

330

68

420

2

3

18

1
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Lane 1

Lane 2

Lane 3

pET24d/WD5-6
pET24d/WD5-6
(Y532H)

1 Kb DNA
Ladder

we
~5-

10 LB

7 K B

'"••-

4.0 Kb
3.0 Kb
2.0 Kb
1.5 Kb

1.0 Kb

0.5 Kb

Figure 4.2 The WD5-6(Y532H) PCR product. The 5.7 Kb PCR product (Lane 3) is
visualized alongside 1 Kb DNA ladder (NEB), and pET24d/WD5-6 DNA template (Lane
2) in an ethidium bromide stained 0.8% agarose gel.
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After transformation in Rosetta(DE3), the protein expressed from pET24d/WD56(Y532H)

was found to be insoluble, leading to low yield for the mutant protein.

Expressing WD5-6(Y532H) as a fusion protein with thioredoxin was pursued since (1)
the solubility of expressed protein was likely to increase, (2) the presence of a polyhistidine tag would aid in the purification process, and (3) if the insoluble protein
persisted, refolding could be performed with the protein remaining bound on a HisPrep
column. The gene encoding WD5-6(Y532H) was inserted into the pET32XaLIC vector
using the LIC method discussed in Chapter 3 (Section 3.3.1).

The amplification

reaction conditions are shown in Tables 4.3 and 4.4. The amplified PCR product (450
bp) is shown in Figure 4.3. The LIC cloned insert was confirmed by restriction mapping
with BamH I and Bgl II, and primer extension DNA sequencing (Figure 4.4).

4.2.2

Discussion
The mutagenesis of Y532H into domains WD5-6 was straight forward. The

primers were designed with a high content of guanine and cytosine to ensure correct
binding to the DNA template. The PCR product was incubated for 2 h with Dpn I instead
of the recommended 1 h. The extended incubation not only decreased chances of false
positives due to parental DNA, but also made screening for the mutant plasmid easier.
Unlike the WD 1-6 gene insert, the amplification of WD5-6 containing the Y532H
mutation (hereafter referred as WD5-6(Y532H)) with LIC primers went perfectly. The
amplification of WD5-6(Y532H) gene insert using LIC primers by PCR did not show
any specificity to a particular DNA polymerase and needed no thermocycler optimization
or external additives.
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Table 4.3 The WD5-6(Y532H) gene amplification reaction with LIC-qualified
primers.
Component

Volume (fiL)

5X HotStar DNA polymerase buffer (Qiagen)f

20.0

Water

74.15

pET24d/WD5-6(Y532H) (13.5 ng/^L)

1.0

WD5 XaLIC Fwd primer (10 pM)

1.93

WD6 XaLIC Rev primer (10 pM)

1.92

HotStar HiFidelity DNA polymerase (Qiagen)

1.0
100.0

Total

Table 4.4 The PCR reaction conditions for WD5-6(Y532H) gene
amplification with LIC primers.
Cycle

Duration (min)

1

Activation cycle

95

5.0

2

Extension

72

1.0

3

Melting

95

0.25

4

Annealing

60

1.0

5

f

Temperature (°C)

Repeat steps 2 to 4 for 30 cycles

7

Final extension

72

10.0

6

End/store

4

Indefinite

Contained deoxynucleotides (dNTPs) mix.
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Figure 4.3 The amplified WD5-6(Y532H) gene for insertion into pET32XaLIC vector.
Lane 1, the 450 bp PCR product is visualized alongside a 1 Kb DNA ladder, Lane 2, in a
0.8% ethidium bromide stained agarose gel. The Xa before Y532H denotes Factor Xa.

Lane 1

Lane 2

Lane 3

Figure 4.4 Restriction mapping of pET32Xa/WD5-6(Y532H) construct. Lane 1,
pET32XaLIC vector as control, Lane 2, the pET32Xa/WD5-6(Y532H) construct, and
Lane 3, 1 Kb DNA ladder (NEB). This 0.8% agarose gel was stained with 0.5 ng/mL
ethidium bromide solution.
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4.3

4.3.1

Purification of WD5-6(Y532H) Mutant Protein

General Considerations and Results
The purification and characterization of native WD5-6 has been described before

[9]. The protein expresses very well and is easily extracted from the cell pellet by the
freeze/thaw method in liquid nitrogen. When the Y532H mutation was introduced into
the native WD 5-6 domains, the mutant protein expressed at 37°C with 1 mM IPTG was
largely insoluble. The mutant protein yield from extraction by freeze/thaw method in
liquid nitrogen was very low.
The WD5-6(Y532H) mutant protein was then expressed as a fusion protein with
thioredoxin containing Factor Xa cleavage site (TRXx a WD5-6(Y532H). The expression
of WD5-6(Y532H) as a fusion did not increase the solubility as expected. Therefore, the
entire fusion protein was purified using an inclusion body protocol, followed by
denaturation with 6 M GnHCl and refolding. The thioredoxin fusion protein was
subsequently cleaved off with Factor Xa. The WD5-6(Y532H) prepared by the refolding
method and Factor Xa cleavage was prone to precipitation and degradation. The
expression and purification of WD5-6(Y532H) without a fusion protein (pET24d/WD56(Y532H) plasmid construct) was later optimized. The induction temperature was
lowered between 28-30°C from 37°C and the concentration of IPTG was increased from
1 mM to 3 mM. The induction time was also extended from 3-4 h to 4-6 h. The
purification methods and SDS-PAGE results are discussed in following sections.
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4.3.1.1 DEAE (diethylaminoethyl) Cation Exchange Chromatography
The non-fusion WD5-6(Y532H) protein (expressed from pET24d/WD56(Y532H) plasmid construct) was first purified by a cation exchange sepharose column.
The negatively charged WD5-6(Y532H) protein bound while positively charged proteins
did not. Figure 4.5 (A) shows 15% Tricine SDS-PAGE gel of time-course induction of
WD5-6(Y532H) at 37°C and Figure 4.5 (B) shows WD5-6(Y532H) protein extraction
using different methods before modification of expression and purification methods.
After development of the new method to express the protein at 28°C, it was extracted by
the freeze/thaw method, followed by sonication and purification with DEAE Sepharose
column. Figure 4.6 shows eluted DEAE fractions of WD5-6(Y532H) obtained after
conditions were optimized.

4.3.1.2 Immobilized Metal Affinity Chromatography (IMAC) Purification
The inclusion bodies resulting from the expression of TRX Xa WD5-6(Y532H)
were processed according to the description given in materials and experimental methods
section (see Section 2.4.2). The denatured fusion protein was then directly loaded on the
column; the bound denatured protein was washed with 20 mM phosphate, pH.7.5, 500
mM NaCl, and 20 mM imidazole, causing simultaneous refolding of the protein in situ.
The refolded fusion protein was then eluted with 300-500 mM imidazole (Figure 4.7).

4.3.1.3 Fusion Protein Cleavage of TRX Xa WD5-6(Y532H)
The refolded fusion protein recovered from inclusion bodies was relatively pure.
The refolded TRX Xa WD5-6(Y532H) had high precipitation rates when buffer conditions
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( A ) W D 5 - 6 ( Y 5 3 2 H ) non-fusion protein induction
Time (min)
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180 2 1 0 2 4 0

4 5 . 0 KJ
30.0 K

( B ) W D 5 - 6 ( Y 5 3 2 H ) non-fusion protein extraction

Figure 4.5 Expression and purification of non-fusion WD5-6(Y532H). (A) Time-course
induction at 37°C with 1 mM IPTG. (B) Protein extraction with different methods, Lane
1, BugBuster® reagent extract; Lane 2, cell pellet after Bugbuster® reagent extraction;
Lane 3, cell pellet after freeze/thaw extraction; Lane 4, freeze/thaw extract; Lane 5,
induced cell pellet as a control. Arrows indicate the protein of interest.
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Figure 4.6 The purification of non-fusion WD5-6(Y532H) from optimized conditions.
Arrow indicates the protein of interest. Lanes 1-8, protein elution fractions from DEAE
Sepharose column. The protein eluted -0.16 M NaCl. Lane 9 is crude extract
(supernatant) before DEAE purification.

Figure 4.7 The refolded TRX Xa WD5-6(Y532H) purification. The 10% Tricine gel shows
isocratically eluted TRX Xa WD5-6(Y532H), Lanes 1-8, from a HisPrep FF 16/10 column
charged with nickel. Molar mass of the fusion protein is 33 kDa.
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were altered to Factor Xa buffer (50 mM Tris/Cl, pH 8.0, 100 mM NaCl, 5 mM CaCl2).
Even though Factor Xa cleavage was kept under 16 h, significant amounts of protein
were lost to precipitation.

The cleaved thioredoxin tag was removed using a 5 mL

HisPrep column pre-charged with nickel and the refolded WD5-6(Y532H) was purified
further by gel filtration. TRXx a WD5-6(Y532H) digestion by Factor Xa is shown in
Figure 4.8 below.

Figure 4.8 Thioredoxin tag cleavage from TRX Xa WD5-6(Y532H). Lanes 1, 2, WD5-6
as a control; Lanes 3, 4, the cleavage of TRX Xa WD5-6(Y532H); A, B, and C indicate the
positions of TRX Xa WD5-6(Y532H), TRX and WD5-6(Y532H), respectively in lanes 3
and 4 after 16 h. The protein samples were loaded in duplicate but varying amounts for
clarity.
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4.3.1.4 Size Exclusion Chromatography of WD5-6(Y532H) Protein
Size Exclusion Chromatography (gel filtration) was the final purification step. It
enabled removal of contaminating proteins and residual protease from the digestion
reactions. The protocol for this step is discussed in the material and experimental
methods section (Section 2.5.2). The SDS-PAGE gel of WD5-6(Y532H) recovered from
optimized growth and purification conditions is shown in Figure 4.9 with an elution peak
at 94.85 mL from the 120 mL Superdex 200 16/60 column. Before gel filtration, WD56(Y532H) obtained by refolding and Factor Xa cleavage method was first purified with a
HisPrep tag column to remove the thioredoxin tag. The elution trace for this WD56(Y532H) from the 320 mL superdex 75 26/60 column is shown in Figure 4.10. The
molar mass of 15N, ,3 C isotopically labeled WD5-6(Y532H) for NMR studies determined
by MALDI-TOF mass spectrometry is shown in Figure 4.11. The protein was 99.8%
isotopically labeled; the molar mass obtained by MALDI-TOF mass spectrometry was
16,896 Daltons, whereas the actual molar mass of a fully

15

N,

13

C isotopically labeled

WD5-6(Y532H) is 16,924 Daltons.

4.3.1.5 Caveats of WD5-6(Y532H) Purification
The solubility of the thioredoxin tagged TRXxaWD5-6(Y532H) protein was not
better than that of the protein without the fusion tag. The protein extraction by
freeze/thaw method and BugBuster® reagent extraction methods could only recover
minute quantities. With protein rich inclusion bodies, protein solubilization and refolding
method was an appropriate option. The fusion protein was first processed to remove
extraneous protein matter following the BugBuster® protein extraction protocol and then
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Figure 4.9 Gel filtration of WD5-6(Y532H) recovered under optimized conditions.
Lanes 1, 2, 3 are protein fractions with contaminants; lanes 4, 5 are fractions with pure
WD5-6(Y532H). The UV trace on the top is for the 120 mL Superdex 200 16/60 prep
grade column and corresponding elution volume for each fraction is shown at the bottom
of the gel. Arrow indicates the protein of interest.
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Figure 4.10 Gel filtration of WD5-6(Y532H) obtained by refolding/Factor Xa cleavage
method. Lanes 1-7 are elution fractions sampled by 10% Tricine SDS-PAGE gel from
Superdex 75 26/60 column. The UV trace for elution profile is shown on top while the
elution volume for each fraction is indicated at the bottom of gel. Arrow indicates the
protein of interest.
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Figure 4.11 The MALDI-TOF of 13C, 15N labeled WD5-6(Y532H), -16, 896 Daltons,
obtained after refolding and thioredoxin cleavage; Department of Pharmaceutical
Sciences, University of Florence, Italy. Actual molar mass of a fully 13C, 15N isotopically
labeled WD5-6(Y532H) is 16,924 Daltons.

solubilized with 6 M GnHCl, loaded on HisPrep nickel column and refolded in situ by
washing the bound protein with HisPrep binding buffer (20 mM Na Phosphate, pH 7.4,
500 mM NaCl, 20 mM imidazole). The drawbacks of inclusion body processing and
refolding were time and cost.

In addition, WD5-6(Y532H) obtained by the

refolding/Factor Xa cleavage method was unstable especially when exchanged from high
to low salt buffer. For example, protein was stable in phosphate buffer with 500 mM
NaCl and 500 mM imidazole near pH 7 but precipitated when exchanged into 50 mM
Tris/Cl, 100 mM NaCl.
Although the cleavage of fusion protein with Factor Xa was efficient, aggregation
of cleaved WD5-6(Y532H) hindered recovery. The analysis of WD5-6(Y532H)
degradation by SDS-PAGE gel revealed two protein fragments, 5 kDa and 10 kDa in
size.

Degradation of the protein might have been due to poorly refolded protein

undergoing self autolysis or digestion of misfolded protein by residual Factor Xa.
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Due to the limited storage life of the WD5-6(Y532H) obtained by refolding/Factor Xa
cleavage method, the protein needed to be expressed and purified continually for
experiments. This proved to be tedious and costly. The expression and purification of
non-fusion WD5-6(Y532H) was modified. The induction of the WD5-6(Y532H) was
done at low temperature (28-30°C), concentration of IPTG was increased up to 3 mM,
and the induction time extended by 2 h. Sonicating the cell suspension after rounds of
freeze/thaw in liquid nitrogen caused more WD5-6(Y532H) protein to be released.
WD5-6(Y532H) recovered by this method was comparable to the native WD-6, both in
yield and physical stability. It is possible that WD5-6(Y532H) expressed at 37°C
(physiological temperature) was prone to misfolding forming inclusion bodies. This
behavior may be the reason this mutation leads to Wilson disease. At body temperature,
the ATP7B enzyme bearing this mutation may have a higher probability of misfolding.

4.4

Biophysical Characterization of WD5-6(Y532H) Protein
Except for NMR, all others experiments were performed on WD5-6(Y532H)

recovered from non-fusion construct, pET24d/WD5-6(Y532H) using optimized
expression and purification methods.

4.4.1

Gel Filtration and Light Scattering
The primary objective for high resolution gel filtration analysis of mutant WD5-

6(Y532H) protein was to find the migratory behavior of the protein through a stationary
phase. The properties evaluated included hydrodynamic radius, aggregation state, and
dimer formation.

In this experiment, a Superdex 75 10/300 column was used for
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separation with the native WD5-6 as the control. The injection volume was 25 pL of 1-5
mg/mL protein. Figures 4.12 and 4.13 show the elution profiles for WD5-6 and WD56(Y532H) proteins through the size exclusion column, respectively. The elution trace for
WD5-6(Y532H) obtained by refolding/Factor Xa cleavage method is not shown but
gives a similar elution time.
Lights scattering measurements were also performed for both WD5-6 and WD56(Y532H). The molar mass distribution determined by static light scattering (SLS) is
shown in Figure 4.14 while calculated molecular weights of different species in the
protein are tabulated in Table 4.5. The hydrodynamic radius, Rh was also determined
using dynamic static scattering (DLS). The autocorrelation function curves for WD5-6
and WD5-6(Y532H) along with the derived translational diffusion coefficient which is
used to calculate Rh are shown in Figure 4.15 and Figure 4.16. The hydrodynamic
radius distribution of the proteins and the constituent species is shown in Figure 4.17.
The RH, the apparent shape, and calculated molar mass of the protein monomers
determined by DLS are reported in Table 4.6.

4.4.2

Discussion
The gel filtration data indicates that both the mutant and native protein domains

do not possess any significant differences that can be determined by this method. This is
also supported by light scattering experiments. The elution times in Figure 4.12 and
Figure 4.13 are within experimental error and both chromatograms show a Gaussian
function. Although the entire elution profile is not shown for gel filtration results,
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Elution volume (mL)
Figure 4.12 High resolution gel filtration of WD5-6(Y532H). The protein elutes at
-12.88 mL using a Superdex 75 10/300 GL column.

Figure 4.13 High resolution gel filtration of WD5-6. The protein elutes at -12.79 mL
using a Superdex 75 10/300 GL column.
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Figure 4.14 Molar mass distribution of WD5-6 and WD5-6(Y532H) by static light
scattering. A plot of molar mass (g/mol) against elution time in min (gel filtration)
monitored by UV at 280 nm is shown. The "non-continuous" lines labeled A-E are
weight average MW for each slice, i.e., measured every 1 s. A: WD5-6(Y532H)
aggregate (blue), B: WD5-6 tetramer (red), C: WD5-6 dimer (red), D: WD5-6
monomer, (red), E: WD5-6(Y532H) monomer (red overlapped with blue color).
Computed values are tabulated in Table 4.5.
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Table 4.5 Calculated molecular weights (MW) of WD5-6 and WD5-6(Y532H)
determined by SLS. The elution profile is shown in Figure 4.15. Note that peaks' elution
is simultaneously monitored by UV, RI and LS detectors.

Sample

WD56(Y532H)

WD5-6

Peak
Elution
at RI
trace
(mL)

MW (kDa)
Calculated by
ASTRA
Average for the
major peak

11.87

16.1

MW (kDa)
Calculated
MW for
by ASTRA
monomer
Range of Mw
(kDa)
observed
15.5-16.5

Mono
disperse
peak
Yes

16
7.9

350

280-420

No

11.89

16.1

15.5-16.5

Yes

10.4

32

31.5-32

9.1

72

64-85

16

Yes
No

Figure 4.15 Autocorrelation function of WD5-6 monomer peak. The translational
diffusion coefficient derived from this exponential graph is shown.
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Translational diffusion coefficient
Dt= (1.19 ± 0.03) e-6 cm2/sec
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Figure 4.16 Autocorrelation function of WD5-6(Y532H) monomer peak.
translational diffusion coefficient derived from this exponential graph is shown.

The

Table 4.6 Hydrodynamic radius of WD5-6 and WD5-6(Y532H) protein
monomers. Molecular weight determined by DLS and apparent shape of the
monomers is also given.
Sample

RH (nm)

MW (g/mol)
DLS

Actual MW
(g/mol)

Apparent shape

WD5-6

2.10±0.06

16,060±20

16,045

Spherical

WD5-6(Y532H)

2.05±0.06

16,140±10

16,031

Spherical
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Figure 4.17 The RH distribution of WD5-6 and WD5-6(Y532H) proteins. A plot of
hydrodynamic radius against elution volume in mL (gel filtration) is shown. The "dotted"
lines, A-D are Rh distributions within the eluting peaks. A: WD5-6, tetramer (red), B:
WD5-6 dimer (red), C: WD5-6 monomer (red) and, D: WD5-6(Y532H) monomer
(blue). The slanted Rh distribution is indication of a polydisperse material in the elution
peak, whereas Rh for a monodisperse material remains relatively constant across the
elution peak.
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dimerization to a higher-order by WD5-6 and WD5-6(Y532H) protein monomers was
detected by light scattering experiments (Figures 4.14 and 4.17). A prior analysis with
SDS-PAGE found that WD5-6(Y532H) dimerized more relative to the native from when
exposed to the air, but this was not detected in freshly prepared samples. The presence of
aggregates of higher-order in WD5-6(Y532H) at 7.9 mL peak (Figure 4.17) but not in
WD5-6 could be due to reduced association stability dimers and tetramers. Unlike the Nterminal metal binding domains, native WD5-6 and mutant WD5-6(Y532H) monomers
were found to be monodisperse and spherical. Thus, the calculated average mass of these
monomers was independent of the averaging method (if a peak contains a mixture of
species of different molar sizes, average molar mass is given). This mean the monomer
peak contains only one type of the macromolecule. The Rh and molar mass determined
by SLS and DLS (Tables 4.5 and 4.6) for both proteins show a negligible deviation from
each other.

It seems that the mutation does not have profound effects on the overall structure
and shape of the native protein, since protein migration in gel filtration is a function of
the overall shape of the macromolecule. As is discussed in Section 4.3.1.3, the WD56(Y532H) protein obtained by refolding followed by thioredoxin cleavage had a tendency
to aggregate and degrade. Because of the small amounts of protein sample injected, it was
hard to estimate the fraction of protein that was been lost due to aggregation. WD56(Y532H) protein recovered by optimized expression and purification methods and the
native WD5-6 were found to be very stable; degradation and precipitation was not
observed. During light scattering measurements, it was possible to recover up to -85% of
the sample that was injected into the size exclusion column. While it is evident that gel
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filtration analysis and light scattering results show no defined effects due to mutation, this
information might provide some insights on how slight perturbations at atomic level due
to missense mutations, can be ultimately lethal without affecting physical properties of a
protein.

4.4.3

4.4.3.1

Circular Dichroism Spectroscopy

Results
The CD data conversion and processing was done with RIS Manager Software

(JASCO). The Origin 7.5 software (Origin Lab) and Microsoft Excel were used for data
plotting and tabulation of the unfolding studies. The CD spectra for WD5-6(Y532H) and
WD5-6 were acquired under the following conditions: (1) in the absence of denaturant,
(2) under increasing molar concentration of GnHCl, and (3) at two different protein
concentrations 14.5 and 29 p.M. The unfolding was monitored from 260-190 nm. The
proteins were freshly purified and samples prepared by mixing with an appropriate
amount of 8 M GnHCl and incubated for 2-6 h.
The CD spectra of WD5-6(Y532H) and WD5-6 unfolding are shown in Figures
4.18-20. To find the relationship in the unfolding pattern between the native and mutant
protein, superimposition of spectra at a select denaturant concentrations is shown in
Figure 4.20. The Gibbs free energy of unfolding, AG (J H2 ° in the absence of denaturant
was calculated using a two-state model as explained in Sections 2.7.4 and 3.6.3.A plot of
Gibbs free energy of unfolding against concentration of denaturant using the data sets in
Tables 4.8 and 4.9 from unfolding curve model model at 222 nm (Figure 4.22) is shown
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Figure 4.18 The unfolding of 29 jaM WD5-6(Y532H) under increasing molar
concentration of GnHCl.
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Figure 4.19 The unfolding of 14.5 |iM WD5-6 under increasing molar
concentration of GnHCl.
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Figure 4.20 The Circular dichroism of 29pM WD5-6 and WD5-6(Y532H) in the
absence of denaturant.

Table 4.7 Helicity loss during denaturation.
GnHCl

% Helicity WD5-6

% Helicity WD5-6(Y532H)

0M

23.9

23.4

1M

23.4

22.4

2M

23.7

16.5

3M

16.3

13.3

4M

9.0

5.3

5M

3.9

3.5

6M

2.7

3.0

180

0

2

4

6

8

GnHCl (M)
Figure 4.21 The loss of helicity during denaturation.

Figure 4.22 Ellipticity of WD5-6(Y532H) and WD5-6 monitored at 222 nm.
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Table 4.8 Y points along the WD5-6 unfolding curve (Figure 4.21) used to plot
the linear extrapolation curve (Figure 4.22). YF; fraction of folded protein at Y,
FF; fully folded protein fraction, K; equilibrium constant, FU; fully unfolded
protein fraction, YU, fraction of unfolded protein at Y.
YF

Y

FF

K

FU

YU

AG(J/Mol)

fGnHCll

-7123

-2615

0.2945

2.3958

0.7055

-733.5

-2165

3.9

-7123

-2179

0.2262

3.4218

0.7739

-733.5

-3048

4.2

-7123

-1867

0.1774

4.6371

0.8226

-733.5

-3801

4.4

-7123

-1571

0.1311

6.6261

0.8689

-733.5

-4685

4.6

-7123

-1369

0.0995

9.0548

0.9005

-733.5

-5459

4.8

-7123

-1044

0.0486

19.592

0.9514

-733.5

-7371

5.2

-7123

-918.7

0.029

33.497

0.971

-733.5

-8700

5.6

-7123

-841.4

0.0169

58.211

0.9831

-733.5

-10069

5.8

-7123

-825.5

0.0144

68.458

0.9856

-733.5

-10471

6

-7123

-6215

0.8578

0.1657

0.1422

-733.5

4453.4

0.59

-7123

-5886

0.8064

0.2401

0.1936

-733.5

3534.5

1.5

-7123

-5267

0.7095

0.4094

0.2905

-733.5

2212.4

2.1

-7123

-4408

0.575

0.739

0.425

-733.5

749.32

2.6

-7123

-3194

0.3851

1.597

0.6149

-733.5

-1160

3.3

-7123

-2675

0.3038

2.2916

0.6962

-733.5

-2055

3.6

-7123

-2030

0.2029

3.9289

0.7971

-733.5

-3390

4.3

-7123

-1727

0.1555

5.4324

0.8445

-733.5

-4193

5.1
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Table 4.9 Y points along the WD5-6(Y532H) unfolding curve (Figure 4.21) used to plot
the linear extrapolation curve (Figure 4.22). YF; fraction of folded protein at Y, FF; fully
folded protein fraction, K; equilibrium constant, FU; fully unfolded protein fraction,
fraction of unfolded protein at Y.
YF

Y

FF

K

FU

YU

AG
(J/MOL)

[GnHCl]

-9574

-8968

0.9309

0.0743

0.0692

-815.3

6441.3

0.59

-9574

-8599

0.8887

0.1253

0.1113

-815.3

5146.3

0.98

-9574

-8132

0.8354

0.197

0.1646

-815.3

4025.2

1.37

-9574

-7663

0.7819

0.279

0.2181

-815.3

3163.1

1.68

-9574

-6944

0.6998

0.429

0.3002

-815.3

2096.6

2.1

-9574

-5876

0.5778

0.7309

0.4223

-815.3

776.81

2.5

-9574

-5136

0.4934

1.0269

0.5066

-815.3

-65.75

-2.8

-9574

-4298

0.3976

1.5149

0.6024

-815.3

-1029

3.1

-9574

-3658

0.3246

2.0807

0.6754

-815.3

-1815

3.4

-9574

-2800

0.2266

3.4133

0.7734

-815.3

-3042

3.8

-9574

-2061

0.1422

6.032

0.8578

-815.3

-4452

4.3

-9574

-1615

0.0913

9.9585

0.9088

-815.3

-5695

4.8

-9574

-1322

0.0578

16.293

0.9422

-815.3

-6914

5.2

-9574

-1148

0.038

25.296

0.962

-815.3

-8004

5.6
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Figure 4.23 The Gibbs free energy of unfolding estimated from a liner extrapolation plot
for WD5-6(Y532H) and WD5-6.

Table 4.10 Parameters characterizing the GnHCl denaturation of Wilson protein
N-terminal domains

8

Parameter

WD4 g

WD 5-6

WD 1-6

WD5-6
(Y532H)

AG/20
(kJ mol"1)

44.5 ± 0.4

7.9 ± 0.6

11.0 ±0.2

8.0 ± 0.0

m
(kJ mol"1 M"1)

-8.3 ±0.1

-2.8 ±0.1

-3.8 ± 0.0

-2.9 ± 0.0

[GnHCl] 1/2, M

5.38

2.82

2.91

2.78

From the PhD Dissertation of Wilson Okumu, Western Michigan University ©2010.
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Figure 4.23. The calculation of A G ^ 2 0 energy, m, and [GnHCl]i/2 values for WD56(Y532H) ), WD5-6, WD4, and WD 1-6 based on the Linear Extrapolation Method,
LEM [10, 11] are tabulated in Table 4.10

4.4.3.2

Discussion
Circular Dichroism can be used to estimate the secondary structure of proteins

[12-17]. This is common especially when the 3-dimensional structure is not available. CD
can be also used to monitor degradation, denaturation and refolding of protein during
purification. The wavelength most utilized for this purpose is 222 nm. The solution NMR
structure of WD5-6, published by members of our lab in collaboration with Bertini group,
CERM, Italy reveals that WD5-6 possesses about 28% P-sheet and 30% a-helical
character [9]. Using CDpro (http://lamar.colostate.edu/~sreeram/CDPro/main.htm') and
the data in Figures 4.18 and 4.19, the tertiary structure for both WD5-6(Y532H) and
WD5-6 in the absence of GnHCl was predicted to be a beta/alpha.
The main objective for WD5-6 and WD5-6(Y532H) CD experiments was to
determine the changes in conformational stability due to the single amino acid mutation.
This phenomenon, monitored by the disappearance of secondary structure in the presence
of denaturant, is shown in Figures 4.18-21, and in Table 4.7. The denaturants alter
equilibrium between the native (folded) and denatured (unfolded) protein states. From the
unfolding spectra, it can be inferred that the stabilities of the native and mutant are
identical, particularly in the absence of denaturant (Figure 4.20). WD5-6 is very stable
up to 2M GnHCl, but the WD5-6(Y532H) mutant begins unfolding immediately upon
addition of 1M GnHCl. There are differences in the loss of helicity during unfolding

(Figure 4.21 and Table 4.7). WD5-6(Y532H) loses more helicity than WD5-6 at each
denaturant concentration. The Gibbs free energy of unfolding in absence of denaturant,
HO

AGu

2

, m, and [GnHCl]i/2 of various N-terminal domains of Wilson protein has been

determined by the Linear Extrapolation Method (LEM), shown in Table 4.5. Due to
small differences in stability (less than a 0.1 kJ/mole) between the mutant and native
protein, the change in free energy of unfolding due to the mutation (AAG) is not
significant. Professor Pace at Texas A&M University, who has extensively studied
conformational stability and the mechanism of folding of proteins, cautions about relying
on a single methodology to calculate the free energies of unfolding. He identifies
deviations from a two-state mechanism, presence of intermediates, and the empirical
nature of LEM as some of the factors that can interfere with precise measurements [18].
The absence of intermediates can be confirmed by differential scanning calorimetry
during thermal unfolding.
A better approach to acquire more accurate measurements is to use multiple
probes to monitor denaturation. They include UV difference spectroscopy, fluorescence
and NMR. The m values for WD5-6(Y532H) and WD5-6 support the hypothesis that
m values correlate strongly with amount of protein surface exposed to the solvent upon
unfolding [19]. The WD5-6(Y532H) mutation is likely to distort the domain 5 structure,
thus, increasing the surface area available for solvent binding, but this is not observed in
this study. Conformational stability values of a protein determined from a variety of
methods have a higher probability of being accurate. Urea and GnHCl are also known to
give AGu" 20 estimates that are in closer agreement [20], though only GnHCl is shown
here.
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4.5

4.5.1

NMR of WD5-6(Y532H) from Refolding and Factor Xa Cleavage Method

The Structural Heterogeneity of WD5-6(Y532H) Mutant Protein
The 'H- I5 N HSQC spectra of WD5-6(Y532H) show well-dispersed resonances

indicative of a folded protein (Figure 4.24). This was also exhibited by CD spectra
indicating that the overall fold of both domains of WD5-6(Y532H) is not disturbed by
mutation. The residues localized in the linker regions, including E73-G77 (E557-G561, in
WNDP), show two sets of assignments in ! H- 15 N HSQC spectrums, indicating the
presence of structural heterogeneity, i.e. two possible relative orientations of the two
domains of WD5-6(Y532H). Amide chemical shifts are highly similar between WD5-6
and WD5-6(Y532H) for domain 6, G80-Q149 (G564-Q633, in WNDP) as shown by
chemical shift variation (CSV) data.
The most affected residues include Q4-F7 (Q488-F491 in WNDP), K47-H(Y)48
(K532-H(Y)532) and V52-I53 (V536-I537 in WNDP) (Figure 4.25). Mapping to the
structure of wild type WD5-6 (Figure 4.26) shows these residues are spatially close to
the mutation. One set of the double conformation of residues, E73-G77 (E557-G561 in
WNDP), also show large variation in combined chemical shift, while the other set of
chemical shifts are quite similar to wild type. This result indicates that one of the two
conformations of this linker region is quite similar to the wild type, whereas the other one
leads to a different conformation.
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Figure 4.24 The heteronuclear single quantum correction (HSQC) chemical shift of
WD5-6(Y532H) overlaid with WD5-6. Red is WD5-6, green is WD5-6(Y532H).
Residues indicated by arrows correspond to the following in WNDP: C6, C490; 146,
1530; Y/H48, Y/H532; D47, D531.
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Figure 4.25 Chemical shift variation between wild type and Y48H-WD5-6(Y532H).
Double conformations of E73-G77 (E557-G561 in WNDP) are shown in green.
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Figure 4.26 Combined chemical shift of WD5-6(Y532H). Residues Q4-F7 (Q488-F491
in WNDP) experiencing CSV values above 0.1 are mapped in green on the structure of
apo WD5-6. Residues V52-I53 (V536-I537 in WNDP) experiencing CSV smaller than
O.lppm but bigger than 0.05 are in pink; H48 (H532) mutation is in red; residues E73G77 (E557-G561 in WNDP) showing double conformations are depicted in blue.

4.5.2

Inter-Domain Motion of WD5-6(Y532H)

4.5.2.1

Results and Discussion

Disease-causing point mutations could alter the global fold and/or dynamic
properties of a protein, thus

15

N relaxation parameters on apo WD5-6(Y532H) were

analyzed for 122 backbone NH groups. As shown in Figure 4.28, residues of domain 6
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had lower R2 values showing that these residues experience faster tumbling than the
overall protein tumbling. Average R] and R2 values for the folded domains are 1.7 ± 0.1
s~' and 11.2 ± 2.1 s"!. While the average Ri and NOE values for the mutant protein are
identical to those of wild type, the R2 values are significant lower than those of the wild
type through the whole peptide sequence (15.4 ± 2.1 s"1 for wild type protein). Our
previous work has shown that the two domains of wild type WD5-6 reorient in solution
as a single molecule instead of two [9]. The decreasing R2 values induced by WD56(Y532H) can be interpreted as the presence of slower breathing motions in domain 5.
By looking at the structure of wild type WD5-6, the loss of the rigidity of the two
domains may arise also from the loss of H-bond interaction between the OH group of
Y48 (H532) and the backbone carbonyl of Y75 (Y559). The missing H-bond is also
likely to be the reason there are multiple backbone conformations for the linker region
(Figure 4.28).
Thus it can be concluded that the mutation Y48H (Y532H) disturbs the
hydrophobic packing in domain 5, which is critical for a compact structure, inducing
motions on the side chain groups, and breaching the rigidity between the two domains,
causing inter-domain motion and structural heterogeneity not observed in wild type
WD5-6.
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Figure 4.27 Sequential plot of 15N relaxation parameters for WD5-6 (black) and WD56(Y532H in WNDP) (red). Relaxation parameters were measured at 600MHz and 298K.

4.5.3

Copper Transfer Studies of WD5-6(Y532H) with ATOX1 (HAH1)

The interaction of WD5-6(Y532H) with ATOX1 was studied by titrating the

15

N-apo-

(WD5-6(Y532H) with unlabelled Cu(I)-ATOXl and following through 'H-^N HSQC
spectra. Copper transfer between the mutant protein and ATOX1 were observed. When 2
eq. Cu(I)-ATOXl were added stepwise to apo WD5-6(Y532H), the copper forms of
WD5-6 were identified. The process is slow over NMR time scales, where the intensities
of apoprotein

signals

decreased

with

increasing

ATOX1

concentration

and,

concomitantly, signals corresponding to Cu(I)-WD5-6(Y532H) appeared and increased
in intensity. As shown in Figure 4.29, the residues showing the largest CSV between apo
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Figure 4.28 The H-H bonding proximity between Y/H48 (Y/H532 in WNDP) and Y75
(Y559 in WNDP).
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80
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Figure 4.29 (Left) Sequential plot of CSV between apo and Cu(I)-WD5-6(Y532H), and
(Right), relaxation parameters of WD5-6(Y532H) at the conclusion of titration. The
peaks whose line widths are too broad to be correctly integrated are excluded from the
list.
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WD5-6(Y532H) and apo WD5-6(Y532H) when titrated with 2 eq. Cu(I)-ATOXl are
localized within the CXXC motif of both domains. This indicates that both domains are
able to receive one copper ion from Cu(I)-ATOXl, consistent with recently published
work on the interaction of ATOX1 with N-terminal domains of WNDP [21].

4.6

Summary
Several mutations in the gene encoding ATP7B (Wilson protein) are known to

cause Wilson disease, a hepatological disorder characterized by copper accumulation
mainly in the liver. Among these mutations is the Y532H substitution found at the
interface of the N-terminal domains 5 and 6 of the human Wilson protein. The
characterization of the Y532H mutation in WD5-6 domains of Wilson protein is
reported.

The Y532H mutation was introduced into a WD5-6 plasmid construct,

pET24d/WD5-6

by

site-directed mutagenesis.

The

resulting plasmid construct,

pET24d/WD5-6(Y532H) was subsequently used for protein expression in Rosetta(DE3)
cells. Despite the good expression of the mutant protein, it formed an inclusion body, an
insoluble form of the protein. Protein extraction using methods that work for the native
WD5-6 was unsuccessful. The protein was then prepared as a fusion protein with
thioredoxin to increase its solubility.
The fusion protein, TRX Xa WD5-6(Y532H), also formed inclusion bodies. The
protein was recovered from inclusion bodies by refolding and Factor Xa cleavage. The
stability of WD5-6(Y532H) obtained by this method was poor; it was prone to
degradation. The expression and purification methods for non-fusion WD5-6(Y532H)
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were then modified and optimized. This led to purification of stable WD5-6(Y532H) and
with high yield.
Biophysical characterization was performed for WD5-6(Y532H) recovered by both
refolding/Factor Xa cleavage and optimized purification methods. Only the NMR method
was used to probe the atomic organization of WD5-6(Y532H) recovered by
refolding/Factor Xa cleavage method. The results revealed that the mutation does not
change the overall structure of the native protein although it may be perturb the hydrogen
bonding in residues near the mutation site. The gel filtration, light scattering, and circular
dichroism data also indicates that the mutation does not change the overall shape and
stability of the native WD5-6 protein. A few distinct differences are observed at the
molecular level, though. When native WD5-6 is expressed at 37°C, it is readily soluble
in the extraction buffer. This is not the case with mutant WD5-6(Y532H); it forms
inclusion bodies, which are not readily soluble. The Y532H mutation is a model for how
various disease-causing mutations can be characterized. While we found no structural
perturbations due to Y532H mutation, we speculate that the mutation may interfere with
the protein's refolding in vivo.
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CHAPTER 5

CONCLUSION AND FUTURE DIRECTION

5.1

Significance of the Studies
The main objective of these studies was to elucidate the biophysical properties of

the N-terminal domains and disease-causing mutations of the human Wilson protein. As
was discussed in previous chapters, the N-terminal domains are unique in that they are
found in the heavy metal transporting P-type ATPases. Copper trafficking in cells is
orchestrated by copper permeases, copper chaperones, and copper transporting ATPases.
Several studies involving isolated domains of the Wilson protein and the related
homologous protein Menkes protein has provided initial understanding of the functions
and structure of the Wilson protein copper pump. Study of the N-terminal domains of
Wilson protein as a whole, however, has been limited by poor availability of stable
purified protein at experimental ambient temperatures. The purified N-terminal region
readily degrades and is prone to precipitation.
A stable protein is very important, especially in studies that are time-dependent and
require the structural integrity to be maintained for a lengthy period of time. Wilson
protein structure in its entirety is not yet available since structural information is hard to
obtain without a good quality protein sample. Within the APTPB gene exists several
mutations that are known to cause Wilson disease. Due to the magnitude and number of
these mutations across the gene, the molecular bases of these mutations have not been
explored and investigations have been confined to genetic and clinical levels. Therefore,
there is need to (1) overcome the challenges that hinder availability of purified stable
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protein and, (2) find ways to stabilize the protein in vitro and (2) design a general model
that can be used to characterize the disease-causing mutations at large.

5.2

Characterization of N-Terminal Domains of the Human Wilson Protein
We have presented and described the approaches that were applied to overcome the

challenges and constraints that prevented the characterization of the N-terminal domains
and disease-causing mutations. We showed that expression and purification of the Nterminal domains is dependent on many factors. The amplification of N-terminal
domains gene might show DNA polymerase specificity and the protein expression can
be dramatically increased by careful optimization of growing culture conditions such as
the temperature, inducer, and lengthy of induction. Expression of protein with fusion
tags is a widespread technique, but the removal of the fusion tag protein using encoded
protease can turn out to be inefficient or fail completely. This phenomena was seen with
expressed TRX Xa /WDl-6 protein, adding another hurdle to the work. We subsequently
developed and applied a simple method to substitute and incorporate any protease
cleavage site within an existing plasmid vector construct without performing trial-anderror screening of proteolytic sites. It is also possible to probe the stability contributions
to a protein of an amino acid residue located at the N-terminal end following the same
method.
The purification of the N-terminal domains was also investigated. New knowledge
was added on the systemic purification not only of the N-terminal domains, but also of
similar recombinant proteins. We showed that large proteins can be released from the cell
by sequential extraction process, for example, using a combination of the freeze/thaw
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method and BugBuster® reagent extraction. Y532H, a mutation known to cause Wilson
disease, was characterized in the attempt to design a model for characterization of the
multifold mutations in the ATP7B gene. The purification protocol followed similar
approaches to that described in preceding paragraphs. In this work, a native versus
mutant approach was adapted. We were able to follow slight deviations between the
native and mutant protein. With this approach, shortcomings were easily identified and
appropriate action taken. To this end, we report the characterization of Y532H mutation
as a model for the characterization of any disease-causing mutation of the Wilson protein.

5.3

Conclusion and Future Work
The improvements in expression and purification of the N-terminal domains of

both mutant proteins ushered in the biophysical studies. The findings and major insights
were described in detail in chapter 3 and 4. In conclusion, we highlight that (1) novel
methods were developed for expression and purification of recombinant proteins, (2) a
stable construct of N-terminal domains protein has been successfully purified for
biophysical studies and (3) mutations may largely hamper polypeptides refolding in vivo
thereby leading to protein misfolding. Further work is recommended in the following
areas: (1) the expression and purification of the entire protein pump for possible atomic
structure determination will aid in understanding in depth functions of the pump and (2)
conformational stability studies of the proteins need to be extended to other methods so
that the data can be inclusive. Many disease-causing mutations in the Wilson protein
remain uncharacterized; therefore, it would be interesting to see the effect of each and
every individual mutation known in the Wilson protein.

199

Appendix
Project Approval Certification

200

Recombinant DNA Biosafety Committee
Project Approval Certification
For rDNA Biosafety Committee Use Oniv

Project Title: Characterization of MetaUoproteins
Principal Investigator: David Huffman
RDBC Project Number: 09-DHd

Date Received by the rDNA Biosafety Committee: 2/27/2009

^

Reviewed by the rDNA Biosafety Committee
[/I

Approved

[ |

Approval not required

2/27/2009

Chair of rDNA Biosafety Committee Signature

Revised 5/02 WMU RDBC
All other copies obsolete

201

Date

